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Zusammenfassung
Das Klasse II Tumorsuppressor-Gen H-REV107-1, ist in normalen Geweben ubiquitär
exprimiert, zeigt jedoch häufig Expressionsverluste, vorzugsweise in Tumoren des
Brustgewebes, des Ovars und der Lunge. Das H-REV107-1 Protein wirkt in vitro und in vivo
als Wachstumssuppressor. Um den Mechanismus der H-REV107-1 bedingten
Wachstumshemmung zu verstehen, haben wir mit Hilfe des LexA-basierten Hefe-2-Hybrid
Systems interagierende Proteine identifiziert. Diese Suche wurde mit einem H-REV107-1
Deletionskonstrukt durchgeführt, dem die Membran-bindende Domäne fehlte. Diese Analyse
lieferte eine Vielzahl von potentiellen Interaktionspartnern, darunter der Retinsäure Rezeptor
RARG, das Calcium-bindende Proteine S100A6, der Translations-Elongationsfaktor ETF und
das weitgehend unbekannte Protein p14.5 Die Bindungen des H-REV107-1 Proteins an die
beiden potentiellen Kandidaten, den Transkriptionsfactor PC4 und die regulatorische
Untereinheit der Protein Phosphatase 2A (PR65), wurden genauer untersucht.
Wir haben dabei einen Proteinkomplex aus H-REV107-1, PC4 und STAT1 (Signal
Transducer and Activator of Transcription 1) identifiziert, der vermutlich eine Rolle in der IFNγ
- abhängigen Wachstumshemmung in Ovarialkarzinom Zellen spielt. Da sich die Expression
des H-REV107-1 Gens durch IFNγ über den Transkriptionsfaktor IRF-1 stimulieren läßt, und
in verschiedenen Zelllinien sowohl zur Hemmung des Wachstums, als auch zur Apoptose
führt, vermuteten wir verschiedene Mechanismen der Wachstumshemmung durch den IFNγ-
Signalweg und H-REV107-1.
Weitere Analysen der H-REV107-1 – vermittelten Apoptose zeigten, daß die Interaktion
zwischen H-REV107-1 und PR65 eine wichtige Rolle in diesem Prozeß spielt. Um die
Proteindomäne zu identifizieren, welche für die direkte Wechselwirkung von H-REV107-1 mit
PR65 verantwortlich ist, wurden H-REV107-1 Mutanten generiert und mittels Co-
Immunpräzipitation getestet. Die Prolin-reiche Sequenz am N-Terminus des H-REV107-1
Proteins konnte als verantwortliche Domäne für die Interaktion bestimmt werden.
Die funktionelle Analyse dieser Interaktion zeigte die Hemmung der Protein Phosphatase 2A
(PP2A) Aktivität in Ovarialkarzinom Zellen durch H-REV107-1. Der Einsatz der Mutanten im
Phosphatase-Aktivitätstest zeigte, daß die selbe Domäne, die die Interaktion vermittelt, auch
für die Hemmung der Phosphatase 2A verantwortlich ist. Diese Fakten deuteten auf eine
wichtige Rolle der Phosphatase 2A in Ovarialkarzinom Zellen hin, weil sowohl die
Verwendung des PP2A Inhibitors (Okadainsäure), als auch die Transfektion der Zellen mit
einem H-REV107-1 - Expressionsplasmid zur Apoptose führten. Damit konnten wir zeigen,
daß PP2A für das Überleben der Ovarialkarzinomzellen notwendig ist, und die Reaktivierung
des H-REV107-1 Proteins durch IFNγ zur Hemmung der Phosphatase und damit zur
Apoptose führt.
Schlagwörter: H-REV107-1, PP2A, Apoptose, IFNγ, Tumorsuppressor.
XAbstract
The H-REV107-1 class II tumor suppressor gene is ubiquitously expressed in normal tissues
and down-regulated in human breast, ovarian and lung tumours. H-REV107-1 has the
capacity to suppress growth of tumour cells in vitro and in vivo. To understand the
mechanism of H-REV107-1 mediated growth suppression I performed a search for H-
REV107-1 interacting proteins using a LexA-based yeast two-hybrid system. I screened a
human kidney cDNA library with a truncated form of the H-REV107-1 as a bait. This analysis
revealed numerous potential interaction partners. Among them the retinoic acid receptor
gamma (RARG), the calcium-binding protein S100A6, the translation termination factor
ETF1, and the potential translational inhibitor protein P14.5.
The interaction of H-REV107-1 with the transcriptional co-activator PC4 and with the
regulatory subunit A of protein phosphatase 2A (PR65) was analysed in detail. H-REV107-1
binds ectopically expressed and endogenous PC4. In addition, a multiprotein complex
between H-REV107-1, PC4 and the signal transducer and activator of transcription 1
(STAT1) was demonstrated. This complex is likely to be involved in IFNγ-mediated growth
suppression of ovarian carcinoma cells. Endogenous H-REV107-1 can be induced after
application of IFNγ through the IRF-1 transcription factor. This up-regulation of H-REV107-1
leads either to growth suppression via a G1 arrest or to apoptosis depending on the cell line,
suggesting different mechanisms of IFNγ-, and H-REV107-1- mediated growth suppression.
Further investigation of the mechanism of H-REV107-1-dependent apoptosis revealed an
important role of the interaction between H-REV107-1 and the PR65 protein. The use of
several H-REV107-1 mutant proteins generated after disruption of the highly conserved
domains identified the proline-rich N-terminal domain responsible for the interaction with
PR65 in Co-immunoprecipitation studies. Functional investigation of the H-REV107-1 – PR65
interaction demonstrated that wild-type H-REV107-1 is able to inhibit PP2A activity, however
a mutant protein lacking the N-terminal domain was devoid of this function. We sought to
identify the functional relevance of the PP2A activity in ovarian carcinoma cells with normally
have suppressed the H-REV107-1 gene. Treatment of OVCAR-3 cells with the PP2A
inhibitor Okadaic acid and transient transfection of the cells with wild-type H-REV107-1
resulted in the activation of caspase-9, suggesting a role for PP2A in the survival of ovarian
carcinoma cells. We suggest, that the down-regulation of H-REV107-1 in ovarian carcinomas
is a prerequisite for the PP2A-dependent activation of yet unknown signalling pathways
mediating tumour cell survival. Reactivation of H-REV107-1 gene expression via IFNγ leads
to the inhibition of PP2A activity and tumour cell death.
Keywords: H-REV107-1, PP2A, Apoptosis, IFNγ, Tumor Suppressor.
11 Introduction
1.1 Multi-Step Progression of Tumors
Experimental approaches, cytogenetic observations and molecular analysis have shown that
tumors result from a subversion of diverse mechanisms controlling growth, division, and
mortality of cells. Tumor development is generally considered as a multi-step process
including consequent dysfunction of genes classified into three categories (Bishop, 1995):
1. proto-oncogenes, which are activated by mutations and become oncogenes. Their
acquired oncogenic functions lead to uncontrolled cellular growth and proliferation.
2. tumor-suppressor genes, which normally negatively regulate cell growth and division
preventing the development of tumor. Loss or mutational inactivation of these genes
leads to the deregulation of cell cycle progression, and other intracellular processes
resulting in cancer progression.
3. genes involved in maintaining the genomic stability and genes encoding the DNA-repair
system. The “loss-of-function” mutations of these genes result in genetic instability
characteristic for tumor cells.
1.1.1 Oncogenes
The oncogenes are genes that are capable of stimulating cellular growth. Their precursors
(proto-oncogenes) are present in eukaryotic cells, and promote the normal growth and
division of cells. Their oncogenic potential can be activated by one of the following
mechanisms (Bishop, 1991). 1 - point mutation or chromosomal rearrangement resulting in
an abnormal protein which has a different biological activity, for example, RasV12 (Satoh et
al., 1992), and Bcr-Abl (Wang, 1988). 2 - gene amplification increasing the number of copies
of a normal proto-oncogene within a cell leading to the activation of its oncogenic potential,
like MYCN (Schwab, 1990). 3 - viral infection resulting in the control of a proto-oncogene by
a more active viral promoter (Lipsick and Wang, 1999).
1.1.2 Tumor Suppressor Genes
The products of tumor suppressor genes normally negatively regulate cell growth (Schwab,
2001). Loss of one or several tumor suppressors is required for the full tumorigenic
conversion of a normal cell. Re-expression of these genes in malignant cells leads to the
restoration of growth regulation and the reversion of the transforming phenotype (Klein,
1998).
First category of these genes consists of known tumor suppressors down-regulated in
transformed cells through chromosomal deletion, loss of heterozygosity (LOH), and
mutagenesis. Positional cloning is a classical approach of molecular genetic to identify this
kind of genes.
2To analyse a difference between normal and tumor cells in more detail, new methods such
as differential gene cloning (Lau and Nathans, 1985) or subtractive hybridisation (Scott et al.,
1983), and improved second generation like differential display (Lang and Pardee, 1992)
subtractive suppression hybridisation, SSH (Diatchenko et al., 1996) were developed.
Analysis and comparison of the expression patterns of normal and tumorigenic cells using
these methods revealed a new category of genes down-regulated but not mutated in tumor
cells. This observation led to the postulation of two classes of the tumor suppressor genes
(Sager, 1997).
class I tumor suppressor genes which inactivated by chromosomal rearrangements like a
deletion or translocation, and by a mutation of one or both alleles (Hanahan and Weinberg,
2000).
class II tumor suppressor genes which are stably down-regulated but were not found to be
mutated in significant subset of cancers and cancer cell lines (Sager, 1997).
1.1.2.1 The Class I Tumor Suppressor Genes
Since the first tumour suppressor was identified, more than 20 other genes have been shown
to be mutated or deleted in tumours, inter alia pRB, p53, WT1, BRCA1, BRCA2, APC, NF1,
and NF2 (McCormick, 2001; Schwab, 2001). The genes disrupted in a majority of human
cancers are the retinoblastoma tumour suppressor gene (RB1), and the TP53 gene. The
breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) were demonstrated to play
an important role in the heredity of ovarian and breast cancers (Beckmann et al., 1997).
The RB1 gene was the first tumor suppressor gene to be isolated and cloned (Friend et al.,
1988). The product of this gene, the retinoblastoma protein, pRB, is a nuclear
phosphoprotein which mediates progression through the first phase of the cell cycle, playing
a major role in the control of cell division and differentiation (Cordon-Cardo et al., 1994).
Cytogenetic studies of chromosomal alterations in a childhood retinoblastoma, and in breast,
lung and pancreatic cancers demonstrated a correlation between tumorigenesis and
chromosomal aberrations on chromosome 13q14 where the RB1 gene is located (Michalova
et al., 1982). The inactivation of one of the RB1 alleles by point mutation or deletion was
demonstrated to be often accompanied by loss of heterozygosity (LOH) on chromosome 13
(Lee et al., 1988; Hesketh, 1997). In order to explain the nature of retinoblastoma formation,
Knudson suggested the so called “two-hit hypothesis” (Knudson, 1971). He proposed that
two inactivating mutations affecting both copies of a gene are necessary for retinoblastoma
development. The first could be either a germline or somatic mutation, whereas the second
mutation is always somatic.
3This hypothesis illustrated how somatic and inherited mutations might collaborate in
tumorigenesis, and also proposed that mutations of tumor suppressor genes have a
recessive character, behave recursively at the cellular level.
The TP53 tumor suppressor gene was demonstrated to carry homozygotic somatic
alterations in roughly 50% of all human tumours. Mutations in the single copy TP53 gene are
the most frequent genetic changes yet shown in human cancers and occur in 70% of all
tumors. Germline mutations of the gene have been shown to be associated  with the Li-
Fraumeni syndrome (Levine, 1997). Further investigations revealed that in contrast to the
pRB protein and Knudsons “two-hit hypothesis” in some tumours the TP53 gene carries
mutations leading to cancer in a dominant negative fashion (Brachmann et al., 1996).
The TP53 gene encodes a transcription factor activated in response to physical or chemical
stress. The p53 protein controls induction of apoptosis, cell cycle progression into G1 and G2
phases, modulation of DNA replication and repair, preventing proliferation of cells with
damaged genetic material. Overexpression of wild type TP53 in different cell types leads to
growth inhibition (Casey et al., 1991), or to the induction of apoptosis in squamous
carcinoma cell lines (Liu et al., 1995). The major down-stream p53 effector participating in
the control of the cell cycle check-points is the cyclin dependent kinases inhibitor p21WAF1,
functioning as a tumour suppressor itself (el-Deiry et al., 1993; Sheikh et al., 1994). Other
p53 effectors playing a critical role in apoptosis signalling are the death signalling receptor
Apo-1/Fas (el-Deiry, 1998), the repressor of apoptosis Bcl-2, its inhibitor BAX-1 (Sheikh et al,
1994), and the death receptor DR5 (Burn et al., 2001). Several members of the DNA repair
machinery, for example, auxiliary subunit of polymerase δ (PCNA), and replication protein A
(RPA) were also described as p53 targets (Schwab, 2001).
1.1.2.2 The Class II Tumor Suppressor Genes
The class II of tumor suppressors is represented by genes which, unlike class I, are not
mutated during tumorigenesis but rather have sustained a blockage of their expression
through diverse mechanisms (Sager, 1997). Interestingly, that some genes exhibit features
of class II tumor suppressors in one type of cancer, whereas in other type they are known to
belong to the class I tumor suppressors. Thus, allelic loss of IRF1 occurs frequently in the
acute myeloid leukemia, myelodysplastic syndrome (Boultwood et al., 1993), and gastric
cancer (Tamura et al., 1996), whereas in ovarian cancer IRF1 is described as a class II
tumor suppressor (Sers et al., 2002). Dysfunction of maspin via mutation was identified in
prostate cancer (Umekita et al., 1997), whereby down-regulation of this gene is characteristic
for many other tumors where the gene is not mutated (Sager, 1990).
4An important feature of the class II tumor suppressor genes is that their down-regulation is
reversible. The normal genes are present, and their re-expression might be induced by drugs
or other treatments, that makes such genes attractive targets for cancer therapy. It is known
that inactivation of the expression takes place on the transcriptional and translational levels
during cancer progression. But until now the mechanisms of the gene silencing have not yet
been elucidated in much detail.
1.1.3 Mechanisms of Gene Silencing
1.1.3.1 DNA Methylation and Deacetylation
One of the important mechanisms of gene silencing is DNA methylation. The nonmethylated
CpG islands within promoter regions were demonstrated to be primary targets for the
aberrant hypermethylation in tumour cells (Bird, 1995). Loss of expression, associated with
the hypermethylation of the promoter CpG islands, was shown for the RB1 gene in 10% of
the patients with the sporadic form of retinoblastoma (Greger et al., 1994). Methylation of
WT1 and calcitonin appears in 68-74% of the analysed colon carcinomas (Hiltunen et al.,
1997). The p21WAF1, APC, p15/INK4B, and p16/INK4 genes were also described to be
methylated in tumours (Cameron et al., 1999; Baldwin et al 2000; Roder et al., 2002).
Interestingly, for several tumor suppressor genes like BRCA1, RB1, and p16/INK4,
methylation was described as an additional mechanism of down-regulation in these types of
cancer, where the genes are only rarely mutated (Garinis et al., 2002).
The de novo methylation has two consequences: first, it leads to the inhibition of transcription
factors binding (Baylin et al., 1998). Second, methylation attracts other proteins that
specifically bind the modified DNA. This blocks an access of the transcription factors required
for gene expression to DNA (Bird, 1995), and induces a secondary DNA modification,
histone deacetylation, resulting in DNA compaction. This process makes DNA less
accessible for the transcriptional machinery (Rountree et al., 2000).
Reactivation of tumor suppressor gene expression often required both de-methylation, and
inhibition of histone deacetylation, suggesting that these two processes act synergistically in
gene silencing, and may both contribute to oncogenesis and cancer progression (Cameron
et al., 1999).
1.1.3.2 Inhibition of Positive Regulators of Transcription
Inactivation of the class I tumor suppressors by mutations or deletions leads to a reduced
expression of downstream target genes. The first evidences for such an indirect inactivation
of tumour suppressors was described for the p21WAF1 gene down-regulated after loss of p53
due to mutations in the TP53 gene in a variety of human malignancies and cancer cells lines
(Shiohara et al., 1994).
5Further investigations demonstrated that the loss of p53 results in the down-regulation of
many other tumor suppressors, such as the signaling regulator caveolin-1 (Bist et al., 2000),
the angiogenesis inhibitor thrombospondin (Dameron et al., 1994), and serine protease
inhibitor maspin (Zou et al., 2000). The tumor suppressor gene maspin was originally
identified in normal breast epithelial cells (Zou et al., 1994). Further investigation
demonstrated down-regulation of maspin in breast, prostate and colon tumors (Zou et al.,
2000; Umekita et al., 1997). Investigation of maspin expression revealed a correlation
between its down-regulation and p53 inactivation that led to a proposition that maspin might
be a target of p53. The hypothesis was confirmed by the fact that over-expression of wild
type p53 in prostate and breast cancer cells led to the rapid induction of the maspin
expression via direct binding to the promoter sequence (Zou et al., 2000). Thus, tumor
development includes the inactivation of class I tumor suppressors such as p53, followed by
the down-regulation of their down-stream target genes, the class II tumor suppressors.
1.1.3.3 Inhibition of Expression by Activation of Oncogenic Signaling
Activated oncogenes might also suppress the transcription of negative growth regulators.
Thus, the oncogene Myc, activated in a large number of human cancers (Adams and Cory,
1992), was demonstrated to act not only as a transcriptional trans-activator but also to
mediate down-regulation of a variety of genes (Kato et al., 1990). The mechanism of a direct
transcriptional repression by Myc is poorly understood, but resent data suggest that Myc
mediates repression via negative interference with transcriptional coactivators. Thus,
expression of the tumor suppressor p15INK4b is repressed by Myc through association with
Miz-1 transcriptional factor (Staller et al., 2001). The alternative mechanism of Myc-mediated
suppression of transcription is an association with transcriptional repressors and recruitment
of histone deacetylases to the promoter region of target genes (Satou et al., 2001).
Oncogene Ras negatively regulates expression of a number of genes not via a direct
inhibition of transcription but through the activation of its down-stream effectors, such as AP1
transcriptional factor. Activation of AP1 results in the negative regulation of various tumor
suppressors, for example p21WAF1 (Chang et al., 2002).
To identify genes, expression of which is suppressed via activation of the RAS-downstream
signaling, a comparison of the expression patterns of the non-tumorigenic rat fibroblasts
208F and its malignant HRAS-transformed derivative, FE-8, was performed (Zuber et al.,
2000). Stable down-regulation of a significant subset of class II tumor suppressors was
identified. Expression of a fraction of these genes was recovered in the FE-8 cells after
inhibition of the MEK1 kinase, a downstream effector of HRAS, via addition of PD 98059. Re-
expression of cdc21 (Mcmd4), lysyl oxydase (Lox), STAT5a, and other genes was obtained
(Zuber et al., 2000).
6Down-regulation of lysyl oxidase in many human tumors has been reported, but mutation of
the lysyl oxidase encoded gene (Lox) was described only in colorectal tumors, suggesting
that lysyl oxidase belongs to the class II tumor suppressors (Csiszar et al., 2002).
Interestingly, inhibition of the lysyl oxidase expression in rat kidney fibroblasts led to the
development of the transformed phenotype, activation of the Ras oncogene, anchorage
independent growth, and tumorigenicity in nude mice (Giampuzzi et al., 2001). Resent
investigations demonstrated that overexpression of lysyl oxidase inhibits Ras-mediated
transformation by prevention of NF-kappa B activation, highlighting its particular role in
controlling Ras activity (Jeay et al., 2003), and confirming its role as a class II tumor
suppressor in the reversion of the malignant phenotype.
Rat H-rev107 was identified as a gene down-regulated in HRAS transformed fibroblasts, and
up-regulated in revertant and transformation-resistant fibroblasts (Hajnal et al., 1994).
Further investigation demonstrated that H-rev107 possesses growth and tumor-inhibitory
capacity and, therefore, belongs to the class II tumor suppressors (Sers et al., 1997).
Interestingly, similar to the lysyl oxidase gene, down-regulation of H-rev107 was found to be
reversible. Recovery of its expression was obtained in KRAS transformed rat ovarian surface
epithelial cells after inhibition of MAP/ERK signalling pathway (Sers et al., 2002). The human
H-REV107-1 gene and its related gene H-REV107-2/TIG3/RIG1 were cloned several years
ago (Husmann et al., 1998; Di Sepio et al., 1998). Both were demonstrated to possess
transformation suppressive properties. H-REV107-1 was shown to be implicated in IFNγ
signaling, and its expression was recovered in ovarian carcinoma cells after induction with
IFNγ (Sers et al., 2002). H-REV107-2/TIG3/RIG1, originally isolated from retinoid-treated
cultured epidermal keratinocytes, was demonstrated to participate in the retinoic acid
signaling, and negatively-regulate c-Jun N-terminal kinase and p38 mitogen-activated kinase
(Huang et al., 2002). In the meantime it is known that an H-REV107-like subfamily of proteins
is exists, and consists of 5 members, which were demonstrated to be down-regulated in
various human tumors. Their functions have not yet been elucidated in much details, but
resent phylogenetic analysis of the NlpC/P60 protein hydrolases demonstrated that H-
REV107-like proteins belong to this superfamily (Anantharaman and Aravid, 2003).
1.2 H-REV107-1 is a Member of the NlpC/P60 Protein Superfamily
1.2.1 The NlpC/P60 Protein Superfamily
The H-REV107-like proteins harbour the NlpC/P60 domain specific for bacterial peptidases.
Phylogenetic analysis revealed a large superfamily of proteins related to the E. coli
lipoprotein NlpC, and possessing the so called NlpC/P60 catalytic conservative domain,
essential for the hydrolytic activity of these proteins (Anantharaman and Aravind, 2003).
7Fig. 1 Schematic presentation of the NlpC/P60 protein superfamily
The NlpC/P60 superfamily consists of four major protein families. Three of them
are represented by bacterial and viral proteins (green letters): the p60-like family,
the YaeF-like family, and the AcmB-like family. The fourth group, the LRAT-like
protein family, contains eukaryotic (blue letters) and viral 2A proteins (green
letter).
The superfamily encompasses four diverse groups of proteins: the P60-like family, the
Acm/LytN-like family, the YaeF-like family, and the LRAT-like family (Anantharaman and
Aravid; Fig. 1). The P60-like family was typified by the P60 protein of Listeria monocytogenes
(Pilgrim et al., 2003), and includes bacterial peptidases with an extracellular location. The
NlpC/P60 domain has been demonstrated to be essential for their catalytic activity (Pointing
et al., 1999). The Acm/LytN-like family is a very divergent family of proteins typified by its two
members, the putative peptidoglycan hydrolase, AcmB (Huard et al., 2003), and a novel cell-
wall hydrolase LytN (Sugai et al., 1998). This family is represented by extracellular or
membrane proteins functioning mostly as cell-wall hydrolases (Anantharaman and Aravind,
2003). The YaeF-like protein family is typified by the E. coli protein YaeF, and shows a
peculiar phylogenetic distribution being present in bacteria and in poxviruses. A function of
these proteins is not known, but a similarity with other members of the NlpC/P60 protein
superfamily suggests that they might function as proteases (Anantharaman and Aravind,
2003).
8The LRAT family was found only in eukaryotes and animal viruses. The lecithin retinol
acyltransferase (LRAT) was identified on the basis of its enzymatic activity, the conversion of
all-trans-retinol into retinyl esters, the storage form of retinol (Ruiz et al., 1999). The LRAT
ortholog, Egl-26 in C. elegans, has been implicated in vulval development (Wendy and Han,
2002). Other members of the LRAT-like family belong to three subfamilies, the H-REV107-
like subfamily containing several tumor suppressors, the subfamily of viral 2A proteins, and a
novel, NSE-like protein subfamily (Fig. 1).
Fig. 2 Circular permutation of the NlpC/P60 conservative domain
The NlpC/P60 domain in the Acm/LytN-like and P60-like families has a length of
about 60 aminoacids, and following order of the motifs: NCE, GDL, and HWAY.
Circular permutation of the domain leads to the rearrangement of the
conservative motifs, and distribution through the whole length of a protein. Thus
in the LRAT-like proteins the GDL motif is the most amino-terminal, followed the
HWAY, and then the NCE motif at the most C-terminus of the protein.
* alternative aminoacid residues presented in several members of the NlpC/P60
protein superfamily
9The NlpC/P60 domain, shared by all four protein families, contains three highly conservative
motifs, the NCE, the GDL, and the HWAY motif (Fig. 2). Remarkably, the members of the
P60-like, and Acm/LytN-like families have a canonical distribution of these motifs. Namely,
the NlpC/P60 domain has a length of about 60 aminoacids, and the following order of the
motifs: NCE, GDL, and HWAY. In contrast, a non-canonical distribution of these motifs was
demonstrated in the LRAT-like protein family. A circular permutation of the NlpC/P60 domain,
and distribution of the conservative motifs through the whole length of the proteins were
revealed. The GDL motif became the most amino-terminal, followed the HWAY, and the NCE
motifs (Fig. 2; Anantharaman and Aravind, 2003).
Such a circular permutation of the NlpC/P60 catalytic domain, leading to the rearrangement
of the GDL motif to the N-terminus, and NCE motif to the C-terminus, supposes different
biochemical activities of the members of the NlpC/P60 protein superfamily. It was
hypothesised that the genes were acquired by the eukaryotes through lateral transfer of the
bacterial precursor. During evolution, the genes underwent drastic changes resulting in a
considerable divergence in biochemical functions between the eukaryotic proteins and the
bacterial precursors (Anantharaman and Aravind, 2003).
Protein Identity Similarity
H-REV107-1/HRASLS3 100% 100%
HRASLS2 (HRAS like suppressor 2) 60% 82%
H-REV107-2/RIG1 (Retinoid inducible gene 1) 51% 66%
HRLP5 (H-rev107 like protein 5) 51% 64%
HRASLS (HRAS like suppressor) 46% 64%
NSE2 31% 46%
Similar to NSE1 31% 46%
NSE1 23% 42%
LRAT (lecithin retinol acyltransferase) 25% 44%
Table 1 Human proteins belonging to the LRAT-like family of proteins
NCBI BLAST search revealed 9 human proteins with a high homology to the H-
REV107-1. The first 5 proteins complete the H-REV107-like subfamily, 3 NSE
proteins belong to the novel NSE protein subfamily. All non-redundant GenBank
CDS and translations+PDB+SwissProt+PIR+PRF databases were used for the
search.
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Fig. 3 Aminoacid sequence alignment of the nine human proteins belong to the
LRAT-like protein family
Conserved GDL, HWAY, and NCE motifs found in all NlpC/P60 proteins are
shown in blue boxes. A transmembrane domain predicted in several proteins
indicated in red letters. Proline-rich sequences characteristic for several members
of the family only are indicated in green.
1.2.2 The LRAT-Like Protein Family
The LRAT-like family consists of eukaryotic proteins, and 2A non-structural proteins of
picorna, Aichi, and avian encephalomyelitis (AEV) viruses (Hughes and Stanway, 2000). The
function of the viral proteins is not completely elucidated. Several 2A non-structural proteins
are trypsin-like or cystein proteases involved in polyprotein processing (Ryan and Flint,
1997), the role of others is unclear.
The human members of the LRAT-like family include 9 homologous proteins: LRAT, 5
proteins belonging to the H-REV107-like subfamily, and 3 proteins forming a novel NSE
subfamily (Table 1). The result of an alignment of members of the H-REV107-1, the NSE
subfamilies, and LRAT is depicted in the Figure 3.
Thus, proteins of the LRAT-like family share four highly conservative motifs: GDL, HWAY,
NCE, and a transmembrane domain at the C-terminus. Additionally, several members
contain a prolin-rich region at the N-terminus (Fig. 3, green letters). The function of this
region is unknown, although such motifs might be important for protein-protein binding (Kay
et al., 2000).
The best-characterised member of the LRAT-like family is the lecithin retinol acyltransferase
(LRAT). It is an essential enzyme in vitamin A metabolism mediating the conversion of retinol
into retinyl ester (Ruiz et al., 1999). The enzyme is found in those tissues known to be
involved in the processing and mobilisation of vitamin A, including the retinal pigment
epithelium, the liver, and the intestine. It has been demonstrated that a conserved Cys
residue within the NCE motif is essential for LRAT catalysis. The nucleophilic Cys residue
reacts with lecithin and becomes acetylated to generate a thiolacyl enzyme intermediate.
This fatty acyl fraction reacts then with the vitamin A, and generates retinyl esters (Mondal et
al., 2000). Further investigation demonstrated that in addition to the Cys, two His residues,
distinguished from the His residues in the HWAY motif are important for the catalysis of
LRAT (Mondal et al., 2002).
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The NSE subfamily is a novel subfamily of proteins. These proteins have one aminoacid
exchange in the NCE domain: Cys to Ser, resulting in an NSE domain. The NSE2 protein
was identified as a protein associated with the plasma membrane in tumor-derived breast
cancer cell lines using a proteomics tool. Its potential role in cancer was predicted because
of its unique cancer expression profile and identified protein-binding partners which were
demonstrated to be implicated in breast cancer tumorigenesis (Adam et al., 2003).
The members of the H-REV107 subfamily are rather poorly characterised, with the exception
of the H-REV107-1 and H-REV107-2/TIG3/RIG1 proteins. The HRASLS mouse homologue,
Ac1, has been cloned by differential display comparing two mouse cell lines: embryonic
fibroblast C3H10T1/2 and chondrogenic ATDC5. The gene is expressed in skeletal muscle,
heart, brain, and bone marrow in adult mice. It was demonstrated to posses growth inhibitory
capacity, and to revert the phenotype of HRAS transformed NIH3T3 cells, proposing that Ac1
can modulate HRAS-mediated signalling pathways (Akiyama et al., 1999).
The H-REV107-2/TIG3/RIG1 is an H-REV107-1 homologous gene (Husmann et al., 1998)
which has been identified as a retinoid-responsive gene in primary human keratinocytes (Di
Sepio et al., 1998), and as a novel retinoid-inducible gene 1 in human gastric cancer cells
(Huang et al., 2000). H-REV107-2/TIG3/RIG1 is a class II tumor suppressor acting as a
growth regulator that mediates some of the growth suppressive effects of retinoids. Analysis
of truncated forms of this protein demonstrated that the C-terminal hydrophobic domain (Fig.
3) has an important role in determining the intracellular localisation. Both the amino- and
carboxy-terminal regions of H-REV107-2/TIG3/RIG1 are required for optimal growth
suppression of cells (Deucher et al., 2000). Recently it has been demonstrated that the H-
REV107-2/TIG3/RIG1 protein induces apoptosis by negatively regulating extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated kinase
(Huang et al., 2002).
Similar to H-REV107-2/TIG3/RIG1, H-REV107-1 belongs to the class II tumor suppressors,
and acts as a negative growth modulator (Husmann et al., 1998) by contributing to IFNγ-
dependent growth arrest and apoptosis in ovarian carcinoma cells (Sers et al., 2002).
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1.3 Purpose of this Work
The H-REV107-1 has been identified as a gene down-regulated in RAS-transformed cells
(Hajnal et al., 1994). And was shown to suppress cellular growth (Hajnal et al., 1994; Sers et
al., 1997). At the begin of this analysis the H-REV107-1 sequence did not provide any clue to
the mechanism of its action. No related proteins were found in the databases at this time.
In view of its down-regulation in tumors and tumor cell lines, and its functioning as a growth
suppressor, it was decided to study the mechanism of the H-REV107-1 – mediated anti-
proliferative effect. To better understand the mechanism of H-REV107-1 cellular function, I
performed a yeast two hybrid screening which resulted in the identification of a number of
potential interacting partners.
Interaction with these candidates was tested in COS-7 cells using co-immunoprecipitation. A
further intention was to determine the H-REV107-1 protein domains responsible for protein-
protein interaction. Most importantly, I aimed to define a role for the identified protein-protein
interactions in the H-REV107-1 mediated growth suppression and apoptosis.
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals
All chemicals used in this work were purchased from Calbiochem, CA, USA; J.T. Baker,
Deventer, Holland; Merck, Darmstadt, Germany; R&D Systems Inc., MN, USA; Serva
Electrophoresis GmbH, Heidelberg, Germany; Sigma-Aldrich Chemie GmbH, Munich,
Germany; Sigma, MS, USA.
MiliQ 18 Ω water was used in all procedures if required.
2.1.2 Kits
QIAprep Spin Miniprep Qiagen GmbH, Hilden, Germany
Annexin-V-FLUOS Staining Kit Roche Diagnostics GmbH, Mannheim, Germany
Anti-HA Sepharose conjugate Sigma, MS, USA
Apoptosis Sampler Kit Cell Signaling Technology, Inc., MA, USA
Bcl-2 Family Antibody Sampler Kit Cell Signaling Technology, Inc., MA, USA
Developer RP X-OMAT EX Eastman Kodak Company, NY, USA
ECL Western Blotting Detection Kit Amersham Biosciences GmbH, Freiburg, Germany
Fast-LinkTM DNA Ligation and
Screening Kit
Biozym Diagnostik GmbH, Oldendorf, Germany
Fixer RP X-OMAT LO Eastman Kodak Company, NY, USA
Immunoprecipitation Kit (Protein G) Roche Diagnostics GmbH, Mannheim, Germany
PhosphoPlus Stat1 Antibody Kit Cell Signaling Technology, Inc., MA, USA
Protease inhibitors Cocktail Roche Diagnostics GmbH, Mannheim, Germany
QIAGEN Plasmid Midi and Maxi Qiagen GmbH, Hilden, Germany
QuikChange Mutagenesis Kit Stratagene, CA, USA
RediPack GST Purification Module Pharmacia Biotech Inc., CA, USA
SequaGel XR National diagnostics, GE, USA
SequiTherm EXCELTM II DNA
Sequencing Kit
Biozym Diagnostik GmbH, Oldendorf, Germany
Ser/Thr Phosphatase Assay Kit 1 Upstate Biotechnology, NY, USA
Western Blot Recycling Kit Alpha Diagnostic International, TX, USA
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2.1.3 Enzymes
Lyticase Sigma-Aldrich Chemie Gmbh, Munich, Germany
Ampli Taq DNA Polymerase Perkin Elmer, MA, USA
Ampli Taq Gold DNA Polymerase Perkin Elmer, MA, USA
Restriction Endonucleases: EcoRI,
BamHI, HindIII, XbaI,
Promega, Mannheim, Germany
2.1.4 Antibodies
Anti-BRCA1 (H-1000) Santa Cruz Biotechnology, Inc., CA, USA
Anti-cleaved caspase-3 Cell Signaling Technology, Inc., MA, USA
Anti-cleaved caspase-9 Cell Signaling Technology, Inc., MA, USA
Anti-GST antibody Cell Signaling Technology, Inc., MA, USA
Anti-HA Sigma, MS, USA
Anti-HA Sepharose Conjugate Sigma, MS, USA
Anti-Histone 3 Cell Signaling Technology, Inc., MA, USA
Anti-H-rev107, rat (08B6) C. Sers, Charité, Berlin, Germany; (Sers et al.,
1997)
Anti-H-REV107-1 (315) C. Sers, Charité, Berlin, Germany; (Sers et al.,
2002)
Anti-IRF1 Santa Cruz Biotechnology, CA, USA
Anti-IRF2 Santa Cruz Biotechnology, CA, USA
Anti-p14.5, G. Schmitz, University of Regensburg, Germany
(Schmiedeknecht et al., 1996)
Anti-p21 Santa Cruz Biotechnology, CA, USA
Anti-pan-actin Chemicon, CA, USA
Anti-PC4 R. Heilbronn, Free University Berlin, Germany
(Weger et al., 1999)
Anti-PR65 (6F9) Covance Research Products Inc., CA, USA
Anti-STAT1 Cell Signaling Technology, Inc., MA, USA
Anti-V5 Invitrogen, CA, USA
peroxidase-conjugate  goat anti-mouse Dianova, Hamburg, Germany
peroxidase-conjugate goat anti-rabbit Cell Signaling Technology, Inc., MA, USA
peroxidase-conjugate goat anti-rabbit Dianova, Hamburg, Germany
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2.1.5 Fluorophore-Labelled Antibodies
AlexaFluor 488 fragment of goat anti-mouse IgG (H+L) MoBiTec, Göttingen, Germany
AlexaFluor 594 fragment of goat anti-mouse IgG (H+L) MoBiTec, Göttingen, Germany
AlexaFluor 546 fragment of goat anti-rabbit IgG (H+L) MoBiTec, Göttingen, Germany
AlexaFluor 594 fragment of goat anti-rabbit IgG (H+L) MoBiTec, Göttingen, Germany
2.1.6 cDNA Library
Pre-made human kidney LexA cDNA library cloned into the pJG4-5 vector containing AD,
and carrying the yeast TRP1 transformation marker for selection in Trp– yeast (Clontech, San
Diego, TX, USA).
2.1.7 Mammalian Cell Lines
A27/80 Human Ovarian carcinoma cell line, European Cell Culture Collection
COS-7 African green monkey kidney fibroblasts, American Type Culture
FE-8 HRAS-transformed derivative of the immortalised non-tumorigenic rat
fibroblasts 208F (Griegel et al., 1986)
FE-8 H-rev107 FE-8 cells harbouring H-rev107 cDNA under tetracycline-inducible
promoter (Sers et al., 1997)
FE-8 pUHD FE-8 cells harbouring an empty vector containing tetracycline-inducible
promoter (Sers et al., 1997)
OVCAR-3 Human Ovarian carcinoma cell line, American Type Culture Collection
2.1.8 E. coli Strains
KC8 pyrF, leuB600, trpC, hisB463 BD Biosciences,
Clontech, CA, USA
XL2-blue recA1 endA1 gyrA96 thi-1 hsdR17 suoE44 relA1 lac
[F’ proAB laclqZ∆M15 Tn10(Tetr) Amy Camr]a
Stratagene, La Jolla,
Canada
Sure 2 e14– (McrA–)∆(mcrCB-hsdSMR-mrr)171 endA1
supE44 gyrA96 thi-1 hsdR17 relA1 lac recB recJ
Stratagene, La Jolla,
Canada
B21 E. coli B F– dem omp T hsdS(rB-mB-) gal Pharmacia Biotech Inc.,
CA, USA
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2.1.9 Yeast Strains (OriGene Technologies, Inc., MD, USA)
EGY48 MATα trp1 his3 ura3 leu2::6 LexAop-LEU2 (high sensitivity)
RFY206 MATa trp1∆::hisG his3∆200 ura3-52 lys2∆201 leu2-3 (mating strain)
2.1.10 Plasmids and Expression Constructs
∆C107-∆N The expression construct was generated by PCR-amplification
of a 375-bp fragment of ∆CH-REV107-1HA, using the ∆N-fw
and ∆N-rv primers, followed by insertion of the PCR-product
into the BamHI sites of a pcDNA3.1 plasmid
∆C107-HWAY The expression construct was generated using the QuikChange
Mutagenesis Kit from the ∆CH-REV107-1HA expression vector,
with the hway-fw and hway-rv primers
∆C107-NCE The expression construct was generated using the QuikChange
Mutagenesis Kit from the ∆CH-REV107-1HA expression vector,
with the nce-fw and nce-rv primers
∆CH-REV107-1HA The ∆CH-REV107-1HA fragment was created by PCR-
amplification of 454-bp of H-REV107-1 cDNA including 49 bp of
5’-untranslated region, and 405 bp of a coding region. The
107HA-fw, and 107HA-rv reverse primer containing sequence
encoding HA-epitope were used. The amplified fragment was
cloned into the BamHI and XbaI sites of a pcDNA3.1 plasmid
107-GST The ∆CH-REV107-1 fragment was obtained from H-REV107-1
expression vector using PCR-amplification with 107-TH-fw and
107-TH-rv primers. PCR product was cloned into the BamHI
sites of a pGE-2TK plasmid
BRCA1 Full length BRCA1 cDNA cloned into pcDNA3.1 expression
vector was kindly provided by T. Ouchi, The Mount Sinai School
of Medicine, NY, USA
EGFP (enhanced green
fluorescent protein)
Clontech, San Diego, TX, USA
H-REV107-1 full length
expression vector
pcDNA3.1 expression plasmid contains the complete open
reading frame, 62 bp of 5’-untranslated region and 174 bp of 3’
untranslated region of the H-REV107-1 cDNA (Husmann et al.,
1998)
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H-REV107-1V5 The expression construct was generated by PCR-amplification
of the full length H-REV107-1 cDNA using 107-HA-fw and 107-
rv primers. The amplified fragment of 415 bp was ligated into
the BamHI sites of a pEF6/V5 vector
pEF6/V5 Invitrogen, CA, USA
p8op-lacZ, URA3, AmpR Clontech, San Diego, TX, USA
PC4-V5 The PC4 expression vector containing PC4 full length cDNA
fused with V5 epitope, was purchased from GeneStorm
Collection (Invitrogen, CA, USA)
PcDNA3.1 Invitrogen, CA, USA
ETF1-HA The ETF1 full length cDNA was PCR-amplified from the yeast
expression cDNA library, using pJG-Hindfw and BCO3-Hindrv
primers. The fragment was ligated into the HindIII sites of a
pcDNA3.1 expression plasmid
p14.5 The p14.5 full length cDNA was PCR-amplified from the yeast
expression cDNA library, using pJG-Hindfw and BCO3-Hindrv
primers. The fragment was ligated into the HindIII sites of a
pcDNA3.1 expression plasmid
PcDNA3.1/GS GeneStorm Collection (Invitrogen, CA, USA)
pEG202, HIS3, AmpR OriGene Technologies Inc, MD, USA
pEG202-107 ∆CH-REV107-1 yeast expression plasmid containing 405 bp of
the human H-REV107-1 cDNA with a deletion of 81 bp
encoding a C-terminal membrane binding domain. The H-
REV107-1 fragment was generated by PCR-amplification of H-
REV107-1 cDNA using 107-TH-fw and 107-TH-rv primers, and
cloned into the BamHI sites of a pEG202 plasmid
pGE-2TK Pharmacia Biotech Inc., CA, USA
pJG4-5, TRP1, AmpR OriGene Technologies Inc, MD, USA
PR65-V5 The PR65-expression vector containing full length PR65α-
encoded cDNA fused with V5 epitope, was purchased from
GeneStorm Collection (Invitrogen, CA, USA)
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RARG-V5 The RARG-expression vector containing full length of RARG
cDNA fused with V5 epitope was purchased from GeneStorm
Collection (Invitrogen, CA, USA)
S100A6HA The S100A6 full length cDNA was PCR-amplified from the
yeast expression cDNA library, using pJG-Bamfw and BCO3-
Xbarv primers. The fragment was ligated into the BamHI and
XbaI sites of a pcDNA3.1 expression plasmid
STAT1 The STAT1-expression vector was kindly provided by S.
Vinkemeier, Institute of Molecular Pharmacology, Berlin,
Germany
2.1.11 Oligonucleotides (MWG-Biotech, Ebersberg, Germany)
Oligonucl. Labelling Sequence
∆N-fw 5’ – CGG GAT CCC GAA GAT GGG AGA CC GAT TGA GAT
TTT TCG – 3’
∆N-rv 5’ – CGG GAT CCC GTT AGG CAT AAT CAG GGA CGT CAT
AAG G – 3’
107HA-fw 5‘ – CGG GAT CCA TGC GTG CGC CCA TTC CAG AG – 3’
107-HA-rv 5’ – TTA GGC ATA ATC AGG GAC GTC ATA AGG ATA AGG
ATA GAT GAT GAC ATC TCT GAC CTG G – 3‘
107-rv 5’ – CGG GAT CCT TAG ATG ATG ACA TCT CTG ACC TGG –
3’
BCO3 IRD800 5’ – GTC AAG TCT CCA ATC AAG GTT – 3’
BCO3-Hindrv 5’ – TCC GAA GTC AAG TCT CCA ATC AAG GTT – 3’
BCO3-Xbarv 5’ – AGA TCT GTC AAG TCT CCA ATC AAG GTT – 3’
BCO5 IRD800 5’ – TAA CGA TAC CAG CCT CTT GC – 3’
BCO5-5 IRD800 5’ – CGA GGA GTG CAA TGC – 3’
hway-fw 5’ – CGC CCT TTC TAC AGA GCC TGG GCC GCC TAT GTT
GTT GGC GAT GG – 3’
hway-rv 5’ – CCA TCG CCA ACA TAG GCG GCC CAG GCT CTG TAG
AAA GGG CG – 3’
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nce-fw 5’ – CCA GTG AGA ACA GCG AGC ACT TTG TGA ATG AGC –
3’
nce-rv 5’ – GCT CAT TCA CAA AGT GCT CGC TGT TCT CAC TGG –
3`
pEF6-rv 5’ – CTA GAA GGC ACA GTC GAG GC – 3’
pGE-fw IRD800 5’ – GGG CTG GCA AGC CAC GTT TGG TG – 3’
pGE-rv IRD800 5’ – CCG GGA GCT GCA TGT GTC AGA GG – 3’
pJG-Bamfw 5’ – CGG GAT CCG AAG ATG GTC TAC CCT TAT GAT GTG
CC – 3’
pJG-Hindfw 5’ – AAG CTT GCC ACC ATG GTC TAC CCT TAT GAT GTG
CCA G – 3’
Sp6 IRD800 5’ – CGA TTT AGG TGA CAC TAT AG – 3’
T3 IRD800 5’ – AAT TAA CCC TCA CTA AAG GG – 3’
T7 IRD800 5’ – TAA TAC GAC TCA CTA TAG GG – 3’
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2.2 Methods
2.2.1 Yeast Two-Hybrid System
2.2.1.1 Yeast Expression Vectors and General Procedure
To identify H-REV107-1 interacting proteins, a LexA-based Yeast Two-Hybrid system was
used. We screened a human kidney cDNA library with a truncated form of the H-REV107-1
protein. For this purpose, a pEG202-107 expression vector was generated. We subcloned
405 bp of human H-REV107-1 cDNA, encoding the H-REV107-1 protein without 27 C-
terminal aminoacids, into the pEG202 yeast expression vector in frame with the DNA-binding
domain (DNA-BD). The pEG202 vector carries a yeast HIS3 marker for selection on HIS–
medium. The DNA-BD was provided by the prokaryotic LexA protein, which normally
functions as a suppressor of SOS genes in E.coli when it binds to LexA operators (Ebina et
al., 1993). A premade cDNA library, purchased from Clontech, contained inserts cloned into
the pJG4-5 vector. This vector carries a yeast TRP1 transformation marker for selection on
the TRP– medium and a transcriptional activation domain under the control of a GAL1
promoter. The transcriptional activation domain (AD) was an 88-residue acidic E.coli peptide
(B42) (Ma and Ptashne, 1987). To activate transcription from the GAL1 promoter,
transformants must be grown in medium containing galactose (Gal) and raffinose (Raf) as
the carbon source. Interaction between a target library-encoded protein fused with the AD,
and H-REV107-1 fused with the DNA-BD resulted in the reconstitution of a novel
transcriptional activator with binding affinity for LexA operators (Gyuris et al., 1993). Two
reporter genes with up-stream LexA operators, the LEU2, integrated in the EGY48 genome,
and the lacZ, located on the p8op-lacZ reporter plasmid, made an interaction phenotypically
detectable. If the proteins did not interact with each other, the reporter genes were not
transcribed (Fig. 4).
The EGY48 yeast host strain was first transformed with the p8op-lacZ reporter plasmid
carrying the lacZ reporter gene and stored in SD/-Ura (Table 2) medium/25% glycerol for
further experiments. These transformants were then used for the co-transformation with
pEG202-107 and pJG4-5 library plasmids. After library transformation, cells were plated on a
minimal synthetic dropout (SD) non-induction medium that selected for both pEG202-107
and the AD/library plasmid, but not for the interaction directly, to maximise plasmid copy
number in each cell. After this step colonies were plated on the SD induction medium lacking
leucine and containing X-gal for detecting protein-protein interactions (Fig. 5). Individual blue
colonies were isolated by restreaking on the same medium  and stored as master plates.
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Fig. 4 Schematic diagram of the LexA Two-Hybrid System (BD Biosciences,
Clontech, CA, USA)
The bait, the H-REV107-1 protein fused to the DNA-BD, and the pray, library
proteins fused to the AD cannot activate transcription of the reporter genes by
themselves. The Interaction between the bait and a pray leads to the close
proximity of the binding and activation domains, and  activation of transcription of
the reporter genes.
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Fig. 5 Screening of a AD fusion library for proteins that interact with H-REV107-1
(BD Biosciences, Clontech, CA, USA)
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Table 2 Generated yeast strains and respective selective media
Plasmids used for the transformation of
the yeast strain EGY48
Media used to select transformants
p8op-lacZ SD/-Ura
pEG202-107 SD/-His
pJG4-5 SD/-Trp
pEG202-107, pJG4-5, p8op-lacZ SD/-His/-Trp/-Ura
Media used to activate reporter genes
EGY48[pEG202-107, pJG4-5, p8op-lacZ] SD/-His/-Leu/-Trp/-Ura to activate the LEU2
reporter gene
EGY48[pEG202-107, pJG4-5, p8op-lacZ] SD/Gal/Raf/-His/-Trp/-Ura/X-gal to activate the
LacZ reporter gene
EGY48[pEG202-107, pJG4-5, p8op-lacZ] SD/Gal/Raf/-His/-Leu/-Trp/-Ura/X-gal to activate
both the LEU2 and lacZ reporter genes
2.2.1.2 Yeast Strain Storage and Culturing
2.2.1.2.1 Storage
To prepare a  yeast glycerol stock, a single colony was scraped from the agar plate. Then
the cells were resuspended in 200–500 µl of YPD medium (or the appropriate SD medium) in
a 1.5-ml microcentrifuge tube. After dispersing the cells by vortexing, sterile 50% glycerol
was added to a final concentration of 25%. The vials were frozen at –70°C. Transformed
yeast strains were stored in the appropriate SD dropout medium to keep selective pressure
on the plasmid.
To recover frozen yeast, a small portion of the frozen glycerol stock was streaked onto a
YPD (or appropriate SD) agar plate. The plate was incubated at 30°C until yeast colonies
reach ~2 mm in diameter (this took 3–5 days). These colonies were used as a working stock.
The plates were sealed with parafilm and stored at 4°C for up to two months.
2.2.1.2.2 Culturing
Fresh (<2-months old) colonies from the working stock plate were used. One large (2–3-mm
diameter) colony or several small colonies were inoculated in 5 ml of medium, and vigorously
vortexed  for ~1 min to disperse the cells. The Suspension was incubated at 30°C for 16–18
hr with shaking at 230–270 rpm. This yielded a stationary phase culture (OD600 > 1.5). To
obtain a mid-log phase culture, the overnight culture was transferred into fresh medium and
incubated at 30°C for 3–5 hr with shaking (230–250 rpm) to produce an OD600 = 0.2–0.3.
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2.2.1.3 Yeast Transformation
2.2.1.3.1 Preparation of Fresh Competent Yeast
Several colonies, 2–3 mm in diameter were inoculated in 1 ml of YPD or SD, and vortexed
vigorously for 5 min to disperse any clumps. Then the cells were transferred into a flask
containing 50 ml of YPD or the appropriate SD medium and incubated at 30°C for 16–18 hr
with shaking at 250 rpm to yield a stationary phase culture (OD600>1.5). 30 ml of this
overnight culture were transferred to a flask containing 300 ml of YPD and incubated at 30°C
for 3 hr with shaking (230 rpm) until the OD600 reached 0.4–0.6.
Cells were placed in 50-ml tubes and centrifuged at 1,000 x g for 5 min at room temperature
(20–21°C). Cell pellets were resuspended in H2O, then pooled into one tube (final volume
25–50 ml) and Centrifuged again at 1,000 x g for 5 min at room temperature. The cell pellet
was resuspended in 1.5 ml of freshly prepared, sterile 1X TE/1X LiAc.
2.2.1.3.2 Transformation
For small scale transformation 0.1 µg of p8op-lacZ plasmid DNA and 0.1 mg of salmon
testes carrier DNA were added to a fresh 1.5-ml tube and mixed.
For simultaneous co-transformation of pEG202-107 and library plasmids a large scale
transformation was performed. The following amounts of DNA were used: 50 µg of pEG202-
107 expression vector, 25 µg of library plasmid, and 2 mg of Salmon testes carrier DNA.
0.1 ml of yeast (1 ml for a large scale transformation) competent cells was added to each
tube containing plasmid and salmon testes DNA and mixed well by vortexing. Then 0.6 ml of
sterile PEG/LiAc solution (6 ml for a large scale transformation) were added to each tube and
vortexed at high speed for 10 sec to mix, and incubated at 30°C for 30 min with shaking at
200 rpm. After the addition of 70 µl of DMSO (700 µl for a large scale transformation) the
culture was mixed by gentle inversion.
A heat shock was performed for 15 min in a 42°C water bath and afterwards cells were
chilled on ice for 1–2 min. Cells were centrifuged for 5 sec at 14,000 x g at room temperature
(5 min 1000 x g for a large scale transformation). The cell pellets were resuspended in 0.5 ml
of sterile 1X TE buffer (5 ml for a large scale transformation). 100 µl of the suspension
(volume plated in large scale transformation) were than plated on SD agar plates 10 x 10 cm
(15 x 15 cm for large scale transformation), that selected for the desired transformants.
For a small-scale transformation with the p8op[lacZ] plasmid only, the transformation was
spread on the SD/-Ura plates. For large scale transformation the yeast suspension was
spread on the SD/-His/-Trp/-Ura plates. Additionally, 100 µl of a 1:1000, 1:100, and 1:10
dilution were plated on 10 x 10 cm SD agar plates.
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These plates were used as controls for transformation efficiency. Plates were incubated up-
side-down, at 30°C until colonies appeared (2–4 days). To calculate the co-transformation
efficiency, the colonies (cfu) growing on the dilution plate were counted (optimal 30-300
colonies on the plate with the dilution 1:100).
cfu x total suspension vol. (µl)   /  Vol. plated (µl) x dilution factor x amount of used DNA (µg)*
= cfu/ /µg DNA
Sample calculation:
100 colonies grew on the 1:100 dilution plate (dilution factor = 0.01);
plating volume: 100 µl ; resuspension volume = 0.5 ml; amount of limiting plasmid = 0.1 µg
100 cfu x 0.5 ml x 103 µl/ml   /   (100 µl x 0.01 x 0.1 µg) = 5 x 105 cfu/µg
If a small scale transformation was performed, for example to create an EGY48[p8op-lacZ]
yeast strain, the largest colonies grown after transformation were picked and restreaked on
the same selection medium for master plates. Then they were sealed with parafilm and
stored at 4°C for 3–4 weeks. Alternatively they were stored at -70°C in SD/-Ura/25% glycerol.
If large scale transformation was performed the transformants were harvested as follows:
Plates were placed at 4°C for 3-4 hours to harden. Then 1 ml TE buffer was added to the
surface of each plate. Colonies were scraped into the liquid using a sterile Pasteur pipette.
All liquids were combined into a single sterile 50-ml tube and vortexed to resuspend the cells.
A Glycerol stock of the amplified yeast library was created by adding an equal volume of
sterile 65% glycerol/MgSO4 solution. This stock can be stored at 4°C for one week or at -
70°C up to 1 year.
2.2.1.4 β-Galactosidase Assay
To screen transformants for expression of a lacZ reporter, β-galactosidase assay was
performed. We used two different methods: an in vivo assay and a colony-lift filter assay.
2.2.1.4.1 In Vivo Plate Assay Using X-gal – Containing Medium
Colonies from the master plates were replica plated on selection medium containing X-gal
and BU salts, and incubated at 30°C for 4 days. Plates were checked every 12 hr (up to 96
hr) for the development of blue colour.
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2.2.1.4.2 Colony-Lift Filter Assay
In this assay fresh colonies (i.e., grown at 30°C for 2–4 days), 1–3 mm in diameter were
used. A sterile Whatman filter was placed onto the surface of the plate, and gently rubbed, to
improve attachment of the colonies to the filter. Three holes were poked through the filter in
an asymmetric way to mark the orientation of the filter on the agar plate. When the filter was
evenly wetted, it was carefully lifted off the agar plate with forceps and transferred (colonies
facing up) to a pool of liquid nitrogen. Using the forceps, the filter was completely submerged
for 10 sec. After the filter was frozen completely (~10 sec), it was removed from the liquid
nitrogen and left to thaw at room temperature.
For each plate of transformants to be assayed, a fresh sterile Whatman filter was pre-soaked
by placing it in 2.5–5 ml of Z buffer/X-gal solution in a clean 15 x 15 cm plate. (Avoid trapping
air bubbles under or between the filters).
Then the first filter was carefully placed, colony side up, onto the pre-soaked filter to allow the
X-Gal solution to get into contact with the colonies. The appearance of blue colonies was
checked periodically.
The ß-galactosidase-producing colonies were identified by aligning the filter to the agar plate
using the orientation marks. Corresponding positive colonies were picked from the original
plates to fresh medium and incubated for 1–2 days to re-grow the colony.
2.2.1.5 Secondary Test of Positives Colonies
Positive colonies were re-tested at least once on the SD/-His/-Trp/-Ura plates. After
incubation at 30°C for 4-6 days, colonies were replica plated on the SD/Gal/Raf/-His/-Leu/-
Trp/-Ura induction medium to verify that they maintained the correct phenotype. Restreaked
and re-tested colonies were collected on SD/-His/-Trp/-Ura plates, incubated at 30°C for 4-6
days. After colonies have grown, the plates were sealed with Parafilm and stored at 4°C for
up to 4 weeks. For long term storage, a glycerol stock was prepared.
Recipes for Solutions and Buffers
YPD (rich medium), pH 5.8
20 g/l Tryptone
10 g/l Yeast extract
20 g/l Agar (for plates only)
20 g/l Glucose
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SD-ura-his-leu-trp (selective medium)
6.7 g/l Yeast nitrogen base w/o amino acids
20 g/l Agar (for plates only)
0.6 g/l -his-ura-trp-leu dropout mix
20 g/l Galactose
20 g/l Raffinose
20 g/l Agar (for plates only)
80 mg/l X-Gal
100 ml/l 10 x BU salts
All media were sterilised by autoclaving 120°C 20 min. The galactose, raffinose, X-Gal, and
10 x BU salts solutions were filter sterilised and added after autoclaving.
10 x BU salts (100 ml), pH 7.0
7 g Sodium phosphate (dibasic)
3 g Sodium phosphate (monobasic)
To prepare other SD selective media, for example lacking one of the aminoacid, following
stock solutions were used:
Trp 10 ml of 4 mg/ml stock per litter of medium (0,04 mg/ml final concentration)
Ura 5 ml of 4 mg/ml stock per litter of medium (0,02 mg/ml final concentration)
Leu 15 ml 4 mg/ml stock per litter of medium (0,06 mg/ml final concentration)
His 5 ml of 4 mg/ml stock per litter of medium (0,02 mg/ml final concentration)
Salmon testes carrier DNA
Salmon testes carrier DNA (sodium salt) was dissolved in water (10 mg/ml), and the solution
was stirred on a magnetic stirrer for 2-4 hours at the room temperature. Then the solution
was extracted with phenol and with phenol : chloroform (1:1). The aqua phase was
transferred into a new tube and sheared by passing 12 times rapidly through a 17-gauge
hypodermic needle. The DNA was precipitated by adding 2 volumes of ice-cold ethanol.
DNA was recovered by centrifugation, and re-dissolved at a concentration of 10 mg/ml in
water, boiled and stored in small aliquots at –20°C. Just before use, the solution was heated
for 5 minutes in a  boiling water bath and quickly chilled on ice.
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PEG/LiAc solution
Final Conc. 10 ml solution
PEG 4000 40% 8 ml 50% PEG
TE buffer 1X 1 ml 10X TE
LiAc 1X 1 ml of 10X LiAc
Z buffer  (pH 7.0), sterilised by autoclaving
16.1 g/l Sodium phosphate (dibasic)
5.50 g/l Sodium phosphate (monobasic)
0.75 g/l Potassium chloride
0.25 g/l Magnesium sulphate
Stock solutions:
50% PEG3350 prepared with H2O
10 x TE: 0,1M Tris-HCl, 10 mM EDTA, pH 7.5, autoclaved
10 x LiAc: 1M lithium acetate (pH 7.5 , adjusted with acetic acid), autoclaved
65% glycerol/MgSO4 solution (sterilised by autoclaving)
Final Conc.
Glycerol 65% v/v
MgSO4 100 mM
Tris-HCl, pH 8.0 25 mM
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) was dissolved in DMF (N,N-
dimethyformamide) at a concentration of 20 mg/ml and stored in the dark at – 20°C.
2.2.1.6 Mating Test
To test positive clones isolated in a library screening for interaction with  H-REV107-1 a,
mating assay was performed. Two yeast strains of opposite mating type, EGY48 – MATa,
and RFY206 – MATα were used. Mating occurred when the haploid cells of opposite mating
type came into a contact and  fused  into a diploid  yeast strain.
The EGY48 cells were transformed with the p8opLacZ plasmid and with either the pJG4-5
vector without insert or with the pJG4-5 vector containing candidate inserts chosen after
sequencing analysis. Transformants were selected on the SD/-Trp/-Ura plates. The RFY206
cells were transformed with pEG202 or pEG202-107. Transformants were selected on the
SD/-His plates. Then the two strains were mixed on  SD/-His/-Trp/-Ura/-Leu/X-gal plates,
where they formed diploid cells in which H-REV107-1 and one of the potential interacting
partners have the opportunity to interact and to activate the reporter genes.
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For each candidate of the library plasmid the follow matings were done:
Plasmid in EGY48 Plasmid in RFY206 LacZ phenotype for a
true positive
Leu2 phenotype for a
true positive
pJG4-5 without
insert
pEG202 without
insert
White no growth
pJG4-5 with library
insert
pEG202 without
insert
white no growth
pJG4-5 with library
insert
pEG202-107 Blue growth of colonies
pJG4-5 with insert pEG202-107 White no growth
Mating procedure:
One colony (2-3 mm) of each type used for the mating analysis was picked and placed
together in a 1.5-ml microcentrifuge tube containing 0.5 ml of YPD medium, vortexed and
incubated at 30°C with shaking at 250 rpm overnight. An aliquot (20µl) of the mating culture
was spread on 100-mm, SD/-His/-Trp/-Ura plates and incubated at 30°C for 3-5 days to allow
diploid colonies to form visible colonies. Then the diploid transformants were replica plated
on the SD/Gal/Raf/-His/-Leu/-Trp/-Ura induction plates to assay for LEU2 an LacZ
expression. True positives were those library clones which exhibited activation of the reporter
gene expression only in presence of pEG202-107 plasmid.
2.2.1.7 Yeast Plasmid Isolation
A large (2-4 mm) fresh (2-4-day old) yeast colony was inoculated into 0,5 ml of the
appropriate SD liquid medium and vortexed vigorously to resuspend the cells. The culture
was incubated at 30°C overnight with shaking at 230-250 rpm. Then cells were spun down
by centrifugation at 14,000 x g for 5 min, the supernatant was poured off and pellets were
resuspend in the residual liquid (total volume ~ 50 µl) by vortexing or pipetting up and down.
10 µl of lyticase (5 units/µl in TE buffer) was added to each tube, and cells were thoroughly
resuspended by vortexing or pipetting up and down. Tubes were incubated at 37°C for 30-60
min with shaking at 200-250 rpm. Then 10 µl of 20% SDS was added to each tube, and
vortexed for 1 min to mix. All samples were incubated for 15 min at –20°C, than thawed and
vortexed again to ensure complete lysis of the cells. (If necessary, samples were stored
frozen at –20°C). The volume of each sample was brought up to 200 µl in TE buffer (pH 7.0).
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Then 200µl of phenol : chloroform : isoamyl alcohol (25:24:1) was added and vortexed for 5
min. After centrifugation at 14,000 x g for 10 min, the upper phase was transferred to a fresh
tube, 8 µl of 10 M ammonium acetate and 500 µl of 95-100% Ethanol were added. The
solution was mixed carefully and placed at –70°C for 1 hour. Afterwards the tubes were
centrifuged at 14,000 x g for 10 min. The supernatant was discarded, the pellet was dried
and resuspend in 20 µl of H2O. This solution was used for transformation into competent
E.coli KC8.
2.2.1.8 Preparation of Electrocompetent E. coli KC8
To prepare electrocompetent E. coli KC8 cells 1l of a 2x YT medium was inoculated with 100
ml of a fresh overnight culture, and incubated at 37°C with shaking until the OD600 reached
0.5–0.7. Then the flask was chilled for 15-30 min on ice, and centrifuged at 3,000 x g for 10
min in a pre-chilled rotor. The cells were washed in half of the original volume of sterile ice
cold 1 mM Hepes pH 7.0, then spun down by  centrifugation at 3,000 x g for 10 min in a pre-
chilled rotor, and washed a second time with 50 ml of sterile ice cold water. The cells were
centrifuged, and the pellet was resuspended in 2 ml of sterile ice cold water. The prepared
cells were used directly for electroporation.
2.2.1.9 Transformation of the  Electrocompetent E. coli KC8 with Yeast Plasmids
To transform E. coli KC8 with yeast plasmids, 40 µl of electrocompetent cells were mixed
with 3 µl of yeast plasmid DNA, and transferred into a pre-chilled micro-electroporation
chamber. For electroshock the following conditions were used: 1700 Volts, 200 Ohms, pulse
control units were set to 25 µF. Directly after the shock, 1 ml of freshly prepared SOC
medium was added to every sample and incubated with shaking for 1 hour at 37°C. Then
200 µl bacterial culture from every transformation were plated on M9 Agar plates to select
transformants containing a yeast library plasmid.
2 x YT medium
16 g/l bacto-tryptone
10 g/l bacto-yeast extract
5 g/l NaCl
pH was adjusted to 7.0 and sterilised by autoclaving
SOC medium
20 g/l bacto-trypton
5 g/l bacto-yeast extract
0.58 g/l NaCl
0.19 g/l KCl
pH was adjusted to 7.0 with NaOH, and sterilised by autoclaving. Then 1 ml of 2 M Mg2+
stock and 1 ml of 2 M Glucose was added to 98 ml of autoclaved medium.
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Stock solutions
2 M Mg2+ stock (for 100 ml solution): 
20.33 g MgCl2 6H2O
24.65 g MgSO4 7H2O
H2O was added to 100 ml and autoclaved.
2 M Glucose : 36.04 g of glucose was diluted in 100 ml of H2O and filter sterilised.
M9 minimal medium
200 ml 5 x M9 salts
2 ml 1M MgSO4
20 ml 20% glucose
0.1 ml 1M CaCl2
20 g/l agarose (for plates only)
The medium was sterilised by autoclaving for 15 min at 120°C, and cooled down to 50°C.
Then the following components were added per 1 l of the M9 medium:
1 ml ampicillin 50 mg/ml
1 ml thiamine-HCl solution
100 ml 10 x /-Trp supplement dropout (SD)
5 x M9 salts stock solution
64 g/l NaH2PO4 7H2O
15 g/l KH2PO4
2.5 g/l NaCl
5.0 g/l NH4Cl
2.2.1.10 Yeast Protein Isolation
For each clone to be assayed 5 ml of overnight culture were prepared in the appropriate SD
selection medium. As a negative control untransformed yeast was cultured in 5 ml of YPD
medium. The overnight cultures were inoculated in 50 ml of YPD medium and incubated at
30°C with shaking at 250 rpm until OD600 reached 0.4-0.6 (4-8 hours).
Each culture was chilled by pouring it into a pre-chilled 100-ml tube halfway filled with ice,
and centrifuged for 5 min at 1000 x g by 4°C. The supernatant was poured off, and pellets
were resuspend in 50 ml of ice-cold water. Cells were again centrifuged for 5 min at 1000 x g
by 4°C, and frozen immediately by placing them in liquid nitrogen or dry ice. The cells where
either   be stored at -70°C, or  used directly for further preparation.
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The cell pellets were thawed and resuspend in 100 µl of pre-warmed (60°C) cracking buffer.
Because PMSF degrades rapidly, every 7 minutes 1 µl of 100 mM PMSF was added to each
sample. The suspensions were transferred into 1,5-ml microcentrifuge tubes containing 80 µl
of glass beads. Then the samples were heated for 10 min at 70°C, vortexed vigorously for 1
min, and centrifuged for 5 min at 14,000 x g by 4°C.
Supernatants were saved on ice (supernatant I), the pellets were incubated for 3-5 min at
100°C, vortexed, and centrifuged again. The supernatant II was combined with supernatant I
of each sample. Proteins were boiled for 1 minute and immediately loaded on a SDS-PAGE.
Alternatively proteins were stored at -70°C.
PMSF 100 mM stock solution
0.17 g of PMSF was dissolved in 10 ml isopropanol
Protease inhibitor solution (688 µl were prepared freshly before use)
Inhibitor Stock solution Final concentration
Pepstatin A 66 µl of 1 mg/ml stock solution 0.1 mg/ml
Leupeptin 2 µl of 10,5 mM stock solution 0.03 mM
Benzamidine 500 µl of 200 mM stock solution 145 mM
Aprotinin 120 µl of 2.1 mg/ml stock solution 0.37 mg/ml
Cracking buffer stock solution (100 ml)
48 g Urea 8M
5 g SDS 5% v/v
40 mg Bromphenol blue 0.4 mg/ml
4 ml 1M Tris-HCl, pH 6.8 40 mM
20 µl 0.5 M EDTA 0.1 mM
Cracking buffer complete (prepared before use)
1 ml Cracking buffer stock solution
10 µl β-mercaptoethanol
70 µl Protease inhibitor solution
50 µl PMSF stock solution
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2.2.2 Bacterial Culture
2.2.2.1 Routine Culturing and Storage Conditions
The E. coli cultures were routinely grown at 37°C on Luria-Bertani (LB) agar or in LB broth,
containing Ampicillin (75 µg/ml), Kanamycin (30 µg/ml), or Zeocine (25 µg/ml).
For long-term storage, a fresh overnight culture was prepared: bacteria were streaked onto
an agar plate of the respective selective medium, and incubated at 37°C overnight. Several
colonies were transferred separately into a 10 ml? Falcon tube containing 2 ml liquid media,
and incubated for 14-16 hours at 37°C with shaking at 180-200 rpm. Then 800 µl of bacterial
culture were transferred into the storage tube and sterile glycerol was added to a final
concentration of 20%. The vials were snap-frozen in liquid nitrogen, and stored at –70°C until
use. To recover a bacteria culture, a small proportion of the frozen glycerol stock was
streaked onto an LB agar plate, containing the appropriate antibiotic.
The plate was incubated overnight at 37°C. These colonies were used as a working stock.
The plates were sealed with parafilm and stored at 4°C for up to four weeks. Alternatively a
small portion of the frozen glycerol stock was transferred in 2 ml of LB broth containing the
appropriate antibiotic, and incubated overnight at 37°C with shaking at 180-200 rpm.
LB Broth (Agar)
10 g/l NaCl
10 g/l Tryptone
5 g/l yeast extract
20 g/l agar (for plates only)
pH was adjusted to 7.0 with NaOH and H2O was added to a final volume of 1 litter.
To  prepare agar plates, the LB agar was cooled to 50°C, appropriate antibiotics were added
and petri dishes were poured (~15 ml/100-mm plate).  If a β-galactosidase assay was done,
LB agar plates were prepared with 80 µg/ml X-gal (5-bromo, 4-chloro-3-indol-β-D-
galactopyranisode), and 20 mM IPTG (isopropyl-l-thio-β-D-galactopyranoside). IPTG was
prepared in sterile water, and X-gal in dimethylformamide (DMF).
2.2.2.2 Transformation
Competent E. coli XL2-blue or Sure2 were purchased from Stratagene. Transformation was
performed according to the protocol supplied by the manufacturer. Competent cells were
thawed on ice and mixed gently. For each transformation, 100 µl of the cells were transferred
into a microcentrifuge tube and 2 µl of β-mercaptoethanol were  added. After incubation on
ice for 10 min, 10 ng of plasmid DNA were added, swirled gently and incubated on ice for 30
min.
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NZY+ broth was pre-heated to a 42°C. Tubes with bacteria were heat-pulsed in a 42°C water
bath for 30 seconds. Then the tubes were incubated on ice for 2 min, 900 µl of the pre-
heated NZY+ broth were added to every tube and incubated at 37°C for 1 hour with shaking
at 225-250 rpm. 100 µl of each transformation mixture was plated on the appropriate plates
using a sterile spreader and incubated overnight at 37°C.
2.2.2.3 Mini-Preparation of Plasmid DNA
For mini-preparation of plasmid DNA from bacteria a QIAprep Spin Miniprep Kit from Qiagen
was used. For isolation of ~10 µg of plasmid DNA, 2 ml overnight culture of E. coli in LB
medium was prepared. Plasmid DNA was isolated according to the manufacturer’s
recommendations. DNA was eluted in 30 µl of the EB buffer (10 mM Tris-HCl, pH 8.5) and
stored at -20°C.
2.2.2.4 Large-Scale Preparation of Plasmid DNA
For a large-scale plasmid isolation a QIAGEN Plasmid Midi and Maxi Kit was used. Plasmid
DNA was isolated according to the supplier’s manual, a 200 ml E.coli overnight culture was
prepared for each experiment. An additional purification step was included in the protocol.
The pellet, resuspended in 400 µl of EB buffer was precipitated with 0,7 volumes of 4 M
NaAc and 2,5 volumes of ethanol, and incubated for 1 hour at –70°C.
Then the solution was centrifuged at 14,000 x g for 30 min at 4°C, the pellet was washed
with 1 ml ice-cold 70% ethanol, and centrifuged a second time at 14,000 x g for 5 min at 4°C,
dried and resuspend in 200 µl of  EB buffer.
2.2.2.5 Measurement of DNA Concentration
Concentration of DNA was measured using a UV-Spectrophotometer (Hitachi) by  the wave
length of 260 nm. The Amount of DNA was calculated regarding that OD260 = 1 corresponds
to 50 µg/ml double-stranded DNA.
2.2.3 Enzymatic Manipulation and Analysis of DNA
2.2.3.1 Digestion of DNA with Restriction Endonucleases
Digestion of DNA with restriction endonucleases was performed according to the
recommendations of the manufacturer. For the digestion of 5-10 µg of DNA, 10U of enzyme
were added with an appropriate buffer to the DNA in a final volume of 15 ul.  Reactions were
incubated for 2 hours if PCR-fragments were digested, or 4-6 hours if plasmid DNA was
digested.
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2.2.3.2 DNA Ligation
For the ligation of cDNA fragments into plasmid vectors, a Fast-Link DNA Ligation and
Screening Kit purchased from Biozym was used. Experiments were performed according to a
protocol by the supplier. For ligations, 200 ng of a digested plasmid DNA were used. The
amount of insert was calculated according to a molar ration 3:1 (insert : vector). The
reactions were incubated for 1 hour at room temperature. To inactivate the Fast-Link Ligase
the reaction was transferred to 70°C for 15 min. To determine  the efficiency  of ligation, 5 µl
of the reaction mix were run on an agarose gel and visualised with ethidium bromide. If the
ligation was successful, 1-5 µl of the reaction mix was used for transformation of E.coli.
2.2.3.3 Vector Dephosphorylation
Prior to ligation of a digested plasmid DNA with an insert, the protruding 5’-end of the vector
was dephosphorylated  using a HK Thermolabile Phosphatase (Biozym). The reaction was
performed according to the recommendations of the supplier. For dephosphorylation of 10 µg
plasmid DNA 10 units of the phosphatase were used.
Digestion proceeded for 2 hours at 30°C, then the phosphatase was deactivated at 65°C for
15 min.
2.2.3.4  Polymerase Chain Reaction (PCR)
The PCR reactions were performed in a PCR Thermal Cycler (Techne). Amplification of DNA
was performed according to the following protocol:
Template DNA 20,0 ng
10 x PCR buffer (including 15 mM MgCl2) 2.50 µl
dNTP (each 10 nM) 0.25 µl
5’- and 3’ – oligonucleotide primers 1.00 µl (each)
H20 filled up to 24.0 µl
AmpliTaq Gold (1U) 0.25 µl
The Following program was used to amplify inserts:
Activation of the AmpliTaq polymerase 95°C 12 min
Denaturation of double stranded DNA 95°C 30 sec
Annealing of oligonucleotides to the template DNA Tan 30 sec 30 cycles
Elongation 72°C 60 sec
Extension 72°C 5 min
Chilling 4°C 1 hour up to overnight.
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Annealing temperatures were calculated using further formula: Tan = Tm - 4°C,
where Tm is the melting temperature of the primers used for amplification . Tm of each
oligonucleotide primer was calculated: Tm = 4 x (G + C) + 2 x (A + T), where G – guanine, C
– cytosine, T – thymine, A – adenine.
2.2.3.5 Purification of PCR-Amplified Fragments of DNA
For purification of PCR-amplified DNA fragments a QIAquick PCR Purification kit from
Qiagen was used. The purification was performed according to the supplier’s protocol.
Purified PCR fragments were controlled using agarose gel electrophoresis.
2.2.3.6 Site-Directed Mutagenesis
To generate the ∆C107-NCE and ∆C107-HWAY mutants of the H-REV107-1 protein,  in vitro
site-directed mutagenesis was performed using a QuikChange Site-Directed Mutagenesis Kit
(Stratagene). The basic procedure utilised the ∆CH-REV107-1HA-expression plasmid and
two oligonucleotide primers (sense and antisense) harbouring the desired mutations.
The primers were annealed to the denatured template DNA (∆CH-REV107-1HA-expression
plasmid ) and subsequently extended during temperature cycling using a PfuTurbo DNA
polymerase. The incorporation of the primer sequence  resulted in the generation of a single
stranded, mutated plasmid containing a staggered nick. To digest the parental DNA
template, the Dpn I endonuclease, specific for methylated and hemimethylated DNA, was
used. Afterwards, the doublestranded plasmid containing the mutated base pairs was
transformed into competent bacteria and amplified.
Two mutated H-REV107-1 proteins were generated. The first contained the His/Ala
exchange at position 23 (the ∆C107-HWAY mutant), the second contained the Cys/Ser
exchange at position 112 (the ∆C107-NCE mutant). For each mutagenesis a primer pair
(sense and antisense) of 30-35 bp was used. For the His/Ala exchange, primer pair 1
contained mutated nucleotides G and C (wild type C and A, respectively). For the Cys/Ser
exchange, primer pair 2 contained mutated nucleotide A (wild type T).
1sense (His/Ala) 5’ – CCT TTC TAC AGA G/CC/AC TGG GCC ATC TAT GTT GGC – 3’
1antisense (His/Ala) 5’ – GCC AAC ATA GAT GGC CCA GG/TC/G TCT GTA GAA AGG –3’
2sense (Cys/Ser)5’ – CCA GTG AGA ACA/T GCG AGC ACT TTG TGA ATG AGC – 3’
2antisense (Cys/Ser) 5’ – GCT CAT TCA CAA AGT GCT CGC T/AGT TCT CAC TGG – 3’
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The reaction was set the following way
5 µl – 10 x reaction buffer
1 µl – template DNA (10 ng)
1 µl – oligonucleotide primer 1ps/2ps (125 µg)
1 µl – oligonucleotide primer 1ns/2ns (125 µg)
1 µl – dNTP mix
H20 filled to 50 µl; Then 1 µl of PfuTurbo DNA polymerase (2.5 U/µl) was added.
Cycling parameters:
Activation of the PfuTurbo DNA polymerase 95°C 30 sec
Denaturation of double stranded DNA 95°C 30 sec
Annealing of oligonucleotides to the template DNA 55°C 60 sec 16 cycles
Elongation 68°C 12 min
Chilling 4°C 1 hour up to overnight
Amplification was checked by electrophoresis of 10 µl of the product on a 1% agarose gel. If
a band was visible on the gel, a digestion with the Dpn I restriction enzyme was performed to
digest the parental non-mutated supercoiled double stranded DNA. 1 µl of the enzyme was
directly added to each amplification reaction and incubated for 1 hour at 37°C.
 For  transformation of the amplified, mutated cDNA, 1 µl of the reaction mix was used.
Several colonies were selected for plasmid preparation and sequencing analysis to control
that selected cloned contained the desired mutations.
2.2.3.7 Sequencing
Sequencing analysis was performed on a LI-COR automated DNA sequencer using
fluorescent primers labelled with the tricarbocyanine dye IRD800 at their 5’-end.
Gel components were pre-mixed the following way
30 ml Sequagel XR (Biozym)
7.5 ml Sequagel buffer (Biozym)
400 µl DMSO
300 µl 10% APS
and polymerised for 45 min.
Cycle sequencing reactions were done using a SequiTherm ExcelTM II DNA Sequencing Kit-
LC (Biozym) according to a protocol of the supplier:
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The reactions were pre-mixed in the following way
2 µl 2 pmol IRD800-labelled primer
100-250 fmol DNA template
7.2 µl 3.5X SequiTherm EXCEL II Sequencing Buffer
1 µl  SequiTherm EXCEL II DNA Polymerase (5 U/µl)
H20 filled to 17 µl of a total reaction volume
The pre-mix was distributed in four tubes, 4 µl in each, 2 µl of the SequiTherm EXCEL II-LC
Termination Mix A/C/G/T was added to each tube.
The following parameter were used for a cycle-sequencing:
30 sec  95oC
15 sec  Tan 30 cycles
1 min 70oC
Each reaction was stopped with 3 µl of a Stop/Loading Buffer. Samples were then analysed
by electrophoresis or stored at -20oC. The annealing temperature of the primers was used
equal to their melting temperature, and calculated as described in 2.2.3.5.
The reaction tubes were heated for 3-5 minutes at ≥ 70°C to denature the samples, and
chilled on ice. Then 1,2 µl/well were loaded onto a sequencing gel, and run for 5-6 hours.
Results were analysed using a Datalogger user program (LI-COR).
2.2.3.8 Electrophoretic Separation of DNA
Gel electrophoretic separation of DNA was performed in 1,0 – 1,5% agarose gels run at 30-
50V with 1 x TBE as a running buffer. Gels contained 0,2 µg/ml ethidiumbromid, samples
were run with 6 x Blue Loading Dye (Promega).
10 x TBE
108 g/l Tris Base
55 g/l Boric Acid
20 ml/l 0.5M EDTA
2.2.3.9  Elution of DNA Fragments from a Gel
To elute DNA fragments from a gel, a QIAquick Gel Extraction-Kit (QIAGEN) was used. The
DNA fragments were cut from the gel on UV-light, and handled as recommended by the
supplier. DNA was eluted in 30 µl of elution buffer.
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2.2.4 Culturing of Mammalian Cells
2.2.4.1 Routine Culturing
All mammalian cell lines were maintained at 37°C and 95% humidity in the presence of 5%
CO2. Human epithelial ovarian carcinoma cell lines A27/80 and OVCAR-3, African green
monkey kidney fibroblasts COS-7, and FE-8 cells (HRAS-transformed derivative of 208F rat
fibroblasts described by (Griegel et al., 1986), were cultivated in Dulbecco’s modified Eagles
Medium (DMEM) supplemented with 10% fetal calf serum and 2 mM glutamine. Tet-inducible
FE-8 transformants (Sers et al., 1997) were cultured in DMEM medium supplemented with
10% tetracycline-free fetal calf serum and 2 mM glutamine either in the presence or in the
absence of 2 µg/ml doxycycline.
For sub-culturing of the cells, the medium was removed, and the cells were rinsed with 1 x
PBS buffer. Then the buffer was removed and 2 ml of trypsin-EDTA solution was added per
75 cm2 culture flask. The flask was incubated for a few minutes at 37°C until the cells
detached. 8 ml of a  fresh culture medium was added, aspirated and dispensed into new
culture flasks. Split ratio: 1:10  for A27/80, COS-7, FE-8, and OVCAR-3 cells, and 1:2 for the
Tet-inducible FE-8 cells. Fresh medium was added every 2 to 3 days.
Trypsin-EDTA 10 x stock solution (Biochrom AG) contained  0,5 % Trypsin and 0,2 % EDTA.
For use in  cell culture the solution was diluted 1:10 with PBS, filter-sterilised, and frozen at -
20°C in 80 ml aliquots. Before use, an aliquot was thawed in a water bath at 37°C and used
as described above.
PBS 10 x stock solution (pH 7.2)
2,3 g/l NaH2PO4
11,5 g/l Na2HPO4
87,5 g/l NaCl
2.2.4.2 Freezing and Thawing Procedure
Cells were allowed to grow until they were 70% confluent, then medium was removed, and
the cells were rinsed with 1 x PBS buffer, and 2 ml of trypsin-EDTA solution was added per
75 cm2 culture flask. The flask was incubated for a few minutes at 37°C until the cells
detached,  then they were transferred into a 15 ml Falcon tube and centrifuged at 800 x g for
3 min at 25°C. The cell pellet was resuspended in 900 µl of culture medium, and 100 µl of
DMSO was added, mixed carefully and transferred into a cryo-tube and placed into a cryo-
container with fresh isopropanol. The cells were kept at –70ºC for 24 hours to allow them to
freeze slowly. After this time, they were stored in liquid nitrogen.
41
Thawing of cells was performed quickly. Frozen cells were thawed in a 37ºC water bath for 1-
2 minutes and transferred immediately in a 15 ml Falcon tube. Ten ml of pre-warmed culture
medium were added drop-wise and cells were resuspended. Then the tube was centrifuged
at 800 x g for 3 min at 25°C to remove DMSO. The cell pellet was resuspended in 10 ml of
fresh medium, transferred into a 75 cm2 culture flask, and cultured as described above.
2.2.4.3 Cell Treatments
OVCAR-3 cells were allowed to grow in their culture medium until they were 70% confluent.
Stock solutions of 100 nM OA, and 500 µM LY294002 were prepared in DMSO. The cells
were treated with 0,5 nM and 10 nM OA, and 50 µM LY294002, respectively for 48 hours in
their culture medium. Cells were treated for 1 hour with 2 nM OA for the phosphatase assay.
Control plates were treated with the vehicle, DMSO.
2.2.4.4 Transfection of Mammalian Cells
COS-7 and OVCAR-3 cells were transfected using FuGENE 6 transfection reagent (Roche)
according to a protocol of the supplier. For transfection in 6-well plates 5 x 104 cells were
seeded. Twenty four hours later, cells were transfected with 0,5 µg plasmid DNA and 1.2 µl
FuGENE reagent per well. For transfection in 10 mm dishes 3 x 105 cells were seeded and
cultured for 24 hours, then transfected with 3 µg of total plasmid DNAs and 7 µl FuGENE
reagent.
To control the transfection efficiency, cells were transfected with an EGFP plasmid
(enhanced green fluorescent protein; Clontech) and viewed on UV light 48 hours after
transfection. The number of green fluorescent cells was visually estimated.
2.2.4.5 Colonie Formation Assay
The colony formation assays, was performed by Jacqueline Hellwig (Institute of Pathology,
Berlin, Germany) as described by Sers et al., (2002). Shortly, 2x105 cells per well of a 6 well
plate were transfected with 1.5 µg plasmid DNA using FuGENE 6 transfection reagent
(Roche). Forty-eight hours post transfection, G418 was added at 0.6 mg/ml to the culture
medium. Selection was continued for 10 to 14 days until colonies were visible. Colonies were
fixed in methanol, stained in methylen blue and counted.
2.2.5 Apoptosis Assays
We used two different assays to measure apoptosis. One assay was based on the altered
nuclear morphology visible in apoptotic cells, the second assay measured the expression of
Annexin V on the outer cellular membrane during apoptosis.
2.2.5.1 DAPI-Staining of Apoptotic Nuclei
For immunofluorescence cells were grown on the glass coverslips. After fixation with 3%
paraformaldehyde in 1 x PBS for 20 min.
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Cells were permeabilised using 0.2% Triton X-100 in 1 x PBS for 1.5 min. Coverslips were
incubated with 100 ng/ml DAPI in 1 x PBS/1% BSA for 30 min, washed 3 times with 1 x PBS
and mounted with 2.3% DABCO.
The cells were viewed using a confocal microscope TCS (Leica), and photographed. A
number of cells exhibiting a nuclear morphology characteristic for apoptosis was calculated.
PBS 10 x stock solution (pH 7.2)
2.3 g/l NaH2PO4
11.5 g/l Na2HPO4
87.5 g/l NaCl
DAPI (4',6'-diamidino-2-phenylindole hydrochloride) stock solution
100 µg/ml diluted in sterile H2O and stored at -20°C.
DABCO (1,4 – 1,4-Diazabicyclo (2,2,2)-octane) solution
2.3% w/v DABCO diluted in Glycerol/0,2 M Tris pH 8.0, ratio 9:1.
2.2.5.2 Flow Cytometric Analysis of Annexin V
OVCAR-3 cells were harvested 48 and 72 hours after incubation with 10 nM OA or the
vehicle DMSO by trypsin-EDTA treatment and washed twice with ice-cold PBS. Apoptotic
cells were detected using an Annexin-V-FLUOS Staining Kit (Roche) based on the dual
staining technique with Annexin V, specifically staining apoptotic cells, and propidium iodide,
staining all damaged cells. The experiment was performed according to the
recommendations of the supplier. In a FACScan automate (Becton Dickinson), 10 000 cells
were analysed in channels FL-1 for detection of the Propidium iodide stained cells, and FL-3
to detect Annexin V stained cells. The experiment was performed by Cornelia Giseler
(Institute of Pathology, Charité, Berlin, Germany). The fraction of apoptotic cells was
calculated using CellQuest software.
2.2.6 Analysis of Proteins
2.2.6.1 Protein Isolation from Mammalian Cells
Cells were grown in 10 cm dishes, and harvested when they reached confluency of 70%.
The Medium was aspirated and cells were washed 3 x with ice-cold PBS. Then the cells
were incubated with TNE lysis buffer for 30 min on ice. The lysed cells were scraped off the
plates,  transferred into microcentrifuge tubes and centrifuged for 15 min at 14,000 x g at
4°C. The Supernatants were removed, and pellets were discarded. An equal volume of 2 x
SDS Sample buffer was added to each sample, the samples were boiled for 10 min, then
chilled on ice and microcentrifuged for 5 min. Aliquots were stored at –20°C until use.
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TNE lysis buffer
10 mM Tris-HCl, pH 7.8
150 mM NaCl
1% NP-40
1 mM EDTA
1/20 ml protease inhibitor complete TM tabs
2 x SDS Sample buffer
50 mM Tris-HCl, pH 6.8
100 mM DTT
2% w/v SDS
10% w/v Glycerol
0.1% w/v bromophenol blue
Prior to Western Blot analysis of caspases, an alternative protocol was used for the
preparation of cellular extracts. The cells were allowed to grow for 48 hours then the medium
was aspirated, transferred into pre-chilled Falcon tubes, and kept on ice. The cells were
washed 3 x with ice-cold PBS and scraped into PBS. Then the tubes with medium and cells
in PBS were centrifuged for 5 min at 1,000 x g. The supernatants were discarded, and
CHAPS cell extract buffer (one volume of cell pellet) was added to the cell pellets.
The cells were resuspended in CHAPS buffer, frozen and thawed three times to lyse them,
and centrifuged at 14,000 x g for 15 min at 4°C. The Supernatants were transferred into fresh
tubes, an equal amount of SDS-Sample buffer was added, boiled for 10 min, and chilled on
ice. The aliquots were stored at -20°C until use.
Chaps cell extract buffer
50 mM Pipes/NaOH, pH 6.5
2 mM EDTA
0.1% Chaps
5 mM DTT
20 µg/ml Leupeptin
10 µg/ml Pepstatin
10 µg/ml Aprotinin
1 mM PMSF
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2.2.6.2 Subcellular Fractionation
Cells were seeded in 10 cm dishes and allowed to grow in their culture medium until they
were 70% confluent. The medium was aspirated, cells were washed 3 x with ice-cold PBS,
and incubated with hypotonic-lysis buffer (1 ml per 10 cm plate/2 x 106 cells) for 5-10 min on
ice. Samples were transferred into Dounce Homogenizers, pre-chilled on ice and
homogenised by repeated strokes to disrupt the cells. To pellet the nuclei cells were
centrifuged at 1000 x g for 10 min at 4°C. Supernatants were transferred into Beckman tubes
(13 x 15 mm), the pellets containing nuclei were saved on ice.
To recover membrane-associated proteins, the supernatants were centrifuged in a TLA
100.3 rotor at 100 000 x g for 30 min at 4°C. The supernatants containing cytoplasmic
proteins were removed and transferred into Corex tubes, pellets were dissolved in 50µl ice-
cold PBS and saved on ice.
To collect cytoplasmic proteins, a methanol/chloroform precipitation was used (Wessel and
Flugge, 1984). To each supernatant prepared in the previous step, 4 ml pre-cooled methanol
was added, then 1 ml pre-cooled chloroform was added and mixed, then 3 ml pre-cooled
sterile water was added and mixed. The solution was centrifuged at 9 000 x g for 15 min at
4°C. The upper phase was discarded, and 3 ml methanol were added to each sample, mixed
and centrifuged again 9 000 x g for 15 min at 4°C. The pellets were dried and dissolved in
SDS sample buffer.
SDS-sample buffer was added to all fractions, samples were boiled for 10 min, chilled on ice,
and stored at -20°C until use.
Hypotonic lysis buffer
10 mM Tris-HCl, pH 8.0
0.1 mM DTT
1 tab/20 ml protease inhibitor complete TM tabs
2.2.6.3 Determination of Protein Concentration
The protein concentration was determined using the BSA Protein Assay (PIERCE) according
to the recommendations of the supplier.
2.2.6.4 One-Dimensional SDS Gel Electrophoresis (PAGE)
Protein samples were separated by polyacrylamide gel electrophoresis (PAGE). 50 µg of
protein extract for detection of H-REV107-1 protein, and 30 µg for detection of caspases
were loaded on a 12 % gel, run 30 min at 65V, and 2,5 hours at 98V in 1 x  running buffer.
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Separating gel: 10 ml of a 12% gel
3.35 ml H2O
2.5 ml 1,5 M Tris-HCl, pH 8,6
4 ml 30% acrylamide/bisacrylamide
100 µl 10% SDS
50 µl APS
5 µl TEMED
Stacking gel: 10 ml of 4% gel
6.1 ml H2O
2.5 ml 1,5 M Tris-HCl, pH 8,6
1.33 ml 30% acrylamide/bisacrylamide
100 µl 10% SDS
50 µl APS
10 µl TEMED
5 x running buffer
15.1 g/l Tris-base
75 g/l Glycine
5 g/l SDS
2.2.6.5 Western Blot Analysis
After gel electrophoresis was finished, the stacking gel was discarded, and the separating gel
was immersed in transfer buffer for 15 min. A PVDF-membrane was immersed in methanol
for 5 sec, then in water for 2 min with shaking on a rotor platform, then the membrane was
incubated 15 min in transfer buffer. On a Bio-Rad Transblot 3 sheets of Whatman paper pre-
wetted in transfer buffer, the PVDF membrane, the gel, 3 sheets of pre-wetted Whatman
were assembled.
Proteins were transferred to the PVDF membrane during 35 min at 16 V. After the transfer
was finished, the membrane was washed briefly in TBST buffer, and blocked for 1 hour in 15
ml of blocking solution at  room temperature with shaking on a rotor platform.
The gel was stained in Comassie blue solution to control for equal loading of protein amounts
and efficient transfer. Afterwards the gel was photographed and discarded.
After the blocking procedure, the membrane was washed 3 x 10 min in 15 ml TBST, and
incubated overnight with the primary antibody in blocking solution. The next day the
membrane was washed 3 x 10 min in 15 ml TBST, and incubated for 1 hour with the
corresponding secondary antibody.
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The membrane was washed again 3 x 10 min in TBST, and the signal were developed using
an ECL kit (Amersham), according to the supplier’s recommendations.
To strip a membrane, a Western Blot Recycling kit (Alpha Diagnostic) was used. Membranes
were incubated in stripping solution for 45 min up to 1 hour, and rinsed with blocking solution
supplied with the kit 2 x 5 min. After an additional washing in TBST for 10 min the membrane
was ready for re-probing with other antibodies.
Primary antibodies, corresponding secondary antibodies, and their dilutions
Primary antibody Dilution Secondary antibody Dilution
Anti-cleaved caspase-3 (Cell
Signaling Technology, Inc., MA,
USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Cell Signaling
Technology, Inc., MA, USA)
1:2000
Anti-cleaved caspase-9 (Cell
Signaling Technology, Inc., MA,
USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Cell Signaling
Technology, Inc., MA, USA)
1:2000
Anti-HA (Sigma Aldrich, Inc.,
MO, USA)
1:10 000 peroxidase-conjugate  goat anti-
mouse (Dianova, Hamburg,
Germany)
1:10 000
Anti-Histone 3 (Cell Signaling
Technology, Inc., MA, USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Cell Signaling
Technology, Inc., MA, USA)
1:2000
Anti-H-rev107, rat (C. Sers,
Charité, Berlin, Germany; Sers
et al., 1997)
1:500 peroxidase-conjugate goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-H-REV107-1 (C. Sers,
Charité, Berlin, Germany; Sers
et al., 2002)
1:500 peroxidase-conjugate goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-GST antibody (Cell
Signaling Technology, Inc., MA,
USA)
1:1000 peroxidase-conjugate  goat anti-
mouse (Dianova, Hamburg,
Germany)
1:10 000
Anti-IRF1 (Santa Cruz
Biotechnology, CA, USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-IRF2 (Santa Cruz
Biotechnology, CA, USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-p14.5, obtained from C.
Kerkhoff, University of
Regensburg, Germany
(Schmiedeknecht et al., 1996)
1:150 peroxidase-conjugate  goat anti-
rabbit (Dianova)
1:50 000
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Anti-p21 (Santa Cruz
Biotechnology, CA, USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-pan-actin (Chemicon, CA,
USA)
1: 5000 peroxidase-conjugate  goat anti-
mouse (Dianova, Hamburg,
Germany)
1:10 000
Anti-PC4, obtained from R.
Heilbronn, Free University
Berlin, Germany (Weger et al.,
1999)
1: 500 peroxidase-conjugate  goat anti-
rabbit (Dianova, Hamburg,
Germany)
1:50 000
Anti-PR65 (Covance Research
Products, Inc., CA, USA)7
1:1000 peroxidase-conjugate  goat anti-
mouse (Dianova, Hamburg,
Germany)
1:10 000
Anti-STAT1 (Cell Signaling
Technology, Inc., MA, USA)
1:1000 peroxidase-conjugate goat anti-
rabbit (Cell Signaling
Technology, Inc., MA, USA)
1:2000
Anti-V5 (Invitrogen, CA, USA) 1 : 5000 peroxidase-conjugate  goat anti-
mouse (Dianova, Hamburg,
Germany)
1:10 000
Transfer buffer (pH 8.5)
25 mM Tris-Base
0.2 M Glycine
20 % Methanol
TBST (pH 7.4)
8.8 g/l NaCl
0.2 g/l KCl
3 g/l Tris-Base
500 µl/l Tween-20
Blocking buffer 5% non-fat dry milk in TBST
Commasie blue 0.1% Comassie blue R-250 dissolved in 40% Methanol, 10% acetic acid.
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2.2.7 Protein interaction analysis
2.2.7.1 Glutathione-S-Transferase Fusion System
2.2.7.1.1 Production of GST-Fusion Protein in Bacteria
The GST gene fusion system (Pharmacia Biotech, Inc., CA, USA) was used to express an H-
REV107-1 – GST fusion protein in E.coli (107-GST). For this purpose the H-REV107-1 cDNA
encoding a truncated H-REV107-1 protein lacking the membrane binding domain (the ∆CH-
REV107-1) was ligated into the pGE-2TK bacterial expression vector in frame with the
Glutathione S-transferase. The E. coli B21 bacterial strain recommended and purchased by
Pharmacia Biotech was used for the expression of the fusion protein. To maintain the pGE-
2TK plasmid and the 107-GST – expression vector the E.coli Sure 2 strain was used as
recommended by the manufacturer.
Preparation of competent B21 cells
A single colony of a fresh overnight culture was inoculated in 50 ml LB and incubated at 37°C
with shaking at 250 rpm. Cells were grown to an OD600 of 0,4 – 0,5, this took approximately
2.5 – 3 hours. Cells were then centrifuged at 2500 x g for 15 min at 4°C. The cell pellet was
gently resuspended in 5 ml of ice-cold TSS buffer, placed on ice and used for
transformations within the next 30 min.
TSS buffer (Recipe for 100 ml), pH 6.5, filter sterilised
1 g Tryptone
0.5 g yeast extract
0.5 g NaCl
10 g Polyethylene Glycol (MW 3350)
5 ml DMSO
5 ml 1 M MgCl2
Transformation of competent B21 cells
One ml of competent cells was mixed with 10 ng of the pGE-2TK plasmid or 10 ng of the
107-GST expression vector, and incubated on ice for 45 min. All samples were transferred
into a water-bath and incubated for 2 min at 42°C, then chilled briefly on ice. Afterwards, 100
µl of the transformation mix were transferred into a microcentrifuge tube with 900 µl LBG
medium (LB-medium containing 20 mM Glucose) and incubated for 1 hour at 37°C with
shaking at 250 rpm. 100 µl of the transformed cells were plated onto LBG plates containing
100 µg/ml Ampicillin and incubated overnight at 37°C.
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Screening of pGE-recombinant transformants for expression of the fusion protein
Several colonies of E.coli transformants were picked into separate tubes containing 2 ml
2xYTA medium. Liquid cultures were grown to an OD600 of 0,6-0,8 (3-5 hours) with shaking at
30°C. Expression of the fusion proteins was induced by adding 2µl of 100 mM IPTG to each
sample. Incubation was continued for an additional 2 hours. Liquid cultures were transferred
into fresh tubes and centrifuged for 5 sec in a microcentrifuge. Pellets were resuspended in
300 µl of ice-cold PBS, 10 µl were analysed on an SDS-PAGE. To visualise the GST-protein
(made in control cells carrying the parental pGE-2TK vector) and the fusion protein (made in
cells carrying the 107-GST – expression vector), the gel was stained with Commassie Blue.
Alternatively, a Western blot analysis with an anti-GST antibody was performed. The GST-
protein has a size of 29 kDa, the 107-GST protein of 35 kDa. Several transformants,
synthesising the recombinant protein of the predicted size were stored as a glycerol stock, as
described in chapter 2.2.2.1.
2.2.7.1.2 GST Pull-Down Assay
The interaction between bacterially expressed 107-GST fusion protein and PR65-V5, over-
expressed in COS-7 cells, was analysed under cell-free conditions using a GST pull-down
assay.
Preparation of the recombinant 107-GST and GST proteins
To prepare recombinant 107-GST and GST, overnight cultures containing E.coli clones
harbouring the pGE-2TK plasmid, and the 107-GST expression vector were grown. The
overnight cultures were diluted 1:100, and 100 ml of every sample were incubated during 2-5
hours with shaking at 250 rpm at 30°C. Then, expression of the fusion proteins was induced
by the addition of 100 mM IPTG to a final concentration of 0,2 mM. Incubation was continued
for 3 hours. Cells were pelleted by centrifugation at 8000 x g for 10 min at 4°C and
resuspended in 10 ml PBS. To lyse the cells, they were sonicated, and 20% Triton X-100
solution was added to a final concentration of 1%. Cell debris was pelleted at 12000 x g for
10 min at 4°C. Supernatants were transferred into fresh tubes, and 100 µl of 50% freshly
prepared slurry of Glutathione Sepharose 4B were added to each supernatant.
The required amount of 50% Glutathione Sepharose 4B was prepared  according to the
recommendations of the supplier. 2 ml of a Sepharose were used for the purification of 250
µg protein.
For binding of recombinant proteins to Sepharose beads, samples were incubated at room
temperature with gentle agitation for 30 min. Afterwards the suspensions were centrifuged at
500 x g for 5 min, and supernatants were removed. The Glutathione Sepharose beads with
the bound proteins were washed 3 times with ice-cold PBS and added to a freshly prepared
COS-7 cell protein extract.
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GST-pull down assay
For this purpose COS-7 cells were transiently transfected with a PR65-V5 expression
plasmid and incubated for 48 hours post-transfection. The cells were lysed in GST-lysis
buffer, cell lysates were clarified by centrifugation, and saved on ice in 1 mg aliquots. To
each aliquot were added purified recombinant 107-GST, or as a negative control GST
proteins bound to Glutathione Sepharose beads, prepared as described above. The samples
were incubated overnight at 4°C on a rocking platform. Then they were washed 3 times with
GST-lysis buffer and resolved in SDS-PAGE, following Western blot analysis with an anti-
GST, and an anti-V5 antibodies.
GST-lysis buffer
50 mM Tris-HCl, pH 7.5
150 mM NaCl
1 x (per 10 ml) protease inhibitor complete tabs, EDTA free
1% Nonidet P40
10% Glycerol
2.2.8 Co-Immunoprecipitation
COS-7 cells were transiently transfected as described in chapter 2.2.4.4 and incubated for 42
hours post-transfection. The cells were lysed in the appropriate lysis buffer for 5 min,
transferred to a pre-chilled Dounce homogeniser, and homogenised by repeated strokes on
ice to disrupt the cells. Homogenised suspensions were centrifuged at 12,000 x g for 10 min
at 4°C. Equal amounts of the supernatant from each sample were transferred into
microcentrifuge tubes, optimal volume 1 ml. To each sample were added 5 µl of anti-V5,
alternatively, 5 µl of anti-HA antibody, and gently rocked for 4 hours at 4°C. Then 50 µl of
protein G-agarose (Roche, Mannheim, Germany) were added, and incubated overnight on a
rocking platform at 4°C.
Protein complexes were collected by centrifugation at 12,000 x g for 20 seconds in a
microcentrifuge, and washed 3 times with lysis buffer. Traces of lysis buffer after the final
wash were removed, and 30 µl of SDS Sample buffer were added to each sample, heated for
5 min at 100°C, and frozen at -20°C. Precipitated protein complexes were analysed by SDS-
polyacrylamide gel electrophoresis and immunoblotting.
51
Lysis buffer (for co-immunoprecipitation of H-REV107-1 with P14.5, ETF1, PC4, and PR65).
 50 mM Tris-HCl, pH 7.5
150 mM NaCl
1 x (per 10 ml) protease inhibitor complete tabs, EDTA free
1% Nonidet P40
10% Glycerol
For precipitation of S100A6/Calcyclin CaCl2 and ZnCl2 were added to a final concentration of
2 nM.
Lysis buffer for co-immunoprecipitation of H-REV107-1 with RARG (NET buffer)
20 mM Tris-HCl, pH 8.0
200 mM NaCl
1 mM EDTA
0.1% Nonidet P40
10% Glycerol
1 x (per 20 ml) protease inhibitor tabs complete
The following components were used to enhance binding of the RARG protein to H-REV107-
1. They were added to the cell lysates and incubated for 30 min on ice prior to the addition of
the antibody.
1 µg/ml double stranded DR5 RARE or  DR5M oligonucleotides
1 µM ATRA
1 µM TTNPB
2.2.9  Immunofluorescence Analysis and Confocal Microscopy
For immunofluorescence analysis cells were grown on glass coverslips. After fixation with
3% paraformaldehyde in  1 x PBS for 20 min, cells were permeabilised using 0,2% Triton X-
100 in 1 x PBS for 1,5 min, washed 3 x 5 min with PBS and incubated with the primary
antibody.
The H-REV107-1 antiserum was diluted 1:2000, and anti-V5, anti-PR65, anti-PR36
antibodies were diluted 1:300 in PBS/1% BSA. Coverslips were incubated with primary
antibodies for 2 hours at room temperature, then washed 3 x 5 min in PBS and incubated
with the secondary antibodies. A goat anti-rabbit antibody AlexaFluor 594 (Molecular Probes,
Eugene, OR) at 1:500, and a goat anti-mouse antibody AlexaFluor 488 (Molecular Probes,
Eugene, OR) at 1:200 were used. For nuclear staining, cell were incubated with
diamidinophenylindole (DAPI) and analysed using confocal microscopy (Leica TCS).
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Colocalisation of H-REV107-1 with PR65, and ∆N∆C107-1 with PR65 was analysed using a
Leica confocal microscope TCS SL. Colocalisation was semi-quantitatively evaluated using
the standard application LCS program (Version 2.585), and the LCS Multicolor-Software
(Leica) by Kerstin Lehmann (MetaGen, Berlin, Germany).
2.2.10 Phosphatase Assay
Phosphatase activity was measured by using para-nitrophenyl phosphate (p-NPP) as a
substrate with the Phosphatase Assay Kit (Upstate Biotechnology, NY, USA). To investigate
a potential effect of the H-REV107-1 protein, OVCAR-3 cells were transfected with H-
REV107-1 expression plasmid or the control pcDNA3.1 vector without insert, and then
starved for 24 hours. OVCAR-3 cells were pre-treated with or without 2 nM OA for 1 hour at
37°C. Then the cells were lysed in lysis buffer used for co-immunoprecipitation of H-REV107-
1 with PR65. Cell lysates were clarified by centrifugation at 12.000 x g for 10 min. The
clarified supernatants were incubated with the anti-PR65 antibody (Covance Research
Products. Inc., CA, USA) and protein G-agarose (Roche, Mannheim, Germany) for 2 hours at
4°C. The immunoprecipitates were washed 2 times with lysis buffer and 1 time with assay
buffer, resuspended in assay buffer containing 2.5 mM NiCl2, and 900 µg/ml pNPP, and
incubated for 30 min at 37°C. The amount of para-nitrophenol produced by
dephosphorylation was determined by measuring the absorbance at 405 nm.
Assay buffer
50 mM Tris-HCl, pH 7.0
0.1 mM CaCl2
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3  Results
3.1 Identification of Proteins Interacting with H-REV107-1
3.1.1 Screening of a Human Kidney cDNA Library to Identify Potential Interacting
Partners of the H-REV107-1 Protein
To understand the mechanism of H-REV107-1 – mediated growth suppression (Sers et al.,
1997), a search for its potential interacting partners using a Lex-A Yeast Two-Hybrid system
(Fields et al., 1989) was performed. In this approach an H-REV107-1 recombinant protein,
pEG202-107 (bait), fused with a prokaryotic DNA-binding domain of the LexA protein was
generated. The pEG202-107 protein and library cDNA inserts, fused with the E.coli B42
activation domain, were co-expressed in the yeast cell line EGY48 carrying the LexA and
GAL4 reporter genes. Yeast transformants grew on a selection medium, in which activation
of the reporter genes made an interaction phenotypically detectable. The approach is
described in detail in chapter 2.2.1.
As a bait, a truncated form of the human H-REV107-1 protein, lacking the membrane binding
domain that hampered the transport of the hybrid protein into the yeast nucleus where the
interaction takes place, was used. To screen a human kidney cDNA library available from
Clontech, three independent large scale co-transformations were performed. More than two
hundred preliminary positive clones were identified (Fig. 6).
Although the yeast two-hybrid system is a convenient tool for detection of protein-protein
interactions in vivo, one disadvantage of this approach is the abundance of false positives.
To verify putative interacting partners of the H-REV107-1 protein, the following strategy has
been chosen:
Positive colonies were restreaked and re-tested on a selective medium to verify stability of
the interactions.
Inserts of positive colonies were amplified using PCR to find out whether some of the
colonies contain more then one cDNA library plasmid.
The cDNA library plasmids were isolated from yeast and transformed into E. coli KC8, the
plasmids isolated from the clones confirmed in previous steps were sequenced.
Common yeast two-hybrid false positives were excluded from further analysis. The mating
assay was applied to confirm interactions with the candidates chosen in the previous steps.
The interacting partners confirmed in the mating step were tested using co-
immunoprecipitation in mammalian cells and an in vitro binding assay. Confirmed
interactions were analysed functionally.
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Fig. 6 Yeast Two Hybrid screen for H-REV107-1 interacting proteins, and strategy
for their validation
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3.1.2 Sequencing Analysis of Clones Encoding Putative Interaction Partners of the H-
REV107-1 Protein
Screening of the cDNA library and exclusion of colonies containing more than one cDNA
plasmid resulted in the selection of 168 clones appropriate for a sequencing analysis. cDNA
library plasmids were isolated from the E.coli KC8 transformants, sequenced, compared to
each other for elimination of duplicates, and analysed using NCBI Data Base
http://www.ncbi.nlm.nih.gov/BLAST/ in order to determine which genes are present. The
genes encoding potential interacting partners of the H-REV107-1 protein are listed in the
Table 3. In addition, 37 yeast open reading frames, 33 mitochondrial genes, and 45 unknown
genes were identified and excluded from further analysis.
Table 3 List of genes encoding putative interacting partners of the H-REV107-1
protein
cDNA Human Homologue Accession N.
1 23kD highly basic protein (HS23KD) X56932
2 Activated RNA polymerase II transcription cofactor 4 (PC4) NM_006713
3 Alpha-amylase BAA14130
4 BAG-family molecular chaperone regulator-3 (BAG-3) AF095193
5 Beta-2-microglobulin (B2M) NM_004048
6 Calcyclin (PRA, S100A6) NM_014624
7 Carboxypeptidase D (CPD) NM_001304
8 Cathepsin D, lysosomal aspartyl protease (CTSD) NM_001909
9 Cystatin C, amyloid angiopathy and cerebral hemorrhage NM_000099
10 Enoyl Coenzyme A hydratase 1, peroxisomal (ECH1) NM_001398
11 Fasciculation and elongation protein zeta 2 (zyginII,FEZ2) U69140
12 Ferritin L-chain Y09188
13 Heat shock protein 90 (Hsp90) NM_005348
14 L apoferritin (exons 3 and 4) X03743
15 Leukocyte common antigen (CD45) AJ006102
16 Na, K-ATPase beta subunit (ATP1B) NM_001677
17 Pancreatic lipase (PNLIP) NM_000936
18 Plasma membrane Na+/H+ exchanger isoform (NHE3) U28043
19 Proteasome subunit HC2 D00759
20 Proteasome subunit, alpha type, 2 (PSMA1) NM_148976
21 Protein phosphatase 2A regulatory subunit A (PR65/PPP2R1A) NM_014225
22 Putative DNA-directed RNA polymerase III C11 subunit AF126531
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23 Putative permease-related protein (SLCA8) Y18483
24 Retinoic acid receptor gamma (RARG) NM_000966
25 Retinoid inducible gene 1 (RIG1/TIG3/H-REV107-2/RARRES3) AF092922
26 Reversion-induced LIM protein (RIL) P50479
27 Ribosomal protein S14 BC006784
28 RNA-binding protein regulatory subunit (DJ-1) NM_007262
29 Small EDRK-rich factor 2 (SERF2) NM_005770
30 Sterol carrier protein-2 (SCP-2) M55421
31 Syndecan 1 (SDC1) NM_002997
32 TATA element modulatory factor L01042
33 Translation termination factor gene (ETF1) NM_004730
34 Translational inhibitor protein (p14.5) NM_005836
3.1.3 Verification of Specificity of Interactions Using the Mating Test
The mating test was applied to ensure that the proteins identified in the primary yeast two-
hybrid screening activate the reporter genes only due to interaction with H-REV107-1 and not
through unspecific interactions with one of the reporter genes (Russell et al., 1998). To
choose candidates for a mating test, the results from the library screenings were compared
with the list of common false positives, the result of 100 yeast two-hybrid library screenings
done by E. Golemis, Fox Chase Cancer Centre, Philadelphia, PA, USA.(Estojak et al., 1995).
http://www.fccc.edu/research/labs/golemis/InteractionTrapInWork.html
The following genes were noticed there as common false positives:
Table 4 List of known false positives found in yeast two-hybrid screenings
16 heat shock proteins 2 cytoskeletal proteins
14 ribosomal proteins ferritin
5 cytochrome oxydase lamin
3 collagen-related proteins tRNA synthase
3 mitochondrial proteins ubiquitin
3 zink finger proteins vimentin
After excluding these genes, the following candidates were selected for the mating assay:
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Table 5 List of the genes encoding potential H-REV107-1 interacting partners
chosen for the mating test
Activated RNA polymerase II transcription cofactor (PC4)
Beta-2-microglobulin (B2M)
Calcyclin (PRA, S100A6)
Cathepsin D (CTSD)
Cystatin C (CST3)
Protein phosphatase regulatory subunit A (PR65/PPP2R1A)
Retinoic acid receptor gamma (RARG)
Retinoid inducible gene 1 (RIG1/TIG3/H-REV107-2/RARRES3)
Syndecan 1 (SDC1)
Translation termination factor gene (ETF1)
Translational inhibitor protein P14.5 (P14.5)
In this test the specificity of interaction was examined by activation of both the Leu2- and
LacZ- reporter genes in the diploid yeast strain, generated by fusion of the EGY48 and
RFY206 haploid yeast strains. For every interaction three independent mating tests were
performed. Interactions obtained as specific in at least two tests were chosen for further
analysis. As a negative control, I analysed whether these proteins are able to activate the
reporter genes without H-REV107-1. These negative controls are indicated with “-“ in Fig. 7.
A PDZ domain, shown to activate both reporter genes, was kindly provided by E Cuppen,
(Institute of Cellular Signaling, Nijmegen, The Netherlands), and used as a positive control.
Interaction of the H-REV107-1 protein with ETF1, PC4, and S100A6 was shown to be
specific but relatively weak, because activation of the LacZ reporter gene resulted in a light
blue colour of colonies (Fig., upper panel). Interaction with SDC1, CST3, p14.5, and RARG
was strong, although p14.5 and SDC1 activated the Leu reporter gene in one of the negative
control (Fig. 7). Interaction with B2M, CTSD, and H-REV107-2/RIG1 was demonstrated as
unspecific. The B2M and CTSD were able to activate the Leu reporter gene in two negative
control tests, and H-REV107-2/RIG1 activated the Leu reporter gene in three negative
control tests, independent of H-REV107-1 presence (white colonies in the negative control
tests indicated with “-“ in the Fig. 7).
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Fig. 7 Interaction between H-REV107-1 and potential binding proteins found in the
yeast two-hybrid screening is verified using the mating assay
Diploid yeast colonies were grown on Leu – deficient, X-Gal – containing
medium. Stability of an interaction between H-REV107-1 and one of the tested
proteins was monitored through the intensity of the blue colour of the colonies.
The more stable interactions resulted in the development of a dark blue colour
(CST3, SDC1, p14.5, RARG). Weak or transient interactions resulted in growth of
lightly coloured colonies (ETF1, PC4, and S100A6). Colonies in the upper lanes
signed with “+” expressed H-REV107-1 and one of the interacting proteins.
Colonies in the lower lanes signed with “-“ do not contain H-REV107-1, but only
the activation domain and the library cDNA insert. Three mating tests for every
target are depicted.
Fig. 8 Expression of the S100A6, ETF1, PC4, and P14.5 proteins is confirmed in
yeast
Protein extracts were prepared form the yeast colonies used in the mating test.
10µg of the protein lysate was subjected to SDS-PAGE and analysed by Western
blotting. A: analysis with an anti-HA antibody. The S100A6, ETF1, and PC4
proteins were detected. B: analysis with an antibody against P14.5.
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3.1.4 Examination of Protein Expression in Yeast
To choose candidates for further analysis in mammalian cells, the expression of the protein
encoded by the cDNA library inserts in yeast colonies, verified by mating assay, was
examined. All cDNA inserts used in the interaction trap were fused to a sequence encoding
an HA-epitope at their 5’-ends. To control the expression of the recombinant proteins, lysates
from yeast expressing the genes of interest were analysed by Western blotting using
antibodies recognising an HA-epitope or a recombinant protein. The S100A6, ETF1 and PC4
proteins were detected with an anti-HA antibody (Fig. 8 A), and the P14.5 protein was
detected with an antibody against P14.5, kindly provided by C. Kerkhoff, Institute of Clinical
Chemistry and Laboratory Medicine, Regensburg, Germany (Schmiedeknecht et al., 1996;
Fig. 8 B). No signals were detected in the analysis of the yeast expressing SDC1, CST3, and
RARG, possibly, because the conformation of these proteins hampered binding of the HA-
antibody to N-terminal epitopes.
The PC4, ETF1, S100A6, and P14.5 proteins were potential interacting partners of H-
REV107-1 complying the criteria of “true putative positives” of the yeast two-hybrid system.
They were confirmed in the mating test, and expression of the recombinant proteins was
demonstrated in yeast (Fig. 8).
To verify the interaction between proteins identified by yeast two-hybrid system, co-
immunoprecipitation from cellular extracts is the standard procedure. Therefore I used
recombinant mammalian expression vectors to co-express H-REV107-1 and the putative
interacting partners in COS-7 cells.
In addition to the proteins validated by mating assay, co-immunoprecipitation was done with
the RARG and PR65 proteins. Retinoic Acid Receptor Gamma (RARG) is an important
mediator of the retinoic acid cellular response (Holmes et al., 2000). Retinoic acid regulates
cell differentiation and proliferation. Furthermore, it has been demonstrated to inhibit growth
in several tumor cell lines (Ogata et al., 1994). Therefore, the interaction between H-
REV107-1 and RARG was tested by co-immunoprecipitation despite the fact that no RARG
protein has been detected in Western Blot analysis (Fig. 8)
The second potential interaction partner of H-REV107-1 was the PR65 protein, the regulatory
subunit of the protein phosphates 2A. The PR65 encoding cDNA clone identified in the
original yeast two-hybrid screening was lost. However, PR65 is a known regulator of
numerous cellular events appearing to play a privileged role in the regulation of cell growth
(Janssens and Goris, 2001). The catalytic subunit of PP2A was demonstrated to interact with
the ETF1 protein (Andjelkovic et al., 1996), a potential interacting partner of H-REV107-1
found in this yeast two-hybrid screening. It was possible that the interaction with PR65
mediates growth suppressive properties of the H-REV107-1
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3.1.5 Generation of the H-REV107-1V5 and ∆CH-REV107-1HA Expression Vectors.
For co-immunoprecipitation in COS-7 cells H-REV107-1 recombinant proteins fused to HA-,
and V5-epitopes were designed. These two epitopes were used because we wished to test
which antibody is better appropriate for the immunoprecipitation of protein complexes. Full
length and truncated H-REV107-1 recombinant proteins were generated to estimate if the H-
REV107-1 membrane binding domain might influence binding capacity of the H-REV107-1
protein. Thus, the ∆CH-REV107-1HA recombinant protein consisted of a truncated H-
REV107-1 lacking the membrane binding domain, and fused at its C-terminus to an HA-
epitope (Fig. 9 A). The H-REV107-1V5 protein consisted of full length H-REV107-1 fused at
its C-terminus to an V5-epitope (Fig. 9 B).
Fig. 9 The H-REV107-1 HA and V5 fusion proteins
A: ∆CH-REV107-1HA, cDNA without membrane binding domain was amplified
using PCR, and subcloned in frame with the HA-Tag into the pcDNA3 vector.
B: H-REV107-1V5, H-REV107-1 full length cDNA was amplified using PCR, and
ligated into the pEF6/V5 vector in a way that the V5-encoded sequence was
located in frame at the 3’-end behind the membrane-binding domain.
Abbreviations: MBD – membrane binding domain, term – termination of
transcription (stop codon).
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3.2 PC4
3.2.1 H-REV107-1 Interacts with PC4 in COS-7 Cells
The PC4 protein has been isolated as a RNA-polymerase II transcriptional coactivator (Ge et
al., 1994). A mammalian expression vector containing full length PC4 cDNA fused to a V5-
epitope (PC4-V5) was purchased from the GeneStorm collection of Invitrogen. To examine
whether PC4 interacts with the H-REV107-1 protein, COS-7 cells were transiently
transfected with the ∆CH-REV107-1HA and PC4-V5 expression vectors. The PC4-V5 protein
was detected in the precipitated complex containing ∆CH-REV107-1HA, however the
interaction was very weak (Fig. 10, lane 3, arrow). These results were reproduced several
times.
Fig. 10 The PC4-V5 and ∆CH-REV107-1HA proteins interact with each other in
COS-7 cells
COS-7 cells were transiently transfected with PC4-V5 and ∆CH-REV107-1
expression vectors. As a negative control epitope – containing plasmids without
inserts were used. Cell lysates were harvested 48 hours after transfection and
used for immunoprecipitation with a HA-conjugated Sepharose. The
immunocomplexes were subjected to SDS-PAGE and analysed using Western
Blot with anti-V5 and anti-HA antibodies.
Lane 1: both proteins are present in the whole protein extract used for the
immunoprecipitation. Lane 2: negative control. Lane 3: ∆CH-REV107-1HA
precipitated with an HA-conjugated Sepharose, and co-precipitated PC4-V5
detected with an anti-V5 antibody.
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3.2.2 Examination of the Intracellular Localisation of the Ectopically Expressed H-
REV107-1 and PC4 Proteins
The PC4 protein is a transcriptional coactivator localised in the nucleus (Ge et al., 1994),
whereas H-REV107-1 was described as a non-nuclear protein (Sers et al., 1997). To identify
potential intracellular compartments where the proteins might be colocalised,
immunofluorescence staining of COS-7 cells transiently transfected with the PC4-V5 and H-
REV107-1 expression plasmids was performed. The H-REV107-1 expression vector
containing full length cDNA was used because the role of the membrane binding domain has
been shown to be important for the cellular distribution of the protein (Sers et al., 1997). PC4-
V5 was localised mainly in nucleus, and in some cells in the cytoplasm. The H-REV107-1
protein was detected only in the cytoplasm (Fig. 11). Thus, the preferential localisation of
PC4 in the nucleus prevented efficient interaction with the H-REV107-1 protein.
Fig. 11 The H-REV107-1 protein is distributed through the cytoplasm in COS-7
cells, whereas the PC4-V5 protein is localised preferably in the nucleus
COS-7 cells were transiently transfected with the PC4 and H-REV107-1 full
length expression vectors. Immunofluorescence staining and subsequent
confocal laser microscopy was done 48h post transfection. Cells were stained
with an anti-H-REV107-1 and anti-V5 primary antibodies, and anti-mouse
AlexaFluor 488 nm, and anti-rabbit AlexaFluor 594 nm secondary antibodies.
DAPI was used for DNA – staining.
To define the intracellular localisation of H-REV107-1 more precisely, we performed a
subcellular fractionation of the H-REV107-1 protein in COS-7 cells transiently transfected
with the H-REV107-1 expression vector. H-REV107-1 was revealed in the cytoplasmic and in
the nuclear fractions (Fig. 12). The presence of two bands was explained by possible post-
translational modification of the protein, like it was described for the rat H-rev107 protein
(Sers et al., 1997).
Thus, the intracellular localisation of H-REV107-1 and PC4 partially overlapped in the
nucleus and in the cytoplasm. This result would explain the weak interaction demonstrated in
the co-immunoprecipitation experiments (Fig. 10).
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Fig. 12 The H-REV107-1 protein is distributed through the nuclear and cytoplasmic
fractions of the transiently transfected COS-7 cells
COS-7 cells were transiently transfected with the H-REV107-1 expression
plasmid. Proteins were harvested 48 hours after transfection and fractionated.
For SDS-PAGE 15µg of protein extracts from every fraction were loaded.
Immunoblotting was performed against a polyclonal anti-H-REV107-1 antibody. A
specific H-REV107-1 band was detected in the cytoplasmic (Cytopl) and nuclear
fractions (Nucl), but not in the membrane fraction (Mem).
3.2.3 H-REV107-1 Interacts with Endogenous PC4 in COS-7 Cells
A further proposition explaining the weakness of the PC4-V5 – ∆CH-REV107-1HA binding
was that the C-terminated epitope of one of the proteins can handicap the interaction. An
interaction of ∆CH-REV107-1HA with other proteins was demonstrated in previous
experiments. The PC4 protein carried at its C-terminus a single-strand DNA-binding domain,
that has been already shown to play a decisive role in a protein-protein binding (Weger et al.,
1999). To prove whether the C-terminal epitope of PC4-V5 has an inhibitory effect, the
interaction between ∆CH-REV107-1HA and endogenous PC4 was investigated in further
experiments.
PC4 expression in COS-7 cells was examined by Western Blot analysis using an anti-PC4
antibody, a generous gift of Professor R. Heilbronn, Free University, Berlin, Germany (Weger
et al., 1999). PA1 cells already described as PC4-positive were used as a positive control
(Kannan et al., 1999). Equal expression of PC4 protein in PA-1 and COS-7 cell lines was
demonstrated (Fig. 13 A). Co-immunoprecipitation with a HA-conjugated Sepharose was
done in COS-7 cells transiently transfected with the ∆CH-REV107-1HA and PC4-V5
expression vectors. More stringent washing of the precipitated protein complex were
performed to check whether the endogenous PC4 or the recombinant PC4-V5 protein
interacts more stably with ∆CH-REV107-1HA.
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Fig. 13 H-REV107-1 interacts with the endogenous PC4 protein 
A: COS-7 and PA1 cells were lysed in SDS-Sample buffer. 15µg of the lysate
was subjected to SDS-PAGE. Upper panel - Western blotting against anti-PC4
antibody, bottom panel – actin was used as a loading control.
B: COS-7 cells were transiently co-transfected with PC4-V5 and ∆CH-REV107-
1HA expression vectors, or with an empty vector containing HA-epitope only as a
negative control. Forty eight hours after transfection cells were lysed and
immunoprecipitated with a HA-conjugated Sepharose. The whole protein extract
(10µg), and the immunoprecipitated complex were resolved by SDS-PAGE, and
analysed via Western blotting. Middle panel – Western blot analysis with an anti-
PC4 antibody. Lane 2 - the immunoprecipitated endogenous and V5-tagged PC4
proteins were revealed (arrowheads). Upper panel – the membrane was stripped
and incubated with an anti-V5 antibody. Bottom panel – after second stripping the
membrane was incubated with an anti-HA antibody. Lane 1 – protein extracts,
lane 2 – co-immunoprecipitation , lane 3 – negative control.
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Western Blot analysis using the anti-PC4 antibody revealed two bands in the protein extract.
The precipitated protein complex contained endogenous PC4 and very low amount of the
ectopically expressed PC4-V5 protein (Fig. 13 B, middle panel, lane 2, arrowheads). The V5-
tagged PC4 protein had a slightly lower mobility in electrophoresis gel due to the V5-epitope
(Fig. 13 B, middle panel, lane 1, 2). Immunoblotting with the anti-V5 antibody revealed a
single band in the protein extract (Fig. 13 B, upper panel, lane 1). Incubation with the anti-HA
antibody exhibited ∆CH-REV107-1HA protein, expressed in the COS-7 cells, and
precipitated with a HA-conjugated Sepharose (Fig. 13 B, bottom panel, lane 1 and 2,
accordingly). This experiment demonstrated that H-REV107-1 interacts more stably with the
endogenous PC4 protein.
Thus, interaction with the endogenous protein suggested that the H-REV107-1 – PC4
binding takes place in vivo. A potential role of this interaction in H-REV107 function was
investigated in further experiments.
3.2.4 H-REV107-1, PC4, and STAT1 Form a Protein Complex related to IFNγ-signaling
The PC4 protein participates in the regulation of RNA-polymerase II activity, and interacts
with a variety of other transcriptional regulators (Wu and Chiang, 2001). It has been
demonstrated that PC4 enhances transcriptional activity of the BRCA1 protein (Haile and
Parvin, 1999), which is involved in IFNγ - dependent growth control (Ouchi et al., 1999). A
differential display from rat astrocytoma cells treated with IFNγ recovered the H-rev107 –
sequence (Kuchinke et al., 1995), indicating that this gene is an IFNγ- target. This prompted
us to suppose a potential role of the H-REV107-1 – PC4 complex in IFNγ - signaling.
Therefore, we investigated an effect of IFNγ on the H-REV107-1 expression in human cells.
H-REV107-1 was demonstrated to be down-regulated in most tumor cell lines and in 50% of
human ovarian carcinomas as compared to normal tissue. Increase of H-REV107-1 mRNA
expression under IFNγ-treatment was shown in human ovarian carcinoma cell lines: A27/80
described as IFNγ-sensitive, and OVCAR-3 demonstrated to be resistant to the IFNγ-
treatment. Further investigation revealed that H-REV107-1 is a direct target of interferon
regulatory factor 1, IRF1 (Sers et al., 2002), a tumor suppressor and a mediator of the IFNγ-
signalling (Tanaka and Taniguchi, 2000).
The increase of H-REV107-1 mRNA expression upon IFNγ treatment in OVCAR-3 and
A27/80 cells suggested a potential involvement of the gene in IFNγ-mediated growth
suppression (Sers et al., 2002). To prove this hypothesis, the restoration of H-REV107-1
expression upon IFNγ-induction was examined at the protein level.
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OVCAR-3 and A27/80 cells were treated for 9, 12, 24, 36, and 48 hours with IFNγ, and
analysed using Western blotting. A low but specific H-REV107-1 signal was detected in
OVCAR-3 cells after 36 hours of treatment, which further increased during the following 12
hours (Fig. 14, upper panel). In A 27/80 cells the protein was below detectable level (data not
shown), although up-regulation of mRNA expression was demonstrated (Sers et al., 2002).
To understand the mechanism of the IFNγ -dependent growth suppression, and to pursue a
role of the H-REV107-1 protein in this process, the phenotype of A27/80 and OVCAR-3 cells
treated with IFNγ was investigated using immunofluorescence analysis. In A27/80 cells no
considerable phenotypic changes were detected after 48 hours of induction (data not
shown). In a small fraction of OVCAR-3 cells (below 5%) the H-REV107-1 protein was
detected. Most importantly, up-regulation of endogenous H-REV107-1 correlated with a
nuclear morphology typical for apoptotic cells, and in a fraction of the cells, which underwent
apoptosis, H-REV107-1 was localised in the nuclei (Fig. 15, red arrowheads). This suggested
involvement of H-REV107-1 in the IFNγ-mediated cell death, and supposed that nuclear
localisation of the protein might be important for its growth suppressive properties.
The small fraction of OVCAR-3 cells sensitive to IFNγ-treatment was probably not detected in
growth analysis performed earlier. Therefore, OVCAR-3 cells were assumed to be resistant
to IFNγ-treatment. In contrast, A27/80 cells showed considerable growth inhibition up to 50%
(Sers et al., 2002), but no phenotypic changes were obtained in this cell lines, suggesting
different down-stream mechanisms of the IFNγ-signaling in A27/80 and OVCAR-3 cell lines.
To determine how IFNγ-responses diverse in OVCAR-3 and A27/80 cells, expression of the
major down-stream IFNγ-effectors was investigated in these cell lines. Among them are the
signal transducer and activator of transcription, STAT1 (Schindler and Darnel, 1995), and its
down-stream targets involved in growth inhibitory effects, interferon regulatory factor 1 (IRF1)
and cyclin-dependent kinase inhibitor, p21WAF1 (Naldini et al., 2001). The STAT1 and p21WAF1
proteins were shown to be induced after IFNγ-exposure in several ovarian cancer cell lines
(Burke et al., 1999). The increase of IRF1 expression upon IFNγ-induction in OVCAR-3 and
A27/80 cells has been described (Sers et al., 2002; Fig. 14).
The expression of the STAT1 and p21WAF1 proteins after incubation of OVCAR-3 and A27/80
cells with IFNγ was investigated using Western blot analysis. Up-regulation of STAT1 was
detected after 24 hours and increased up to 48 hours in both cell lines (Fig. 16, upper panel).
Immunoblotting with an anti- p21WAF1 antibody revealed a specific band in A27/80 cells after
24 hours of IFNγ-treatment. The amount of protein was stable during the following 72 hours.
The p21WAF1 protein was not detected in OVCAR-3 cells (Fig. 16, middle panel).
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Fig. 14 Up-regulation of H-REV107-1 expression in OVCAR-3 cells after IFNγ-
induction
Western blot analysis of H-REV107-1 expression in OVCAR-3 cells was
performed after incubation with  100 U/ml of IFNγ. H-REV107-1 was detected
with a specific anti-H-REV107-1 antibody. Then the membrane was incubated
with an antibody against IRF1, and after the next stripping with an anti-IRF2
antibody. Actin was used as a loading control.
Fig. 15 Induction of the H-REV107-1 expression upon IFNγ - treatment leads to cell
death
Immunofluorescence analysis of  OVCAR-3 cells treated for 48 hours with
100U/µl of IFNγ. Cells were incubated with a primary anti-H-REV107-1 antibody,
and secondary anti-rabbit AlexaFluor546 antibody. Nuclei were stained with
DAPI. Only cells expressing H-REV107-1 showed an altered morphology of the
nucleus, indicative of apoptosis (white arrowheads).
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Fig. 16 STAT1 and P21WAF1 expression after IFNγ - induction in OVCAR-3 and
A27/80 cells.
OVCAR-3 and A27/80 cells were treated with 100 and 1000 Units of  IFNγ,
respectively for  24, 48, and 72 hours; 10 µg of nuclear extracts were subjected
to SDS-PAGE followed Western Blot analysis using antibodies against p21WAF1
and STAT-1. Histone 3 was used as a loading control. C – p21WAF1 control
protein.
Thus, up-regulation of different STAT1-targets was demonstrated in OVCAR-3 and A27/80
cell lines in response to IFNγ-treatment. In A27/80 cells, the IFNγ-dependent growth
suppression correlated with the up-regulation of p21WAF1 expression. In contrast, induction of
apoptosis in OVCAR-3 cells was p21WAF1 independent, but correlated with up-regulation of
the IRF-1 and H-REV107-1 proteins.
Two different STAT1-downstream pathways were described earlier (Ouchi et al., 2000). The
first led to IRF1 up-regulation. The second, an IRF-1 independent pathway, led to the
activation of a STAT1 – BRCA1 complex, and up-regulation of their target genes, including
p21WAF1 (Ouchi et al., 2000). This pathway seemed to be activated in A27/80 cells. The tumor
suppressor, breast cancer susceptibility gene 1 (BRCA1) was demonstrated to bind STAT1
in IFNγ-induced cells, thereby enhancing STAT1 activity (Ouchi et al., 2000). Furthermore,
BRCA1 has been demonstrated to act as a transcription factor (Shuai et al., 1994).
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Fig. 17 STAT1 and PC4 proteins interact with H-REV107-1
COS-7 cells were transiently transfected with the STAT1, PC4-V5, and ∆CH-
REV107-1HA expression plasmids, or with the STAT1, PC4-V5, and pcDNA3-HA
as a negative control. Protein extracts were harvested 42 hours after transfection.
The clarified supernatant was incubated with the HA-Sepharose for 10 hours.
The immunoprecipitated protein complex was subjected to SDS-PAGE and
analysed by Western blotting.
Lane 1 – protein extracts, lane 2 – immunoprecipitation, lane 3 – negative
control. Upper panel – incubation of the membrane with STAT1 antibody
revealed the specific band in the primary protein extract used for the precipitation
(lane 1), and a weak signal in the immunocomplex with the H-REV107-1 protein
(lane 2). Middle panel – the PC4-V5 protein was detected with the epitope-
specific anti-V5 antibody. Bottom panel – ∆CH-REV107-1HA detected with an
anti-HA antibody.
Experiments in vitro showed that the transcriptional activation by BRCA1 is maximal in the
presence of the PC4 coactivator, although their direct interaction has not been confirmed
(Haile and Parvin, 1999). Therefore, it was possible that the H-REV107-1 protein, interacting
with PC4, could be a link between PC4 and the STAT1 – BRCA1 complex. This suggested
the existence of a protein complex consisting of STAT1, PC4, H-REV107-1, and BRCA1.
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The interaction between these proteins was tested using co-immunoprecipitation. To ensure
their high expression level, COS-7 cells were simultaneously transfected with either ∆CH-
REV107-1HA, PC4-V5, STAT-1, and BRCA1, or ∆CH-REV107-1HA, PC4-V5, and STAT-1
expressing plasmids. As a negative control, a transfection with PC4-V5, and STAT1
expression vectors, and a plasmid containing the HA-epitope only was done.
Immunocomplexes were purified with a HA-conjugated Sepharose. The precipitated proteins
were analysed using Western blotting. Incubation with an anti-STAT1 antibody revealed a
specific band of approximately 90 kDa in the protein extract and in the immunocomplex
precipitated with the ∆CH-REV107-1HA protein (Fig. 17, lane 1, 2 respectively). The PC4-V5
protein was detected with an anti-V5 antibody (Fig. 17, lane 1, 2). The BRCA1 protein was
detected neither in the protein extract, nor in the precipitated protein complexes, suggesting
that overexpression of this protein failed (data not shown).
Thus, the interaction between H-REV107-1, STAT-1 and PC4 proteins ectopically expressed
in COS-7 cells was demonstrated. Participation of the BRCA1 protein in this complex is still a
question to be answered. A potential role of this interaction in IFNγ-signalling has to be
further investigated.
3.3 PR65
3.3.1 H-REV107-1 Interacts with PR65 in COS-7 Cells
PR65 is the regulatory subunit A of the protein phosphatase 2A (PP2A). PP2A is a highly
conserved serine/threonine phosphatase essential for a number of cellular functions
including signal transduction, translational control, and cell cycle regulation (Millward et al.,
1999; Sontag, 2000; Janssens and Goris, 2001). PP2A was shown to act as a pro-apoptotic
phosphatase (Klumpp and Krieglstein, 2002). The H-REV107-1 protein was demonstrated to
possess growth suppressive properties (Sers et al., 1997), and to induce apoptosis in human
ovarian carcinoma cells (Sers et al., 2002). Therefore, the possible interaction between these
two proteins was analysed.
Mammalian expression vector containing full length PR65 cDNA fused to a V5-epitope
(PR65-V5) was purchased from the GeneStorm collection of Invitrogen. To examine the
interaction between H-REV107-1 and PR65, co-immunoprecipitation in COS-7 cells was
performed. The cells were transiently transfected with the PR65-V5 and ∆CH-REV107-1HA
expression vectors. Protein complexes were purified with an HA-conjugated Sepharose, and
analysed with the anti-V5 antibody (Fig. 18 A). A PR65-V5 – specific band was present in the
protein complex together with ∆CH-REV107-1HA (Fig. 18 A, upper panel, lane 2, arrow), but
not in the control precipitation with the expression vector containing a HA-epitope only (Fig.
18 A, upper panel, lane 3). To ensure a presence of the ∆CH-REV107-1HA protein, Western
blotting with an anti-HA antibody was done (Fig, 18 A, bottom panel).
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Fig. 18 Co-immunoprecipitation of ∆CH-REV107-1HA and PR65-V5 in COS-7 cells
COS-7 cells were transiently transfected with the PR65-V5 and ∆CH-REV107-
1HA expression plasmids. Protein extracts were harvested 48 hours after
transfection, and co-immunoprecipitated with V5 and HA-antibodies. A: Protein
complexes precipitated with the anti-HA antibody. Upper panel – co-precipitated
PR65-V5 protein was detected with the anti-V5 antibody, bottom panel –
precipitated ∆CH-REV107-1HA protein was detected with the anti-HA antibody.
Lane 1 – expression of both ∆CH-REV107-1HA and PR65-V5 proteins in COS-7
cells used for the co-immunoprecipitation. Lane 2 – co-immunoprecipitation of
PR65-V5 with ∆CH-REV107-1HA. Lane 3 and 4 – control immunoprecipitation
where either PR65-V5 or ∆CH-REV107-1HA are present. B: Protein complex was
precipitated with the anti-V5 antibody. Bottom panel – co-precipitated ∆CH-
REV107-1HA protein detected with the anti-HA antibody; upper panel –
precipitated PR65-V5 revealed with the anti-V5 antibody. Lane 2 - co-
immunoprecipitation of the ∆CH-REV107-1HA protein with PR65-V5. Lanes 3, 4
– negative controls.
The reverse experiment, precipitation with the anti-V5 antibody, confirmed that the ∆CH-
REV107-1HA – specific band precipitated together with the PR65-V5 protein (Fig. 18 B,
bottom panel, lane 2, arrow).
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3.3.2 H-REV107-1 and PR65 are Co-Localised in COS-7 Cells
In addition to co-immunoprecipitation, the intracellular localisation of the H-REV107-1 and
PR65 proteins was examined using immunofluorescence analysis of COS-7 cells transiently
transfected with the PR65-V5 and H-REV107-1 expression vectors. Staining was analysed
using a confocal laser microscopy (Fig. 19). Ectopically expressed H-REV107-1 and PR65-
V5 had almost identical distribution patterns in COS-7 cells. Co-localisation of these proteins
was obtained in the perinuclear region (Fig. 19, bottom panel – overlap of the H-REV107-1
and PR65 localisation is shown in yellow).
Fig. 19 The H-REV107-1 and PR65-V5 proteins ectopically expressed in COS-7 cells
are co-localised in the cytoplasm
COS-7 cells were transiently transfected with PR65-V5 and H-REV107-1
expression vectors. Forty eight hours post transfection cells were fixed and
incubated with a monoclonal anti-V5 antibody and polyclonal anti-H-REV107-1
antibody, and with the secondary anti-mouse AlexaFluor 488 and anti-rabbit
AlexaFluor 594 antibodies, respectively. Nuclei were stained with DAPI.
Upper panel: PR65 – green, H-REV107-1 - red, Nuclei - blue. Bottom panel –
overlay of all three staining. The perinuclear region where H-REV107-1 and
PR65 proteins are co-localised had a yellow-green colour (arrow).
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3.3.3 H-REV107-1 Interacts with PR65 in a Cell-Free System
The GST pull-down assay is a well established method to verify the specificity of interaction
between two proteins under cell-free conditions. This method allows excluding of an
influence of other proteins on the interacting partners.
For this experiment the Glutathione S-transferase (GST) Gene Fusion System (Pharmacia
Biotech) was used. GST-fusion proteins can be expressed in E.coli, and purified by affinity
chromatography using Glutathione Sepharose. The ∆CH-REV107-1 protein fused at its N-
terminus with Glutathione S-transferase (107-GST) was purified from E.coli, and incubated
with the clarified cell lysate prepared from COS-7 cells over-expressing PR65-V5. As a
control the COS-7 protein extract was incubated with the purified Glutathione S-transferase
(GST) alone. After washing, proteins bound to the Glutathione Sepharose were separated by
SDS-PAGE and subjected to Western blotting using the anti-V5 antibody. This analysis
revealed PR65-V5 in a complex with the 107-GST fusion protein (Fig. 20, upper panel, lane
4). Control incubation with an anti-GST antibody revealed a specific 107-GST and GST
bands of the predicted size in the E.coli cell lysate (Fig. 20, lane 2 and 1, respectively), and
in the Sepharose-bound protein complexes (Fig. 20, lane 4 and 6, respectively).
These experiments demonstrated that the PR65 and H-REV107-1 proteins interacted in
COS-7 cells as well as in cell-free conditions. Further experiments aimed at identifying the H-
REV107-1 protein domains responsible for the interaction, and understanding the functional
role of the H-REV107-1 – PR65 interaction.
3.3.4 Homodimer Formation of H-REV107-1
Western blot analysis of the COS-7 cells over-expressing the ∆CH-REV107-1HA truncated
protein revealed two bands of different sizes: one band of 16 kDa, corresponding to the ∆CH-
REV107-1HA protein, and the second band of approximately 32 kDa (Fig. 21, middle panel,
lane 2). Co-transfection of COS-7 cells with the ∆CH-REV107-1HA and H-REV107-1V5
expression vectors, and subsequent Western blot analysis with an anti-HA antibody resulted
also in the observation of two bands of different sizes. This suggested that the H-REV107-1
protein formed homodimers in COS-7 cells.
To prove this hypothesis, COS-7 cells were transiently transfected with the ∆CH-REV107-
1HA and H-REV107-1V5 expression vectors, and with the ∆CH-REV107-1HA and PR65-V5
expression vectors as a positive control. Immunoprecipitation was performed with an anti-V5
antibody. Immunoprecipitated protein complexes were analysed by Western blotting with an
anti-HA antibody. The ∆CH-REV107-1HA protein was detected in a complex with H-REV107-
1V5 or PR65-V5 (Fig. 21, bottom panel, lanes 3 and 4, respectively), confirming the ability of
H-REV107-1 to form homodimers in COS-7 cells.
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Fig. 20 H-REV107-1 interacts with PR65 in a cell-free conditions
The H-REV107-1 protein fused at its N-terminus with a GST-epitope (107-GST),
and the GST-epitope alone were over-expressed in E.coli B21, and purified with
GST-Sepharose. Purified proteins were incubated with a lysate from COS-7 cells
over-expressing PR65-V5. 10 µg of total protein extract, and protein complexes
bound to the Glutathione Sepharose were subjected to SDS-PAGE and analysed
using Western blotting.
Upper panel: Western Blot analysis was done with an anti-V5 antibody. Bottom
panel: Western Blot analysis using an anti-GST antibody. Lane 1 – E.coli
B21/GST protein extract after sonication; lane 2 – E.coli B21/107-GST sonicate;
lane 3 - 10µg of the protein extract from COS-7 cells over-expressing PR65-V5;
lane 4 – GST pull-down of PR65-V5 with the recombinant 107-GST protein; lane
5 – GST pull-down of PR65-V5 with the Glutathione-Sepharose; lane 6 – GST
pull-down of PR65-V5 with the GST-protein.
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3.3.5 Determination of the H-REV107-1 Domains Responsible for Interaction with
PR65 and Homodimer Formation
3.3.5.1 Generation of the H-REV107-1 Mutant Proteins
To map the region of H-REV107-1 responsible for protein binding, three mutants were
generated and tested by co-immunoprecipitation. Selection of the domains to be mutated
was based on the analysis of the protein sequence described in the Introduction. In brief,
members of the H-REV107 protein family share a highly conserved domain (H-box), the
function of which is unknown (Hughes and Stanway, 2000). The ∆C107-HWAY mutant was
generated with a point mutation in the H-box leading to the substituting His by Ala at the
position 23. The NCE domain was shown to play an important role for the activity of the
lecithin retinol acyltransferase (LRAT), a protein which belongs also to the H-REV107 family
(Mondal et al., 2000). The ∆C107-NCE mutant comprised the amino acid exchange Cys-112
to Ser-112 in this region. The third ∆C107-∆N mutant carried a deletion of 20 amino acids at
the proline-rich N-terminus (Fig. 22). Such proline-rich domains were shown to be important
for protein binding (Kay et al., 2000). All mutants were fused at the C-terminus with the HA-
epitope.
3.3.5.2 The N-terminal Domain of the H-REV107-1 Protein is Required for the Interaction
with PR65 and for Homodimer Formation
The ability of the ∆C107- NCE, ∆C107-HWAY and ∆C107-∆N mutants to associate with
PR65-V5 was tested using co-immunoprecipitation in COS-7 cells. Proteins were precipitated
with the HA-conjugated Sepharose, and examined using Western blot analysis with an anti-
V5 antibody. The PR65-V5 protein was detected in a complex with the ∆CH-REV107-1HA
protein used as a positive control (Fig. 24 A, upper panel, lane 1), and with the ∆C107-NCE,
and ∆C107-HWAY mutant proteins (Fig. 24 A, upper panel, lanes 2, 3 accordingly). The
∆C107-∆N mutant was unable to bind PR65-V5 (Fig. 24 A, upper panel, lane 4). Upon co-
immunoprecipitation with an anti-V5 antibody similar results were obtained. The ∆C107-NCE,
and ∆C107-HWAY mutants were shown to associate with PR65-V5 (Fig. 24 B, bottom panel,
lane 2, 3). The ∆N107 mutant was not detected in a complex with PR65-V5 (Fig. 24 B,
bottom panel, lane 4). This demonstrated that the N-terminal proline-rich domain of the H-
REV107-1 protein is required for the interaction with PR65.
To define the protein domain responsible for a homodimer formation, COS-7 cells were
transiently transfected with the H-REV107-1V5 expression vector, and a vector expressing
each of the mutants, respectively. Immunoprecipitation was done with the anti-V5 antibody.
The ∆NH-REV107-1 mutant was also deficient in homodimer formation (Fig. 23,  bottom
panel, lane 5).
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Fig. 22 H-REV107-1 mutants generated for search of the domains responsible for
interaction
Fig. 23 The ∆C107-∆N mutant does not form homodimers
COS-7 cells were simultaneously transfected with expression vectors: H-
REV107-1V5 and one of the mutants. Protein complexes were precipitated with
an anti-V5 antibody. Upper panel – Western blot analysis of the precipitated
proteins with an anti-V5 antibody. Bottom panel - Western blotting against anti-
HA antibody. Lane 1 – 10µg of protein extract from COS-7 cells transfected with
the ∆CH-REV107-1HA expression vector. Lane 2 – immunoprecipitation of ∆CH-
REV107HA with H-REV107-1V5 used as a positive control. Lane 3 - negative
control. Lane 4 – immunoprecipitation of ∆C107-NCE with H-REV107-1V5. Lane
5 – immunoprecipitation of the ∆C107-∆N mutant with H-REV107-1V5. Lane 6 –
negative control.
H-REV107-1 protein
MRAPIPEPKPGDLIEIFRPF---HWAIY---NCE----LIGVMFSRNKRQKQ
∆C107-∆N H-REV107-1 mutant lacking 10 N-terminal aminoacids
∆C107-HWAY Mutant carrying a point mutation in HWAY box  resulting in
His/Ala-23 exchange: HWAIY – AWAIY
∆C107-NCE Mutant carrying a point mutation in the NCE domain resulting in
Cys/Ser-112 exchange: NCE - NSE
1 20 23    27 112 162
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Fig. 24 The ∆N107 mutant fails to interact with PR65
COS-7 cells were co-transfected with the following expression vectors: PR65-V5
and ∆CH-REV107-1 (WT), PR65-V5 and ∆C107-NCE mutant (NC), PR65-V5 and
∆C107-HWAY mutant (HW), and PR65-V5 and ∆C107-∆N mutant (∆N). For
negative controls plasmids containing epitopes only were transfected ( - ).
A: immunoprecipitation with HA-conjugated Sepharose. Upper panel –
precipitated protein complexes were analysed with an anti-V5 antibody for the
PR65-V5 detection. Lane 1 – PR65-V5 was obtained in a complex with ∆CH-
REV107-1HA, lane 2 – with the ∆C107-NCE mutant, lane 3 – with the ∆C107-
HWAY mutant. Lane 4 – the PR65-V5 protein does not associated with the
∆C107∆N mutant. Bottom panel – control Western blotting against anti-HA
antibody.
B: reciprocal co-immunoprecipitation with an anti-V5 antibody. H-REV107-1
associating with PR65-V5 was revealed by Western blotting against anti-HA
antibody. Lane 1 – H-REV107-1 was obtained in the complex with PR65-V5, lane
2 – ∆C107-NCE mutant, lane 3 – ∆C107-HWAY mutant. Lane 4 – the ∆C107-∆N
mutant did not associate with PR65-V5. Upper panel – incubation  with an anti-V5
antibody revealed precipitated PR65-V5.
      1         2         3         4        5        6        7
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Thus, the N-terminal domain of the H-REV107-1 protein was shown to be responsible for
both association with the PR65 protein, and for the homodimer formation. Preliminary
experiments were performed to test a potential competition between H-REV107-1
homodimer formation and PR65 binding. In this experiment the PR65 binding eliminated
homodimer formation (data not shown).
3.4 Investigation of a Role of the H-REV107-1 - PR65 Interaction in Apoptosis
3.4.1 H-REV107-1 Does not Induces Apoptosis in Rat Fibroblasts FE-8
The aim of further investigations was to explore the mechanism of H-REV107-1 mediated
cell death and to define a role of the PR65 – H-REV107-1 interaction in this process.
Examination of the role of H-REV107-1 in cell cycle progression by flow cytometric analysis
required establishment of stable transfectants over-expressing H-REV107-1. All attempts to
generate stable clones in human ovarian carcinoma cell lines OVCAR-3 and A27/80 were
unsuccessful, and resulted in the loss of cells over-expressing H-REV107-1. However, an H-
rev107 – tetracycline-inducible system in rat fibroblasts FE-8 was available (Sers et al.,
1997). Therefore, a potential implication of the H-REV107-1 protein in cell cycle control was
tested in this system. Two independent FE-8 clones stably transfected with tet-inducible H-
rev107, and one clone transfected with the empty vector as a control (pUHD) were tested in
this experiment. Cells were cultured for 24, 48, 72, 96, and 120 hours with or without
doxycycline then stained with propidium-iodide (PI) followed flow cytometric analysis. These
experiments were performed by Cornelia Giseler, Institute of Pathology, Charité, Berlin. H-
rev107 expression was controlled by Western blotting against an anti-H-rev107 antibody
(Fig. 25).
Fig. 25 H-rev107 expression after doxycycline induction in FE-8 cells
Cells were cultured for 48 hours with (+) our without (-) doxycycline, then lysed
and subjected to SDS-PAGE. Upper panel – western blot analysis was performed
with a polyclonal anti-Hrev107 antibody, bottom panel – anti-actin antibody was
used as a loading control. Lane 5 - H-rev107 expression in the FE-8 cells
harbouring H-rev107 expression plasmid after induction with doxycycline
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 Cell lines G1(%) G2(%) S(%)
FE-8 pUHD 38,8 27,8 33,4
FE-8 pUHD  + Tet 48h 40,2 21,4 38,4
72h 38,3 25 36,7
96h 35,6 25,3 39,1
120h 37,1 30,3 32,6
FE-8 H-rev107 42,3 22,9 34,8
FE-8 H-rev107 + Tet 48h 51,4 22,9 25,7
72h 55,9 23,1 21
96h 59,7 22,6 17,7
120h 60 18,8 21,2
Table 6 Cell cycle analysis of FE-8 cells harbouring tet-inducible H-rev107
FE-8 cells stably transfected with the empty pUHD vector, and cells harbouring
H-rev107 under the control of a tetracycline-inducible promoter in pUHD were
cultured in Tet-free medium with or without doxycycline. 48, 72, 96 and 120 hours
after the induction, cells were stained with propidium iodide and subjected to flow
cytometry. Cell cycle progression analysis revealed a tendency of the cells over-
expressing H-rev107 to arrest in G1 phase.
Flow cytometry analysis demonstrated that the FE-8 cells over-expressing H-rev107 were
arrested in G1, reaching 60% G1 phase after 120 hours. In contrast, only 37% of the pUHD-
transfected cells were in the G1 phase at the same time (Table 6). Thus, the H-rev107
protein appeared to induce G1 arrest in rat fibroblasts. At the same time nuclear morphology
was analysed using laser confocal microscopy. However no changes were observed after
48, 96, and 120 hours of H-rev107 induction excluding the possibility of apoptosis.
3.4.2 The ∆C107-∆N Interaction Deficient Mutant Fails to Induce Apoptosis in Human
Ovarian Carcinoma Cell Lines A27/80 and OVCAR-3
In contrast to FE-8 cells, forced expression of H-REV107-1 in OVCAR-3 and A27/80 cell
lines was already demonstrated to induce apoptosis (Fig. 15). Therefore, we suggested that
in different cell types and (or) different species H-REV107-1 exerts different effects on
cellular growth. Further investigation of a potential role of the PR65 – H-REV107-1
interaction in the H-REV107-1 – mediated cell death was performed in these cells.
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The growth suppressing properties of H-REV107-1 full length, ∆CH-REV107-1, and the
interaction deficient mutant (∆C107-∆N) were compared using a colony assay. These
experiments were kindly performed by Jaqueline Hellwig (Institute of Pathology, Charité,
Berlin, Germany). The expression vectors were introduced in A27/80 and OVCAR-3 cells.
The number of G418 – resistant colonies was calculated after 2-3 weeks of selection. In
OVCAR-3 cells the full length H-REV107-1 protein reduced the number of colonies to 45% of
the control. The truncated form (∆CH-REV107-1) reduced colonies only to 65%, and the
mutant (∆C107-∆N) was unable to reduce colony formation in OVCAR-3 cells. In A27/80
cells, the colony numbers with full length H-REV107-1 were 78%, the truncated form of the
protein inhibited growth up to 55%, and the (∆C107-∆N) mutant again failed to reduce
number of colonies (Fig. 26).
For further analysis of the H-REV107-1 role in apoptosis induction, the induction of apoptosis
by the H-REV107-1 mutants was analysed in OVCAR-3 cells. The cells were transiently
transfected with the H-REV107-1, ∆CH-REV107-1, ∆C107-NCE, ∆C107-HWAY, and ∆C107-
∆N expression vectors. Nuclei with apoptotic phenotype were calculated 42 hours after
transfection.  Expression of the full length H-REV107-1 cDNA resulted in 18,5% apoptotic
nuclei, the truncated form lacking the membrane binding domain with or without point
mutations led to induction of apoptosis in around 11% of the cells. After transfection of the
∆C107-∆N deletion mutant only 4,3% of the cells underwent apoptosis. The background was
calculated as the number of apoptotic nuclei after transfection with the empty vector, and
was found to be 2,6% (Table 7).
These experiments demonstrated that two H-REV107-1 protein domains were important  for
the growth suppression and induction of apoptosis in OVCAR-3 cells: the C-terminal domain
is responsible for the intracellular localisation of H-REV107-1 (Sers et al., 1997), the N-
terminal domain mediates the binding of the PR65 protein, and is responsible for homodimer
formation.
Table 7 H-REV107-1 N-terminal and C-terminal domains play an important role in
the induction of apoptosis in OVCAR-3 cells
OVCAR-3 cells were transiently transfected with 6 different expression plasmids.
Immunofluorescence analysis was performed 42 hours after transfection. Cells
were fixed and stained with DAPI. Apoptotic nuclei were visually determined and
calculated using Laser Confocal microscopy. For every transfection more than
300 hundred cells were counted. +
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Fig. 26 Reduction of colony formation in OVCAR-3 and A27/80 cells
A27/80 and OVCAR-3 cells were transfected with four different expression
plasmids contained: H-REV107-1 full length cDNA, ∆CH-REV107-1, and H-
REV107-1 lacking N-terminal and C-terminal domains (∆C107-∆N), or pcDNA3
used as a control. G418-resistant colonies were calculated. Number of colonies
transfected with pcDNA3 was equated to 100%. The results of four independent
experiments were evaluated
3.4.3 Cellular Re-Distribution of the Endogenous PR65 Protein Correlates with the H-
REV107-1 Induced Apoptosis in OVCAR-3 Cells
The N-terminal domain of the H-REV107-1 protein was shown to be required for apoptosis in
OVCAR-3 and A27/80 cells. This suggested that the interaction of H-REV107-1 with PR65
can be important for this process. Therefore the phenotype of OVCAR-3 cells transiently
transfected with the H-REV107-1 and ∆C107-∆N expression vectors were investigated at a
single cell level.
In untransfected cells, PR65 was localised mainly around the nucleoli throughout the
interphase, and in the cytoplasm during mitosis (Fig. 27 C, arrow). H-REV107-1 transfection
induced a dramatic change in the intracellular distribution of PR65 and in the appearance of
the nuclei. In the cells expressing H-REV107-1, PR65 immunofluorescence was seen only in
the cytoplasm, that accompanied apoptotic nuclear morphology (Fig. 27 A, yellow arrows).
The ∆N∆C107-1 mutant was distributed through the cytoplasm and the nucleus (Fig. 27 B,
upper right panel).
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The protein was unable either to induce apoptosis, or to change PR65 localisation (Fig. 27 B,
yellow arrows).
Colocalisation analysis of H-REV107-1 and PR65 immunostaining revealed that the change
in the distribution of the PR65 protein induced by H-REV107-1 correlated with a co-
distribution of these two proteins. This can be clearly observed in the overlay images (Fig. 27
A, B, icons “Overlay”) in which yellow colour (a result of the addition of green and red
spectra) indicate colocalisation. Yellow coloured areas were seen only for H-REV107-1 and
PR65 staining, demonstrating that these proteins are colocalised (Fig. 27 A, icons “Overlay”).
For the ∆N∆C107-1 and PR65 proteins colocalisation regions were not obtained. (Fig. 27 B,
icon “Overlay”). In order to quantify these observations, the yellow, red and green pixels were
counted and depicted as a diagram (Fig. 27 A, B, icons “Colocalisation”; these data were
kindly provided by Kerstin Lehmann, MetaGen, Berlin, Germany).
These results demonstrated a direct correlation between interaction of H-REV107-1 with the
PR65 protein, and the ability of H-REV107-1 to induce apoptosis in OVCAR-3 cells
accompanied by the transport of PR65 from the nucleus to the cytoplasm.
The PP2A protein appears in cells mostly as a dimeric core complex consisting of the 36-kDa
catalytic C subunit (PR36, α or β isoforms) and the 65-kDa “scaffolding” regulatory A subunit
(PR65, α or β isoforms), or as a trimeric complex containing variable regulatory B subunits
bound to the AC dimer (Janssens and Goris, 2001; Millward et al., 1999). The PR65α was
demonstrated to interact with H-REV107-1. We asked whether H-REV107-1 – PR65α protein
complex might interact with the PP2A catalytic subunits, and if over-expression of the H-
REV107-1 protein in OVCAR-3 cells can alter the intracellular distribution of other PP2A
subunits. The localisation of the catalytic subunit PR36 was determined in OVCAR-3 cells
using immunofluorescence analysis.
The commercially available antibody used recognised only the PR36 α isoform.
Immunofluorescence analysis revealed that the catalytic subunit is distributed invariably
through the cytoplasm (Fig. 27 C), and that over-expression of H-REV107-1 did not alter the
protein localisation (data not shown). The expression and the intracellular distribution of other
PP2A subunits is currently investigated.
3.4.4 H-REV107-1 Inhibits PP2A Activity in vitro
Finally, we asked if the interaction between H-REV107-1 and PR65α might influence the
PP2A catalytic activity in OVCAR-3 cells. Therefore, the ability of PP2A, precipitated from
OVCAR-3 cells, to dephosphorylate the synthetic substrate p-Nitrophenyl phosphate (pNPP)
was measured in vitro. OVCAR-3 cells were transfected either with the pcDNA3 vector, or
with the H-REV107-1, ∆CH-REV107-1, and ∆C107-∆N expression vectors. As a control,
OVCAR-3 cells were treated during 1 hour with the PP2A inhibitor okadaic acid at 2 nM.
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Fig. 27 Induction of apoptosis in OVCAR-3 cells after H-REV107-1 over-expression
is correlated with a re-distribution of the PR65 protein.
A, B: OVCAR-3 cells were transiently transfected with the H-RE107-1 (A) and
∆C107-∆N (B) expression vectors. Forty six hours after transfection
immunofluorescence was performed. Cells were stained with monoclonal anti-
PR65, and a polyclonal anti-H-REV107-1 primary antibodies, and anti-mouse
AlexaFluor 488 and anti-rabbit AlexaFluor 594 secondary antibodies. Nuclei were
stained with DAPI. Immunofluorescence was analysed with the help of laser
confocal microscopy. Overlay was performed using LCS Multicolour-Software.
C: Immunofluorescence of untransfected OVCAR-3 cells was performed to
investigate the intracellular localisation of the endogenous PP2A catalytic
subunit, PR36. Cells were stained with monoclonal anti-PR36 or anti PR65
antibodies, and anti-mouse Alexa-Fluor 488 secondary antibody
C
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Fig. 28 The H-REV107-1 protein inhibits the catalytic activity of PP2A in vitro
OVCAR-3 cells were transiently transfected with the H-REV107-1, ∆CH-REV107-
1, and the ∆C107-∆N mutant expression vectors. Cells transfected with the
pcDNA3 empty vector were used as a positive control. For the negative control
untransfected cells were treated for 1 hour with 2 nM okadaic acid. Forty six
hours after transfection cells were lysed in phosphatase lysis buffer and
immunoprecipitated with an anti-PP2A/A antibody. Protein phosphatase activity
of the precipitated protein complexes was measured by pNPP hydrolysis at 405
nm. Absorbance units reflected the phosphatase activity. PP2A activity of cells
transfected with a pcDNA3 vector was set 100%.
The amount of precipitated phosphatase, and H-REV107-1 expression were controlled by
Western Blot analysis of the precipitated complexes and protein extracts, respectively (Fig.
29). The PP2A activity measured in the pcDNA3 transfected OVCAR-3 cells was set 100%.
Treatment of OVCAR-3 cells with okadaic acid inhibited the phosphatase activity up to
94.5%. Surprisingly, the H-REV107-1 protein also inhibited PP2A activity by almost 80%.
The ∆C107-1∆N mutant was unable to inhibit PP2A (Fig. 28).
Thus, PP2A is active in untransfected OVCAR-3 cells, although regulatory and catalytic
subunits are preferentially localised in different cellular compartments. Overexpression of the
H-REV107-1 protein leads to the inhibition of the PP2A activity, and the N-terminus of H-
REV107-1 appeared to be important for the inhibition, suggesting that the interaction
between H-REV107-1 and PR65α is required for this process.
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Fig. 29 Control Western blot analysis of the precipitated protein complexes
Upper panel – precipitated proteins were analysed by western blotting with an
anti-PR65 antibody. Bottom panel – control western blot analysis of the protein
extracts with an anti-H-REV107-1 antibody.
Lane 1 – OVCAR-3 cells transfected with an pcDNA3 plasmid, lane 2 – OVCAR-
3 treated for 2 hours with okadaic acid 2 nM (OA), lane 3 – OVCAR-3 cells
transfected with the H-REV107-1 expression vector, lane 4 – ∆CH-REV107-1,
lane 5 – ∆C107-∆N protein.
3.4.5 Okadaic Acid Induces Apoptosis in OVCAR-3 Cells
Since the induction of apoptosis correlated with the H-REV107-1 ability to bind PR65 and to
inhibit PP2A activity, the natural PP2A inhibitor, okadaic acid was used to study the potential
role of the phosphatase in the cell survival. OVCAR-3 cells were treated with 10 nM okadaic
acid (OA) for 48 hours and 72 hours, as a control DMSO was added to the medium. The
percentages of cells undergoing apoptosis were quantified by dual-coloured flow cytometric
analysis after staining with Propidium iodide and Annexin-V. Treatment of OVCAR-3 cells
with 10 nM OA for 48 hours resulted in 12,1 % apoptotic cells, after 72 hours 54,8% of cells
underwent apoptosis (Fig. 30).
Although in other cell lines PP2A was demonstrated to play a pro-apoptotic role (Klumpp and
Krieglstein, 2002; Moon and Learner, 2003), the protein phosphatase 2 A was likely to be
important for the survival in OVCAR-3 cells.
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Fig. 30 Induction of apoptosis by OA treatment in OVCAR-3 cells
Subconfluent OVCAR-3 cells were treated either with 10 nM OA for 48 and 72
hours or with its vehicle DMSO for 72 hours. After harvesting the cells were
subsequently stained with Propidium iodide (P) and fluorescein isothiocyanate
(FITC)-conjugated anti-Annexin-V antibody (A). The cytograms demonstrate
Annexin – binding (ordinate) versus Propidium iodide  – binding (abscissa) in
DMSO and OA – treated cells. Vital cells (A-/P-), pre-apoptotic cells (A+/P-),
apoptotic cells (A+/P+), and residual damaged cells (A-/P+) are shown in
respective quadrants.
3.4.6 PP2A Inhibition in OVCAR-3 Cells Leads to the Activation of Procaspase-9
Okadaic acid, when applied in a concentration of 10 nM, inhibits the activity of two protein
phosphatases: PP2A and PP1 (Ishihara et al., 1989). The PP2A – specific concentration of
0.5 nM was used in further experiment to test if the induction of apoptosis in OVCAR-3 cells
required only PP2A inhibition. Two known apoptotic pathways result in the activation of
caspases. The first one is receptor-autonomous, depends on the participation of
mitochondria and results in the activation of procaspase-9. The second pathway involves the
interaction of death receptors with their ligands, and results in procaspase-8 activation
(Zimmerman et al., 2001). Induction of these two pathways was investigated in OVCAR-3
cells.
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Fig. 31 H-REV107-1 overexpression and OA treatment of OVCAR-3 cells activate
procaspases –9 and –3
OVCAR-3 cells were transiently transfected with the H-REV107-1, ∆CH-REV107-
1, ∆C107-NCE, ∆C107-HWAY, and ∆C107-∆N expression vectors, or treated
with 0.5 nm and 10 nm OA. Protein extracts were harvested 44 hours after
transfection, and subjected to SDS-PAGE followed by Western Blot analysis.
A: Western blotting against cleaved caspase-9 antibody. Activated caspase-9
was revealed in OVCAR-3 cells after OA, or LY294002  treatment, or after H-
REV107-1 expression.  B: Activated downstream caspase-3 was detected after
treatment with OA 0,5 nM and after H-REV107-1 ectopic expression. DMSO and
pcDNA3 are negative controls.  C: Induction of caspase-9  was tested in OVCAR-
3 cells expressing H-REV107-1 wild type or the mutants. ∆C107-∆N failed to
induce cleavage of the caspase-9.
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Ectopic expression of the H-REV107-1 protein and okadaic acid treatment resulted in
activation of the procaspase-9. Cleaved caspase-8 was not detected (data not shown).
Cleaved caspase-3 was also tested as one of the down-stream caspases. The cleaved
product was revealed after H-REV107-1 transfection and OA exposition (Fig 31 B). This
demonstrated that the H-REV107-1 protein, similar to the PP2A inhibitor okadaic acid,
induces apoptosis through the mitochondrial-dependent pathway.
High level of cleaved caspase-9 and -3 were only found after H-REV107-1 overexpression,
and after treatment with OA of 10 nM, whereas incubation with 0.5 nM OA resulted in
considerably weaker activation of both caspases (Fig. 31 A, B). This suggests that in
OVCAR-3 cells 0.5 nM okadaic acid is insufficient for a complete inactivation of the PP2A
activity.
The ability of the H-REV107-1 mutants to activate cleavage of procaspase-9 was examined
in further experiments. The result confirmed the previous observations. Overexpression of
the ∆CH-REV107-1, ∆C107-NCE and ∆C107-HWAY mutants resulted in a weaker activation
of procaspase-9 in comparison with the wild type H-REV107-1. The ∆C107-∆N truncated
protein failed to induce procaspase-9 cleavage in OVCAR-3 cells (Fig. 31 C).
3.5 Confirmation of Interaction between H-REV107-1 and RARG, S100A6, ETF1, and
P14.5
3.5.1 RARG
The retinoic acid receptor gamma (RARG) belongs to the steroid/thyroid hormone nuclear
receptor superfamily (Evan, 1988). This family contains two distinct sub-classes of proteins,
the all-trans retinoic acid (ATRA) and the 9-cis retinoic acid receptors RAR and RXR. Each
sub-class consists of α, β, and γ isoforms (Gudas, 1992). The RAR and RXR proteins form
homodimers or heterodimers, and act as nuclear transcription factors (Zhang et al., 1992). In
view of the growth suppressive properties of ATRA, and the participation of RARG in this
signaling, we suggested a possible functional co-operation of the H-REV107-1 and RARG
proteins in growth control. Therefore, we analysed the interaction between H-REV107-1 and
RARG in COS-7 cells.
The mammalian expression vector containing full length of the RARG cDNA fused to a V5-
epitope (RARG-V5) was purchased from GeneStorm Collection of Invitrogen. For co-
immunoprecipitation of ∆CH-REV107-1HA and RARG-V5, COS-7 cells were transiently
transfected with the corresponding expression plasmids, however no interaction was
detected (data not shown). From the literature it was known that binding with ATRA or its
antagonists can alter the binding capacity of RARG (Zhang et al., 1992).
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Potential candidates that could improve the interaction between RARG and H-REV107-1
were all-trans retinoic acid (ATRA), an antagonist of ATRA, (E)-4-(2-(5,6,7,8-tetrahydro-
5,5,8,8-tetramethyl-2-naphthelenyl)-propen-1yl benzoic acid) TTNPB, and 27 bp double-
strand oligonucleotides containing the retinoic acid responsive element (RARE), DR5. The
mutated RARE, DR5M was used as a negative control in co-immunoprecipitation (Fig. 32).
H-REV107-1HA did not interact with RARGV5 without supplementary ligands (Fig. 32 A, lane
4). Addition of either TTNPB, or DR5 weakly enhanced the interaction (Fig. 32 A, lane 5; Fig.
32 B, lanes 3, 5). A combination of TTNPB and DR5 had an additive effect (Fig. 32A, lane 6;
Fig. 32 B, lane 2), ATRA did not affect the interaction.
3.5.2 S100A6, ETF1, and P14.5
To verify the interaction between H-REV107-1 and the S100A6, ETF1, and P14.5 proteins by
co-immunoprecipitation, we generated several mammalian expression vectors. The open
reading frames (ORF) encoding S100A6, and ETF1 proteins fused with an HA-epitope, and
P14.5 protein without epitope, were amplified by PCR, and cloned into the pcDNA3.1
mammalian expression vector resulting in the S100A6-HA, ETF1-HA, and P14.5 expression
plasmids. Sequencing analysis of the cloned inserts confirmed that S100A6, and p14.5
contained full length cDNAs. The ETF1 insert included 711 bp encoding the C-terminal
domain of 237 amino acids of the ETF1 protein, which has a full length of 437 aminoacids.
3.5.2.1 S100A6
The S100A6/Calcyclin protein belongs to the S100 subfamily of Ca(2+)-binding proteins
(Ferrari et al., 1987). It was shown to be over-expressed in a variety of tumor cell lines and
human tumours (Maelandsmo et al., 2000), to be associated with invasion in colorectal
adenocarcinoma and metastasis in liver cancer (Komatsu et al., 2002). The first co-
immunoprecipitation experiment under standard conditions revealed a negative result (data
not shown). However, the protein-protein interaction between S100A6 and S100A2 proteins
required an activation of Calcyclin by Ca2+ and Zn2+ ions (Filipek et al., 1999). In the following
experiments a lysis buffer containing different concentration of Ca2+ and Zn2+- ions ranging
from 1 nM to 100 nM was tested. A concentration of 2 nM of both ions was found optimal.
For the co-immunoprecipitation, COS-7 cells were transiently transfected with the H-
REV107-1V5 and S100A6HA expression vectors. The cells were lysed in the lysis buffer
containing 2 nM CaCl2 and ZnCl2, and precipitated using the anti-V5 antibody (Fig. 33). Co-
immunoprecipitation of the S100A6 protein with H-REV107-1 has been reproduced two
times.
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Fig. 32 TTNPB and DR5 are essential for the interaction between RARG and
H-REV107-
COS-7 cells were transiently transfected with the H-REV107-1HA and RARGV5
expression vectors, and lysed 48 hours post transfection. As a negative control
COS-7 cells were transfected with the epitope – containing plasmids without
insert. The whole cell extract was used for immunoprecipitation with an anti-V5
antibody. H-REV107-1 was identified in the immunocomplexes using anti-HA
antibody. RARGV5 was identified using an antibody against V5 epitope. A: lane
2, 3 – negative controls, lane 4 – immunoprecipitation in the absence of
additional ligands; lane 5 – in presence of TTNPB; lane 6 – with both TTNPB
ligand and DR5 RARE. B: Examination of a role of different ligands on the
interaction. Lane 2 – DR5 and TTNPB, lane 3 – DR5, lane 4 – DR5 and ATRA,
lane 5 – TTNPB.
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3.5.2.2 ETF1
Eukaryotic translation termination factor 1 (ETF1) belongs to a family of tightly related
proteins catalysing termination of protein synthesis (Guenet et al., 1999).
Immunoprecipitation with an anti-V5 antibody was performed in COS-7 cells transiently
transfected with the H-REV107-1V5 and ETF1-HA expression vectors. Immunoprecipitated
protein complexes were analysed by Western blotting with anti-HA, and anti-V5 antibodies.
The interaction between these two proteins was very weak (Fig. 34). This correlated with the
results obtained in the mating test where the interaction between H-REV107-1 and ETF1
was also shown to be weak (Fig. 7). A co-immunoprecipitation experiment vice versa with an
anti-HA antibody revealed a negative result (data not shown). These experiments
demonstrated that the interaction between ETF1 and H-REV107-1 in COS-7 cells is very
weak, and it was not investigated further.
Fig. 33 Calcyclin (S100A6) interacts with H-REV107-1 in COS-7 cells
COS-7 cells were transiently transfected with the H-REV107-1V5 and S100A6HA
expression vectors and lysed in the Ca2+ and Zn2+ containing lysis buffer 48
hours after transfection. As a negative control cells were transfected with
epitopes- containing plasmids without inserts. One mg of the protein extract was
used for the co-immunoprecipitation with an anti-V5 antibody. Protein complexes
were subjected to SDS-PAGE and immunoblotted against anti-V5 and -HA
antibodies.
Upper panel – H-REV107-1V5 was immunoprecipitated and detected with an
anti-V5 antibody, Lower panel – co-precipitated S100A6-HA was detected with an
anti-HA antibody. Lane 1 – 15µg of protein extract used for the co-
immunoprecipitation. Lane 2 – negative control. Lane 3 – co-immunoprecipitation
of the H-REV107-1V5 and S100A6HA proteins.
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Fig. 34 H-REV107-1 interacts weakly with ETF1 in COS-7 cells
COS-7 cells were transiently transfected with the H-REV107-1V5 and ETF1-HA
expression vectors. Co-immunoprecipitation was performed 48 hours after
transfection with an anti-V5 antibody.
Upper panel – protein complexes were analysed by Western blotting against an
anti-HA antibody, lower panel – against an anti-V5 antibody. Lane “PE” – 10µg of
protein extract used for the immunoprecipitation. Lane “IP“ – co-
immunoprecipitation of the H-REV107-1V5 and ETF1HA proteins.
Fig. 35 H-REV107-1 fails to bind P14.5 in COS-7 cells
H-REV107-1-V5 and p14.5 – expression vectors were simultaneously transfected
into COS-7 cells. As a negative COS-7 cells were transfected with epitope-
containing plasmids without insert. Immunoprecipitation with an anti-V5 antibody
was performed 48 hours after transfection.
Upper panel: Western blotting with an anti-p14.5 antibody; lower panel: Western
blotting with an anti-V5 antibody.
Lane 1 - protein extracts used for the immunoprecipitation; lane 2, 3 – negative
controls; lane 4 – co-immunoprecipitation of the H-REV107-1 and P14.5 proteins.
Abbreviations: PE – protein extract, IP – co-immunoprecipitation.
1 2 3 4
PE IP
P14.5
H-REV107-1V5
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3.5.2.3 P14.5
The human protein P14.5 was identified in 1996 as the homologue of the rat perchloric acid-
soluble protein. Its weak expression in a variety of liver and kidney tumor cells and high
expression in fully differentiated cells suggested that the protein is involved in differentiation.
The protein was described as an inhibitor of protein synthesis in vitro (Schmiedeknecht et al.,
1996). To prove whether H-REV107-1 interacts with P14.5, COS-7 cells were transiently
transfected with P14.5 and H-REV107-1V5 expression vectors. The cells were lysed 48
hours post transfection, and H-REV107-1V5 was immunoprecipitated using the anti-V5
antibody. Western Blot analysis of the immunoprecipitated protein complexes revealed H-
REV107-1V5 (Fig. 35, lane 4) but not the P14.5 protein, although P14.5 was presented in the
protein extract used for co-immunoprecipitation (Fig. 35, lane 4 and 1, respectively). It was
concluded that under the conditions used, H-REV107-1 does not interact with the P14.5
protein in COS-7 cells.
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4 Discussion
4.1 Yeast Two–Hybrid System
These studies were driven by the desire to understand the mechanism of action of the class
II tumor suppressor gene H-REV107-1. Since the rat H-rev107 gene has been cloned,
several reports were published about H-REV107-1 and its related genes in different species
(Hajnal et al., 1994; Kuchinke et al., 1995; Sers et al., 1997; Husmann et al., 1998; Di Sepio
et al., 1998; Akiyama et al., 1999; Huang et al., 2000; Ito et al., 2001; Sers et al., 2002). The
main common features of these genes are that they are down-regulated in tumors and tumor
derived cell lines, and possess growth suppressive properties. The primary sequence of the
H-REV107-1 product did not provide any clues to the mechanism of its function as a growth
suppressor. In order to elucidate the mechanism of human H-REV107-1 mediated growth
inhibition, we performed a search for interacting proteins using a yeast two-hybrid assay.
Yeast two hybrid systems were developed in 1990 by Stanley and his colleagues, and
provided a novel way of detecting protein-protein interactions in vivo. One of the first
examples of its application was the identification of the Raf Kinase as a Ras interactor and a
downstream effector of Ras function (Vojtek et al., 2003).
We have used a LexA-based yeast two-hybrid system supposed to produce fewer false
positives as compared to the GAL4-based system. This proposition is based on the fact that
in the LexA system the DNA–binding domain (BD) and the activation domain (AD) are
provided entirely by the prokaryotic LexA, and B42 E. coli proteins, respectively. The
prokaryotic proteins are supposed to interact with very few of yeast or mammalian proteins
over-expressed in yeast cells. In contrast, the GAL4 system contains plasmids with
eukaryotic GAL4-DNA binding and activation domains which are supposed to be less
selective. Nevertheless, some interactions can be recognised only by using a LexA-based
yeast two hybrid system, and other interactions can be identified only with the help of the
GAL4-based system (Golemis et al., 1994). The reason for this observation is unknown.
Prior to a large scale transformation for a library screening, the human H-REV107-1 protein
was kindly tested by E. Cuppen (Department of Cell Biology, Institute of Cellular Signalling,
University Nijmegen, The Netherlands) in an established yeast two hybrid approach. This
test demonstrated that for a successful application of the approach, the truncated form of the
H-REV107-1 protein without the membrane binding domain has to be used. Expression of
the full length protein in yeast did not resulted in colony growth. We supposed that the
membrane binding domain hampered a transport of the protein into the yeast nucleus where
the interactions with library proteins take place. Therefore, we performed the entire screen
using a truncated form of the H-REV107-1 protein, lacking the 27 C-terminal aminoacids.
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The use of a truncated protein bears the risk of loosing some interactors, which bind to the
deleted region. However, it was rather doubtful that a transmembrane domain will participate
in protein-protein binding. Most investigations of protein-protein interactions demonstrated
that membrane bound domains do not participate in interaction with cytoplasmic proteins.
There are only a few examples demonstrating that such domains can be involved in
interaction with other proteins, or in the formation of homodimers within a membrane
(Langosch et al., 2002). The bacterial protein glycophorin is known to interact with other
proteins via its transmembrane domain, although the mechanism of this protein-protein
recognition is unclear (Gerber and Shai, 2002). In eukaryotes, large transmembrane proteins
participating in transmembrane channel organisation were demonstrated to form homo- and
heterodimers via the transmembrane regions (Nakayama et al, 2002).
Although the LexA-and GAL4-based yeast two hybrid systems are powerful tools for
detecting protein-protein interactions, they have several disadvantages. They produce false
positives, when library proteins intrinsically modulate transcription, for example when they
function as transcriptional activators or repressors. In addition, the interaction between bait
and pray takes place in the yeast nucleus, where proteins do not undergo posttranslational
modifications like terminal glycosylation, sulfation, phosphorylation or methylation.
Interactions that require protein posttranslational modifications in the cytoplasm can not be
detected by these systems, as well as interactions which require modulating factors present
in the cytoplasm or the cell membrane. These aspects were very important for our assay,
because we supposed that the human H-REV107-1 protein is subject to posttranslational
modification. Five potential tyrosine phosphorylation sites and one serine site were identified
with a score more than 0,6 in the H-REV107-1 protein sequence (Fig. 31) using the NetPhos
2.0 program developed by the Technical University of Denmark
(http://www.cbs.dtu.dk/services/NetPhos/). An additional search for potential myristoylation,
glycosylation or tyrosine sulfation sites of the H-REV107-1 protein revealed negative results.
Furthermore, a Western blot analysis of COS-7 cells transiently transfected with an H-
REV107-1 expression vector revealed two bands of a slightly different mobility in SDS-PAGE
(Fig. 12), which also suggests some kind of posttranslational modification.
Thus, the Lex-A yeast two hybrid assay identified only putative interactors of H-REV107-1
which can bind to the non-modified protein.
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Fig. 36 Prediction of protein phosphorylation sites of the H-REV107-1 protein
Five tyrosine and one serine phosphorylation sites were identified using NetPhos
program. These residues are shown in red.
Unfortunately, after we had established the LexA yeast two-hybrid system, several new two-
hybrid approaches were developed, allowing an improved search for interacting proteins.
One example is the CytoTrap two-hybrid system, which enables the discovery of protein-
protein interactions in the cytoplasm of yeast cells. This system is based on the activation of
Ras signaling pathways in a temperature-sensitive yeast cell line via the recruitment to the
cellular membrane of human Sos protein (hSos) fused to the bait. The target proteins are
anchored to the membrane. Therefore, interaction between bait and target leads to a close
proximity of the hSos and Ras proteins. The hSos protein activates Ras by GDP/GTP
exchange, and allows the yeast cells to grow at 37°C. The system was developed for the
identification of interacting partners of the Jun protein (Aronheim et al., 1997). It is very well
adapted for the identification of protein interactions which take place in the cytoplasm. An
interesting modification of this system is, the so called “reverse Ras recruitment system”, in
which the bait is anchored to the cellular membrane, and the protein partner (the prey) is
fused to a cytoplasmic Ras mutant. Protein–protein interaction between the prey and the bait
results in Ras membrane translocation and activation of a viability pathway in yeast
(Hubsman et al., 2001).
One of the possibilities to identify interactions requiring tyrosine phosphorylation is the so
called “TK (tyrosine kinase) two-hybrid system”. This system is very similar to the standard
LexA-based approach. The difference is that an additional tyrosine kinase domain is ligated
into the LexA-vector, containing the bait. Expression of this vector in yeast leads to the
expression of a bait, and a tyrosine kinase which then phosphorylates the bait protein. Thus,
using this system, a specific search of interacting partners of the tyrosine phosphorylated
protein can be performed (Vojtek and Hollenberg, 1995).
H-REV107-1
MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSE 41
VAGAGAASVMSALTDKAIVKKELLYDVAGSDKYQVNNKHD 80
DKYSPLPCTKIIQRAEELVGQEVLYKLTSENCEHFVNELRY 122
GVARSDQVRDVIIAASVAGMGLAAMSLIGVMFSRNKRQKQ 162
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We screened a human kidney cDNA library with a truncated form of the H-REV107-1 protein.
After rescue of the yeast plasmids from positive colonies, and the following sequencing
analysis, we searched for homology of the isolated cDNA inserts with known genes in the
NCBI database to chose targets for further investigation. This step of analysis is the most
critical in the two-hybrid assay. Among the isolated 168 clones, only a few sequences were
present more than one time. We excluded typical predicted false positives from further
analysis, although it might lead to the loss of putative true positives. For example, heat shock
proteins were described to bind many targets unspecifically in yeast (Golemis et al., 1994).
Therefore, we excluded the Hsp90 heat shock protein from further analysis. However in
many publications it was demonstrated that Hsp90 is a molecular chaperone whose
association is required for the stability and function of multiple mutated, and over-expressed
signaling proteins that promote cancer growth and cell survival. Hsp90 client proteins include
mutated p53, Bcr-Abl, Raf-1, c-Src, Akt, HER2 (Neckers, 2003). It participates in the
prevention of tumor cells from apoptosis (Rashmi et al., 2003). Inhibition of Hsp90 results in
induction of apoptosis through the activation of caspases–9 and -3 in AML HL-60 cells
because of the attenuation of Hsp90-interacting proteins, including Akt, c-Raf-1, and c-Src
protein kinases (Nimmanapalli et al., 2003). We demonstrated that ectopic expression and
induction by IFNγ of H-REV107-1 in ovarian carcinoma cells leads to the induction of
apoptosis through the activation of caspase-9 (Fig. 36). Therefore, in view of these findings,
an interaction between Hsp90 and H-REV107-1 might also be plausible and should not
entirely be excluded.
We also found a number of unknown genes, which we did not prove in a mating assay, and
which were not further analysed in mammalian cells. Putative H-REV107-1 interacting
partners might be among them. Therefore we recently repeated the BLAST search of
sequences found three years ago. For most inserts still no homologies were found. However,
the analysis revealed one novel gene, TSGA10 isolated in 2001 (Madarressi et al., 2001)
without any known function. In addition two cDNA sequences encode proteins which were
characterised in the meantime. One of them is the acid cluster protein ACP33, isolated as a
novel intracellular binding partner of CD4, proposed to modulate a stimulatory activity of CD4
in T cells (Zeitlmann et al., 2001). The second cDNA insert encodes 100 amino acids at the
C-terminus of the novel human protein Scribble, a homologue of the Drosophila protein scrib.
Scrib dysfunction results in the false distribution of apical proteins (Bilder and Perrimon,
2001). It has been demonstrated that scrib acts as a tumor suppressor and participates
together with two other tumor suppressors, lethal giant larvae (lgl) and discs-large (dlg) in the
regulation of cell polarity and growth control (Bilder et al., 2000). The human homologue,
hScrib, was shown to be a target of the papillomavirus (HPV) E6 protein, which stimulates its
ubiquitination and degradation (Nakagawa and Huibregtse, 2000).
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Based on the performed BLAST search analysis, and available literature about found
potential interacting partners of H-REV107-1, we chose 11 clones for a mating test (Table 5).
The mating assay is a powerful supply for the verification of false positives from the yeast
two-hybrid system. Using this assay, we tested whether induction of the reporter genes is a
specific response based on the interaction between H-REV107-1 and the corresponding
target protein. The assay resulted in the exclusion of 5 proteins from further analysis,
because their ability to activate reporter genes was independent of the H-REV107-1
expression (Fig. 7).
For further conformation in the mammalian system, we chose 6 proteins, namely PC4, PR65,
RARG, S100A6, ETF1, and P14.5. The aim of the investigation was to prove if the
interactions identified in yeast also occur in mammalian cells, and to define a role of the
confirmed protein-protein bindings in the H-REV107-1 - mediated growth suppression, and
induction of cell death. We verified that H-REV107-1 protein interacts with PC4, PR65,
RARG, S100A6, and ETF1 proteins, but not with the P14.5 protein in transfected COS-7
cells.
4.2 H-REV107-1 is a Target of IRF-1 and Modulates IFNγ - Dependent Inhibition of
Cellular Growth by Different Mechanisms
Recovery of H-REV107-1 expression upon IFNγ-treatment was demonstrated in human
ovarian carcinoma cell lines. Further experiments revealed that H-REV107-1 is a target of
the interferon regulatory factor 1, IRF-1 (Sers et al., 2002). Therefore we asked how H-
REV107-1 is involved in the known IFNγ-dependent pathways leading to growth suppression
and apoptosis.
Interferon gamma (IFNγ) is a cytokine which was originally identified as the protein
responsible for the induction of cellular resistance to viral infection. Subsequently, much
evidence has been accumulated with regard to its role in cell growth and differentiation
(Pestka et al., 1987). Later, the IFNγ - response has been also postulated to be part of an
endogenous tumor surveillance system (Coughlin et al., 1998). It exerts inhibitory effects on
tumor cell growth, and recently an improved survival of ovarian carcinoma patients after
therapy with IFNγ was described (Windbichler et al., 2000). The biological effect of IFNγ is
mediated through a heterodimeric transmembrane receptor which activates a Janus kinase
(JAK) – STAT pathway. JAK activates signal transducer and activator of transcription
(STAT1) through tyrosine phosphorylation at the cell membrane, followed by dimer formation
and migration of the STAT1 homodimers to the nucleus (Stark et al., 1998). Phosphorylated
STAT1 enhances the recruitment of transcriptional coactivators, such as P300/CBP, to the
promoters of the IFNγ target genes inducing their transcription (Paulson et al., 1999).
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Important mediators of the IFNγ response are the STAT1 – target genes, encoding the
interferon regulatory factors (IRFs). To date, nine members of the IRF family have been
determined, IRF-1 – IRF-9 (Harada et al., 1998). IRF-1 and IRF-2 were identified originally as
a transcriptional activator and its antagonistic repressor, respectively, mediating IFN-α, and -
β signaling (Harada et al., 1989). Further investigations showed that IRF-1 and –2, both play
a key role in cellular growth control, susceptibility to tumorigenic transformation, and
induction of apoptosis. Consequently they were suggested to function as a tumor suppressor
(IRF1) and oncogene (IRF2) (Harada et al., 1993; Sato et al., 2001).
The tumor suppressor activity of the IRF-1 gene is further supported by its localisation at
chromosome 5q31.1, a region frequently deleted in human leukemias (Willman et al., 1993).
The loss of one IRF-1 allele has also been reported in oesophageal and gastric cancer
(Nozawa et al., 1998). Other possible mechanisms of IRF-1 inactivation may be alternative
splicing of the IRF-1 mRNA, producing aberrant IRF-1 in human myelodysplasias and
leukemias (Harada et al., 1994). In breast and ovarian carcinomas the IRF-1 gene exhibits
features of a class II tumor suppressor. Down-regulation of IRF-1, similar to H-REV107-1,
has been demonstrated in high grade human ductal carcinomas and in invasive breast
cancers (Doherty et al., 2001; Sers et al., 2002). Significant reduction of the IRF-1, and H-
REV107-1 mRNA level was revealed in the ovarian carcinoma cell lines OVCAR-3, A27/80,
and PA-1 compared to the non-tumorigenic ovarian epithelial cells HOSE (Sers et al., 2002).
Abrogation of the anti-oncogenic IRF-1 activity can also be achieved by inhibiting of its DNA
binding ability via direct interaction with a putative ribosome assembly factor, nucleophosmin
(NPM)/B23/numatrin, over-expressed leukemias human leukaemia cell lines (Konde et al.,
1997). Summarising these data, IRF-1 is a critical tumor suppressor gene, whose inactivation
through various mechanisms contributes to the promotion of several human cancers.
The precise nature of the IRF-1 – dependent tumor suppression is not very clear, it is
supposed that IRF-1 acts through the up-regulation of a set of genes whose products
function as negative regulators of cellular growth (Harada et al., 1993). A number of IFN-
stimulated genes which are involved in negative regulation of cell proliferation, have been
shown to be IRF-1 targets. Among them are 2-5A synthetase, cyclin-dependent kinase
inhibitor p21WAF1 (Coccia et al., 1999), lysyl oxidase (Tan et al., 1996), double-stranded RNA-
dependent protein kinase, PKR (Beretta et al., 1996), and H-REV107-1 (Sers et al., 2002).
We demonstrated that H-REV107-1 is a direct target of IRF-1 in NIH3T3 cells harbouring
estrogen-inducible IRF-1, and in a subset of ovarian cancer cell lines (Sers et al., 2002).
Investigation of the H-REV107-1 and IRF-1 expression demonstrated their low level in
A27/80 and OVCAR-3 cell lines, which was enhanced after IFNγ-exposition.
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However, IFNγ suppresses growth of only A27/80 cells, OVCAR-3 cells were demonstrated
to be resistant to the treatment (Sers et al., 2002). Analysis of the phenotype of the treated
A27/80 and OVCAR-3 cells revealed no changes in A27/80 cells after 48 hours of incubation
with IFNγ (data not shown). In contrast approximately 5% of the OVCAR-3 cells revealed a
strong up-regulation of the H-REV107-1 expression, which correlated with an apoptotic
morphology of nuclei (Fig. 15). This supposed that H-REV107-1 is directly involved in IFNγ -
mediated apoptosis in OVCAR-3 cells. However, due to the low number of cells up-regulating
H-REV107-1 after IFNγ - treatment this effect had remained undetected in cell growth assay
performed earlier.
To investigate the mechanism of H-REV107-1 – mediated growth suppression, A27/80 and
OVCAR-3 cells were transiently transfected with H-REV107-1 expression vector. In both cell
lines apoptotic nuclear morphology was observed only in cells expressing H-REV107-1
protein (Shayesteh al., 1999; Sers et al., 2002). Thus, forced H-REV107-1 expression leads
to a cell death in both cell lines, whereas IFNγ is likely to suppress growth of these cells by
different mechanisms. We observed increase of IRF-1, IRF-2 and H-REV107-1 protein levels
upon IFNγ - induction only in OVCAR-3 cells (Fig. 14). In contrast in A27/80 cells expression
of these proteins was below detection limits (data not shown). To define further the IFNγ -
dependent signaling in A27/80 and OVCAR-3 cells, we analysed the expression of the
STAT1 protein, which, as was previously described, mediates most of the IFNγ-responses
(Stark et al., 1998). In addition we analysed expression of the p21WAF1 cyclin dependent
kinase, a central mediator of growth arrest and senescence in mammalian cells (Waldman et
al., 1995). Increased p21WAF1 expression leads to cell growth arrest which occur in both G1
and G2 phases of cell cycle (Niculescu et al., 1998), and is accompanied by the development
of morphologic and phenotypic markers of senescence (McConnell et al., 1998). p21WAF1 is
regulated in response to DNA damage in a p53-dependent manner, but also via IRF-1
(Tanaka et al., 1996). The p53-independent induction p21WAF1 expression in response to
IFNγ is mediated by STAT1, through direct binding of IRF-1 to the p21 promoter (Coccia et
al., 1999). We have asked whether p21WAF1 participates in the IFNγ-response in OVCAR-3
and A27/80 ovarian carcinoma cells. We observed up-regulation of STAT-1 expression in
both cell lines 24 hours after IFNγ treatment, and even enhanced level after 48 hours.
Notably, up-regulation of p21WAF1 was observed only in A27/80 cells (Fig. 16). This result
supported our hypothesis of different mechanisms of IFNγ-growth inhibition in OVCAR-3 and
A27/80 cells.
We proposed the following model of IFNγ-response in OVCAR-3 cells: cytokine induction
leads to the activation of STAT1, which stimulates IRF-1 expression. IRF-1 induces H-
REV107-1, and IRF-2 transcription.
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IRF-2 activates a negative feed-back loop, probably suppressing expression of H-REV107-1
and other IRF-1 targets. Expression of IRF-2 protein was detected already 24 hours after
IFNγ treatment, suggesting rapid reverse of the IRF-1 effect (Fig. 14). It is still an open
question why a minority of cells express high level of H-REV107-1 upon IFNγ-induction, and
undergo apoptosis, whereas other cells are resistant to the IFNγ-treatment.
Although we observed up-regulation of mRNA H-REV107-1 and IRF-1 genes in A27/80 cells
after IFNγ-induction, the amount of synthesised proteins was below the sensitivity of the
method. Alternatively, the proteins were rapidly degraded, before we could perform Western
blot analysis. The ubiquitin-proteasome pathway has been reported to play a key role in the
down-regulation of the mouse IRF-1 protein (Nakagawa and Yokosawa, 2000). To prove if
this pathway mediates degradation of the human H-REV107-1 and IRF-1 proteins, we
treated several ovarian tumor cell lines with the MG115 and MG132 protease inhibitors after
induction with IFNγ. We observed a stabilisation of the proteins only in human
teratocarcinoma cells PA-1 but not in OVCAR-3 and A27/80 cell lines (data not shown).
Thus, a protein destabilisation in PA-1 cell line is proteasome dependent, whereas in
OVCAR-3 and A27/80 cell lines other mechanisms are responsible for the destabilisation of
the H-REV107-1 and IRF-1 proteins.
Analysis of IRF-1, H-REV107-1, and STAT1 expression in A27/80 cells rather suggested an
IRF-1 independent growth suppression in A27/80 cells after IFNγ - treatment. Observed up-
regulation of p21WAF1 suggested that this protein might participate in the IFNγ-response. In
addition to p53 and IRF1, the alternative regulator of the p21WAF1 expression was
demonstrated to be the breast cancer susceptibility gene 1, BRCA1 (Ouchi et al., 1998).
The tumor suppressor BRCA1 has been reported to be implicated in the DNA-repair process
(Sculli et al., 1997), and in growth control specifically in breast and ovarian cancer cell lines,
but not in colon and lung cancer cells or fibroblasts (Holt et al., 1996). Direct interaction of
BRCA1 with the p300/CBP coactivator and with RNA polymerase II holoenzyme suggested
that BRCA1 also plays a role in transcriptional regulation (Pao et al., 2000). Later findings
have also implicated BRCA1 as a transcriptional regulator of the P21WAF1 and MDM2 genes
harbouring a p53-responsive element in their promoter regions. This suggested that BRCA1
can enhance p53-dependent gene regulation (Ouchi et al, 1998). Moreover, p21WAF1 was
reported to be required for the BRCA1-mediated growth suppression (Somasundaram et al.,
1997). It has been demonstrated that activation via IFNγ leads to the interaction between
STAT1 and BRCA1 proteins, which stimulate the P21WAF1 gene transcription independent of
IRF-1 (Ouchi et al., 2001). Thus, BRCA1 is a critical component of the IFNγ - regulated anti-
tumor response, and a possible regulator of the P21WAF1 expression in A27/80 cells.
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The status of the BRCA1 gene in OVCAR-3 and A27/80 cells is unknown, but regarding the
failure of the p21WAF1 up-regulation in OVCAR-3 cells after IFNγ-induction, it is likely that
BRCA1 is mutated in this cell line. In A27/80 cells BRCA1 might participate in p21WAF1
induction.
Transcriptional activity of BRCA1 has been demonstrated to be maximal in the presence of
PC4, although direct interaction between PC4 and BRCA1 was not shown (Haile and Parvin,
1999). We hypothesised that H-REV107-1 might serve as a PC4, and BRCA1, STAT1
binding protein. Such a prediction arose from the fact that we found the PC4 transcriptional
coactivator in yeast two-hybrid system as a true H-REV107-1 interacting partner. PC4 serves
as a potent coactivator of a diverse group of transcriptional activators in standard in vitro
transcription systems (Ge et al., 1994). It interacts both with a variety of activation domains
and with members of the RNA II polymerase transcriptional machinery, such as the TFIIA
general transcriptional factor (Kaiser et al., 1995). We asked whether H-REV107-1 might
potentially co-operate with STAT1 and BRCA1 in the IFNγ-response through a formation of a
multiprotein complex including STAT1, BRCA1, PC4, and H-REV107-1.
We precipitated a multiprotein complex, consisting of H-REV107-1, PC4, and STAT1
proteins from COS-7 cells transiently transfected with the appropriate plasmids. However,
the majority of the PC4 and STAT1 proteins remained in the protein extract, and only a minor
fraction was bound to the H-REV107-1 (Fig. 17). We failed to express BRCA1 protein in
COS-7 cells. Therefore potential binding of BRCA1 to the protein complex consisting of
STAT1, PC4, H-REV107-1 proteins is unclear.
Summarising our investigation of IFNγ-signaling in the two human ovarian carcinoma cell
lines OVCAR-3 and A27/80, we conclude that there are two different mechanisms of IFNγ -
mediated growth suppression. In OVCAR-3 cells IFNγ leads to cell death trough the
activation of STAT1, IRF1, H-REV107-1 signaling (Fig. 37). In A27/80 cells IFNγ leads to a
cell cycle inhibition through STAT1, p21WAF1, and, hypothetically, BRCA1 activation. Possibly,
in this pathway a STAT1, PC4, H-REV107-1 protein complex with or without BRCA1 protein
is involved.
Hypothetical scheme of IFNγ-dependent growth suppression in OVCAR-3 and A27/80 cells is
depicted in the Figure 37. There are several questions we wish to answer in our future
investigations. Does H-REV107-1 interact with PC4 and other proteins the nucleus, and
when does a transfer of the H-REV107-1 protein from the cytoplasm to the nucleus take
place?. What is the functional role of the PC4, H-REV107-1, STAT1, and, supposedly,
BRCA1 complex in IFNγ - signaling? Does H-REV107-1 influence STAT1 and PC4 activity as
transcriptional activators in these cells, and is it involved in the regulation of expression of
IFNγ - target genes.
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Fig. 37 Hypothetical scheme of H-REV107-1 participation in the IFNγ-signaling in
OVCAR-3 and A27/80 cells
4.3 H-REV107-1 Participates in the Cross-Talk between Retinoic Acid and IFNγ-
Dependent Pathways
Retinoids (vitamin A and its metabolites) modulate cell growth, differentiation, proliferation,
and can act as chemopreventive and chemotherapeutic agents for several types of cancer
(Hong and Sporn, 1997). Notably, one of the H-REV107 – related proteins, lecithin retinol
acyltransferase (LRAT), plays an important role in retinoid metabolism. It catalyses the
esterification of retinol, thereby synthesising retinyl ester, which is supposed to act as a
storage form for retinol in epithelial cells in skin, and breast (Chen et al., 1997). Investigation
of the retinol metabolism in normal and cancer cells revealed that cancer cells have a greatly
reduced ability to metabolise retinol into retinyl ester, This correlated with a significant
reduction of LRAT expression (Guo and Gudas, 1998), suggesting that lack of retinyl esters
in carcinoma cells may contribute to their tumorigenic phenotype (Guo et al., 2000).
It is known that the biologic activity of retinol and retinoic acid metabolism is mediated by
retinoid binding proteins (CRBPs) and diverse retinoid nuclear receptors. There are two
families of receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Each
family consists of three receptor types, alpha, beta, and gamma (Zhang et al., 2000).
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They modulate gene expression by binding to specific DNA sequences (retinoid responsive
elements, RARE) in the promoter regions of retinoid-target genes (Naar et al., 1991).
We identified the retinoic acid receptor gamma (RARG) in the yeast two hybrid system as a
potential interacting partner of H-REV107-1. Interaction between RARG and H-REV107-1
proteins was a rather surprising finding, because this was a first evidence indicating a
potential participation of the H-REV107-1 protein in retinoid signalling. Investigation of the
interaction in COS-7 cells demonstrated that the H-REV107-1 protein does interact with
RARG only in the presence of supplementary ligands.
To stimulate this interaction we used all-trans retinoic acid (ATRA), a synthetic ATRA
antagonist (TTNPB), and a doublestranded sequence of the retinoic acid response element,
DR5, which is known to be a target sequence of the RARs in promoter regions of the retinoid
target genes (Idres et al., 2002). Although ATRA did not influence the interaction between
RARG and H-REV107-1, TTNPB and DR5 weakly enhanced the protein binding. The
specificity of binding was tested using a negative control with the mutated DR5 sequence. No
enhancement of the interaction was detected (Fig. 32). Nevertheless, this interaction
remained very weak, and only a small part of the intracellular H-REV107-1 was identified in
the complex with RARG, a major part of the protein did not bind to the retinoid receptor (Fig.
32). Combining these data we suggest that under in vivo conditions the interaction might take
place in the nucleus, where RARG bound to the promoter of target genes interacts with the
H-REV107-1 protein. The weak interaction is likely to be due to the fact that only a small
fraction of the H-REV107-1 protein exhibits a nuclear localisation.
It is still an open question if the H-REV107-1 – RARG interaction contributes to retinoid
signaling. Recent investigations of RAR – binding proteins shed a new light at the known
interaction partners of the H-REV107-1 protein. The STAT5 protein was identified as a
critical regulator of enhanced RAR transcriptional activity (Si and Collins, 2002). Most
interestingly, the authors described a direct overlap of STAT1 and STAT5-binding sites with
RAR elements within the promoters of several genes, for example, RARβ and RARα
(Langston et al., 1997). Such colocalisation of regulatory elements suggests a previously
unexplored cross-talk between STAT and RAR families of transcriptional factors, following
co-regulation of the IFN– and retinoid– dependent genes. Since the H-REV107-1 protein is a
mediator of IFNγ-signaling (Sers et al., 2002), it will be definitely interesting to investigate the
activity of the RARG in IFNγ-treated cells, and to define a potential role of IFNγ in the
modulation of the RARG – H-REV107-1 interaction in more detail.
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Another interesting aspect of the interaction between H-REV107-1 and RARG is the
enhanced co-immunoprecipitation of the RARG and H-REV107-1 proteins in presence of the
TTNPB ligand (Fig. 32). Binding to diverse ligands is supposed to change the conformation
of the RARG molecule. Current models of the RAR activation suggest that binding of ligands
results in a distinct conformational change, and leads to the release of co-repressors and the
recruitment of transcriptional activators (Zhang et al., 2000), such as CBP, or p300. These
factors are able to trigger RNA polymerase II to transcribe target genes (Kamei et al., 1996).
Interestingly, another coactivator of the RNA polymerase II, the PC4 protein, was also found
in the yeast two hybrid assay, as one of the H-REV107-1 binding proteins. Although a role of
PC4 in the activation of RARs has not yet been described, its participation in this process
cannot be excluded.
In summary, the functional relevance of the H-REV107-1, PC4 and STAT1 proteins on the
RARG activity is still speculative, but provides an attractive hypothesis on the role of H-
REV107-1 in both the IFNγ and retinoic acid signaling.
Importantly, IFN-γ was found to act synergistically with retinoids, and to enhance the growth
inhibitory effect of retinoids in cultured breast and ovarian cancer cells (Hu et al., 2002).
Analysis of the H-REV107-1 expression using cancer profiling arrays demonstrated down-
regulation of the gene in breast, ovarian and lung tumors. IFNγ-treatment recovered H-
REV107-1 expression in ovarian carcinoma cell lines OVCAR-3 and A27/80 (Sers et al.,
2002). Investigation of the additive affect of IFNγ and ATRA revealed that IFNγ-treatment
increased the expression level of RAR-alpha and RARG (Hara et al., 2001). Therefore it will
be of interest to investigate if IFNγ-treatment of OVCAR-3 and A27/80 cells will lead to the
up-regulation of RARG expression. Retinoids were demonstrated also to contribute to the
cross talk between IFN- and ATRA – signaling pathways. In various cell lines, retinoic acid
induces directly the expression of the transcription factors STAT1 and IRF-1, which play
central roles in IFNγ-signal transduction (Chelbi-Alix and Pelicano, 1999). The H-REV107-1
gene was reported to be a target of IRF-1 (Sers et al, 2002). Possibly, H-REV107-1
participates in cross-talk between retinoid and IFNγ-signaling in ovarian tumors, although
regulation of the gene occurs rather through a retinoid – independent pathway.
In contrast, the H-REV107-1 related protein, the H-REV107-2/TIG3/RIG1, is directly
implicated in retinoid acid cellular response (Huang et al., 2000). The H-REV107-
2/TIG3/RIG1 was cloned as an ATRA responsive gene in keratinocytes and cervical and
gastric cancer cells, where it acts as a tumor suppressor (Di Sepio et al., 1998; Hung et al.,
2000; Deucher et al., 2000).
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Further investigation lead to the finding that in gastric carcinoma cells the H-REV107-
2/TIG3/RIG1 protein induces apoptosis trough negative regulation of extracellular signal-
regulated kinase, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated kinase (Huang
et al., 2002). Interestingly, other groups showed that treatment of these cells with ATRA
leads to the inhibition of AP1 activity a subunit of which is the JNK-target protein, c-Jun.
Investigation of retinoid receptors responsible for the ATRA-mediated growth inhibition of
gastric cancer cells revealed that the retinoic acid receptor beta (RARbeta), but not RARG, is
required for the AP-1 inhibition, and contributes to growth suppression (Huang et al., 2002).
Taking these data together, we suppose that H-REV107-2/TIG3/RIG1 and RARbeta are
involved in retinoic acid dependent growth arrest in gastric cancer cells, but not H-REV107-1
and RARG
4.4 H-REV107-1 – Mediated Cell Death through Inhibition of PP2A Activity
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase in eukaryotic cells.
PP2A can be considered a family of phosphatases, minimally containing a highly conserved
catalytic subunit C (PR36) α and β isoforms; and a “scaffolding protein”, the regulatory
subunit A (PR65), α and β isoforms. The isoforms of the PR65 subunit are 86% identical, and
those of the PR36 subunit are 92% identical (Hemmings et al., 1990). The PR65 and PR36
proteins are tightly associated with each other, comprising the so called “core domain”.
(Ruediger et al., 1994; Millward et al., 1998). The activity of the “core domain” is regulated by
regulatory subunits B, bound to PR65. Four protein families B (PR55), B´ (PR61), B´´ (PR72,
PR130, PR49, PR48), and B´´´ (PR93, PR110) are known as regulatory subunits B of PP2A
(Table 8; Janssens and Gors, 2001).
Biological and genetic studies have revealed that PP2A enzymes are abundant, ubiquitous,
and very conserved during evolution. PP2A dephosphorylates a large number of substrates
in vitro, and is involved in the regulation of nearly all cellular activities, such as metabolism,
transcription, cell cycle, signal transduction, and oncogenic transformation (Sontag, 2000).
The PR65β encoding gene, PPP2R1B was characterised as a putative tumor suppressor
down-regulated or mutated in lung, breast, and colon human tumors (Wang et al., 1998;
Janssens and Goris, 2001). PR65α plays a critical role in cell morphogenesis of yeast,
probably through regulation of the cytoskeletal network and cell wall synthesis. Deletion of
the PR65α encoding gene, PPP2R1A is lethal in yeast (Kinoshita et al., 1996). Investigation
of PR65α in human tumors demonstrated that PPP2R1A gene, is mutated in lung and breast
human carcinomas and melanomas (Calin et al., 2000), strengthening a potential role of
PP2A in human tumorigenesis.
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Table 8 Isoforms of the Protein Phosphatase 2A (PP2A) and their alternative
designations.
The homozygous PR36α null mice are embryonically lethal, demonstrating that the PR36α
subunit gene is essential for viability, and cannot be replaced by PR36β (Gotz et al., 1998).
Recent data suggest that embryonic lethality results from defects in cell adhesion caused by
insufficient levels of membrane-associated E-cadherin and β-catenin, suggesting a role of
PP2A in Wnt/β-catenin – signaling (Seeling et al., 1999; Patturajan et al., 2002). The
importance of PP2A in human cells is indicated by the fact that various pathogenic viruses,
namely human immunodeficiency type 1 virus, HIV-1, (Tung et al., 1997), papova viruses
(Pallas et al., 1990) or adenoviruses (Kleinberger and Shenk, 1993) express PP2A
interacting proteins, which modify the phosphatase activity. Human cytomegalovirus (CMV),
a herpesvirus, carries host-derived PP2A, associated with the nucleocapsid fraction
(Michelson et al., 1996).
We demonstrated that the H-REV107-1 protein interacts with the regulatory subunit A α of
the protein phosphatase 2A (PR65α) in COS-7 cells (Fig. 18), and under cell free conditions
(Fig. 20). The interaction of the bacterially expressed H-REV107-1 with PR65α indicated that
H-REV107-1 directly binds this protein. Co-immunoprecipitation assays in COS-7 cells with
H-REV107-1 mutants delineated a region of 10 aminoacid residues on the very N-terminal
end of the protein necessary for the interaction (Fig. 24).
Thus we have presented data demonstrating that the H-REV107-1 mediated apoptosis in
OVCAR-3 cells is due to the inhibition of the PP2A activity through physical interaction
between H-REV107-1 and the PR65 regulatory subunit. A challenge of our investigation was
to define PP2A target proteins whose dephosphorylation plays such important role in cell
survival.
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Ectopically expressed H-REV107-1 protein forms homodimers in COS-7 cells. We tested the
H-REV107-1 mutant proteins for a homodimer formation and observed that the same region
responsible for the interaction with PR65α is also required for a homodimer formation. This
suggests a competitive character of these interactions. Preliminary experiments
demonstrated that binding to the PR65α protein excludes generation of homodimers (data
not shown).
We wished to investigate a molecular mechanism of the correlation between H-REV107-1
mediated cell death and the interaction with PR65α. We observed that H-REV107-1
overexpression in human ovarian carcinoma cells OVCAR-3 results not only in the induction
of apoptosis, but leads also to the transport of PR65α protein from nucleus into the
cytoplasm (Fig. 27). During overexpression of the ∆C107-∆N interaction deficient mutant
neither apoptotic morphology of nuclei, nor transportation of PR65α were obtained. This
suggested that H-REV107-1 – mediated apoptosis correlates with its ability to interact with
the PR65α protein.
Little known about nuclear PR65α and its interacting partners in ovarian carcinoma cells. In
most tissues and cell lines a cytoplasmic localisation of this protein was reported (Thou et al.,
2003). We asked where the catalytic subunit PR36 is localised in OVCAR-3 cells, and if other
PP2A subunits might interact with the nuclear PR65α protein. For example, the PP2A B56
regulatory subunit γ and δ isoforms were also shown to be concentrated in nucleus (McCright
et al., 1996), suggesting that B56 isoforms might somehow be involved in this process.
Preliminary analysis of expression of the genes encoding the B56 α, β, γ - proteins via RT-
PCR revealed that all isoforms are expressed in OVCAR-3 cells (data not shown).
First, we investigated if H-REV107-1 can influence the intracellular localisation only of
PR65α, or of the “core domain” consisting of PR65 and PR36 subunits. Immunofluorescence
analysis of the intracellular distribution of PR36α in OVCAR-3 cells revealed an exclusively
cytoplasmic localisation. Expression of the H-REV107-1 protein did not have any influence
on the localisation of the PR36α protein (data not shown). PR36 is usually bound to the
PR65 protein, and does not exist in a cell in free state. Therefore we supposed that the
second isoform of the PR65 protein, PR65β, might be expressed in OVCAR-3 cells.
We performed a subcellular fractionation of OVCAR-3 cells, and tested the different fractions
with an antibody recognising both, the PR65α and PR65β proteins. Western blot analysis
revealed a strong specific signal in the cytoplasmic and in the nuclear fractions (data not
shown). Therefore, we suppose that the PR65β is expressed in OVCAR-3 cells, and
preferably localised in the cytoplasm, whereas the PR65α is localised in the nucleus, as we
observed using immunofluorescence analysis.
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Thus, it is likely that in the cytoplasm the PR36α - PR65β protein complex might exist. Taking
into consideration that PR65α and PR65β are 86% homologue, we would like to test in our
further experiment if H-REV107-1 might interact with PR65β in the cytoplasm, and if the
PR36α, PR65β, H-REV107-1 complex exists in OVCAR-3 cells.
We determined a basal level of the protein phosphatase 2A enzymatic activity in
untransfected OVCAR-3 cells, and in the cells over-expressing H-REV107-1. As a negative
control we used a phosphatase inhibitor, okadaic acid, in the PP2A specific concentration of
2 nM (Holmes et al., 1990). H-REV107-1 overexpression had a strong inhibitory effect on
PP2A activity, whereas the interaction deficient ∆C107-∆N mutant was unable to inhibit the
phosphatase (Fig. 30). This suggests that the interaction between H-REV107-1 and PR65α
leads to the inactivation of the PP2A enzymatic activity.
The finding that PP2A inhibition leads to apoptosis is rather surprising, because it is in
contrast with many other reports, suggesting that the protein phosphatase 2A is a pro-
apoptotic phosphatase (Klumpp and Krieglstein, 2002). Additionally, OA has been described
as a tumor promoting agent (Afshari et al., 1993; Fujiki and Suganuma, 1993).
A dual role of the protein phosphatase 2A in tumor progression has been already mentioned
by other authors. Although most PP2A inhibitors are implicated in tumor promotion, the
inhibitor fostriecin displayed a significant anti-tumor activity in Chinese hamster ovary cells
inducing a dose-dependent arrest of cell growth during the G2-M phase of the cell cycle
(Cheng et al., 1998). Recent research in Drosophila melanogaster demonstrated that a
trimeric complex PP2A/C, PR65, and B56-regulatory subunit is required for survival and
protect cells from apoptosis (Li et al., 2002). Investigation of the sensitivity of different cell
lines to OA-induced apoptosis revealed an unexpected result. It was shown that the cell lines
harbouring ras mutations are more sensitive than the cell lines with wild-type ras (Rajesh et
al., 1999). Using dual-coloured flow cytometry, we demonstrated that treatment of OVCAR-3
cells with 10 nM OA results in cell death due to apoptosis (Fig. 30). Although OVCAR-3 cells
do not carry Ras mutations (Patton et al., 1998), activation of one of the Ras-dependent
down-stream pathways, the PI3-kinase pathway, has been reported in these cells
(Shayesteh et al., 1999). PI3-kinase plays an important role in a cell survival. Amplification of
its downstream kinases Akt1, and Akt2 was demonstrated in human ovarian cancer, and
inhibition of this pathway led to the cell death (Yuan et al., 2000).
Therefore we included the PI3-kinase inhibitor, LY294002 in further analysis, to test if
LY294002 and OA treatment have a similar effect on the OVCAR-3 cells, like H-REV107-1
ectopic expression. Investigation of the apoptotic pathway after H-REV107-1 overexpression,
LY294002, and OA treatments revealed that a mitochondrion-dependent, but not a death
receptor – dependent pathway is activated in all three cases.
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 Cleavage of the caspase-9, and its down-stream caspases-3 and –7 was detected (Fig. 31;
and data not shown). In contrast, a marker for the death-receptor dependent apoptosis,
cleaved caspase-8 was revealed only after treatment with 10 nM OA (data not shown),
suggesting that the cellular response to higher concentrations of OA includes activation of
additional targets, such as PP1, which activates a death receptor pathway, that differs from
the response to the H-REV107-1 protein. Apoptosis induction after treatment with 10 nM OA,
and after H-REV107-1 overexpression was more pronounced as after treatment with 0.5 nM
OA (Fig. 31, B), probably due to the insufficient inhibition of PP2A activity by low
concentration of okadaic acid. Although PP2A is inhibited by OA with Ki 0.2 nM (Shima et al.,
1994), various cell lines differ in their membrane’s penetrance. Therefore it is difficult to
control intracellular OA concentration, and some unspecific effects can occur.
We have analysed PP2A substrate proteins, such as members of the BCL-2 family, directly
participating in mitochondrion-dependent apoptosis, and proteins involved in RAS.-
dependent signaling. One of the proapoptotic members of this protein family, is the BAD
protein function of which is regulated by reversible phosphorylation. Three phosphatases,
PP1 (Ayllon et al., 2000), PP2A (Chiang et al., 2001), and PP2B (Wang et al., 2000) have
been demonstrated to be implicated in the dephosphorylation of the Ser/Thr residues within
BAD. Inhibition of phosphatase activity by treatment of cells with okadaic acid of different
concentrations demonstrated that in OVCAR-3 cells BAD is rather a target of PP1
phosphatase but not of PP2A (data not shown). Analysis of other members of the BCL-2
family, Bcl-2 and Bxl revealed negative results as well.
The RAS-downstream signaling pathways were of our particular interest. Two pathway
down-stream of Ras, the RAF-MEK-ERK and the PI3K-Akt pathway have been described to
be regulated via PP2A (Millward et al., 1999). PP2A modulates the activity of several
members of the RAF-MEK-ERK pathway, and has both positive and negative effects (Frost
et al., 1994; Alessi et al., 1995; Zhou et al., 2002).
PP2A dephosphorylates an inhibitory site within Raf, Ser-259, the dephosphorylation of
which was shown to be necessary for full activation of this kinase (Abraham et al., 2000). We
analysed activation-phosphorylation of ERK, MEK, and RAF in OVCAR-3 cells treated with 1
nM and 10 nM OA, with LY294002, and transfected with an H-REV107-1 expression vector.
We did not obtained any effect on the phosphorylation of RAF1. Treatment with LY294002
and 1 nM OA led to the reduction of the phosphorylated RAF-down-stream kinase MEK
(Nazarenko, unpublished data), suggesting a cross-talk between PI3-kinase and RAF-MEK-
ERK kinase pathways. One of the PI3-kinase down-stream effectors, the PKC kinase, has
been reported as an activator of MEK (Kolch, 2000).
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A large number of studies demonstrated a PP2A inhibitory effect on the PI3-kinase –
dependent pathways (Sontag, 2000; Yellaturu et al., 2002). Akt, and PKC were described as
substrates of PP2A (Yellaturu et al., 2002; Sontag et al., 1997; Standaert et al., 1999).
Interestingly, that PKC revealed an inhibitory effect on Akt - activity (Wen et al., 2002),
indicating a negative feedback loop within a PI3-kinase pathway.
Thus, PP2A might activate the PI3-kinase pathway, through inhibition of the PKC activity,
and inhibit the PI3-kinase pathway through inhibition of Akt activity. It is possible that different
regulatory subunits of PP2A might recruit the enzyme to either PKC, or Akt kinase, and
modulate therewith a cell survival or cell death, respectively.
Fig. 38 Schematic presentation of the mechanism of H-REV107-1 – mediated cell
death
Inhibition of a pathway is shown with red lines, activation of a pathway is shown
with green lines.
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It is a desire of our further experiments to elucidate if the PKC kinase is a primary target of
PP2A in OVCAR-3 cells. This might answer the question which activity of PP2A, essential for
cell survival, inhibits H-REV107-1. A recent publication, demonstrating that PKCε is
necessary for the IFNγ-response, supports our hypothesis that PKC might be a target of
PP2A in OVCAR-3 cells (Ivaska et al., 2003). The authors demonstrate that the PKCε kinase
phosphorylates, and thereby activates the STAT1 protein. PP2A is responsible for a
deactivation of PKCε via dephosphorylation. This results in attenuation of the IFNγ-induced
phosphorylation of STAT1, and, therefore, inhibition of IFNγ-signaling. It was demonstrated
that that IFNγ - function might be recovered by inhibition of PP2A.
We did not yet prove if OA treatment will recover an IFNγ-response in OVCAR-3 cells, but
the fact that only the cells over-expressing the H-REV107-1 protein, inhibiting PP2A activity,
underwent apoptosis after IFNγ-treatment, substantiates this possibility. A hypothetical
scheme of the PP2A signaling pathway in OVCAR-3 cells is depicted in the Figure 38.
4.5 Possible Participation of H-REV107-1 in Calcium Metabolism
One of the H-REV107-1 interacting partners that was confirmed in yeast and mammalian
cells is the Ca2+ - binding protein calcyclin. Calcyclin belongs to the S100 family of calcium
binding proteins, and was characterised as a marker for the malignant phenotype in human
malignant melanomas (Maelandsmo et al., 1997 ), squamous cell carcinomas (Berta et al.,
1997), breast (Pedrocchi et al., 1994), and colon cancers (Stulik et al., 2000). There is ample
evidence that calcyclin and other members of this family play an important role in neoplastic
progression (Weterman et al., 1992). Recent research supports these earlier findings,
demonstrating that up-regulation of calcyclin in colorectal adenocarcinomas is directly
correlated with Dukes’s tumor stage. This suggests that calcyclin may be involved in the
progression and invasive process of human colorectal adenocarcinomas (Komatsu et al.,
2000; Bronckart et al., 2001).
The interaction between H-REV107-1 and calcyclin is dependent on the presence of Ca2+
and Zn2+ ions in the lysis buffer (Fig. 33). These ions were demonstrated to bind different
sites of calcyclin, independent of each other, changing the protein conformation, and
probably the binding capacity of calcyclin (Kordowska et al., 1998). Therefore, it will be of a
particular interest to investigate separately a role of these ions on the binding of calcyclin to
the H-REV107-1 protein.
Until now we have no further evidences for a functional role of the H-REV107-1 protein in
Ca2+ signaling. Interestingly, one of the regulatory subunits of PP2A, another H-REV107-1
interacting protein, has been described as a calcium binding protein, and a role of PP2A in
calcium metabolism was suggested (Janssens et al., 2003).
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The authors evaluated the effects of Ca2+ on subunit composition, subcellular targeting, and
catalytic activity of a PR72-containing PP2A trimer. Binding of calcium required nuclear
localisation of PR72, and mediated PP2A activity in vitro. H-REV107-1 was demonstrated as
a negative regulator of PP2A activity in vitro, and its forced expression lead to the transport
of the PR65 subunit form nucleus into the cytoplasm.
These data support the notion that the H-REV107-1 protein is directly involved in the calcium
metabolism. Therefore it will be of a particular interest to investigate whether calcyclin is able
to mediate the PP2A activity in OVCAR-3 cells in presence and absence of the H-REV107-1
protein, and to investigate a potential influence of the Ca2+ or Zn2+ ions on the H-REV107-1 –
mediated inhibition of PP2A activity.
In summary, the application of the yeast two hybrid approach revealed multiple interacting
partners of the class II tumor suppressor H-REV107-1, suggesting its participation in various
cellular processes. We demonstrated that the H-REV107-1 protein is an important mediator
of IFNγ signaling, and induces either growth suppression, or apoptosis through different
mechanisms. The STAT1, PC4, H-REV107-1 protein complex is likely to be involved in IFNγ
- mediated growth suppression in ovarian carcinoma cells.
Further studies identified a novel oncogenic role of the protein phosphatase 2 A (PP2A) in
ovarian carcinoma cells. PP2A is a central serine/threonine phosphatase which is involved in
nearly all cellular processes. We demonstrated that for the H-REV107-1 - mediated cell
death, the interaction with the regulatory subunit A (PR65) of PP2A is required. The H-
REV107-1 - PR65 protein binding results in the inhibition of PP2A activity, which is followed
by the induction of apoptotic signaling via a caspase-9 – dependent pathway. The challenge
of our future investigation will be to define the direct target of PP2A which is responsible for
tumour cell survival, and to elucidate the mechanisms of H-REV107-1 mediated growth
inhibition or cell death in more detail.
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